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ABSTRACT
NMR AND COMPUTATIONAL CHARACTERIZATION OF PROTEIN
STRUCTURE AND LIGAND BINDING
Terrence S. Neumann
Marquette University, 2013
Nuclear magnetic resonance (NMR) techniques combined with computational methods
such as docking and cheminformatics were used to characterize protein structure and
ligand binding. The thioredoxin system of Mycobacterium tuberculosis consists of a
thioredoxin reductase and at least three thioredoxins. This system is responsible for
maintaining the cellular protein thiol redox state in normal state. This maintenance is
important as the bacterium is engulfed by the human macrophage. Here it is bombarded
by reactive oxygen and nitrogen species in an attempt to disrupt normal cellular function
in part by perturbing the protein thiols. To this end, the solution structures of the three
thioredoxins, A, B, and C, in the oxidized state were solved by NMR. Additionally, the
reduced form of thioredoxin C was solved as well. Docking and NMR chemical shit
pertubation experiments show promise for the inhibition of the thioredoxin C-thioredoxin
reductase catalytic turnover.
Automated docking is the process of computationally predicting how tightly a ligand
binds to a protein and the correct orientation. The docking of an in-house collection of
10,590 chemicals into a protein called dual specificity phosphatase 5 identified potential
ligands. These compounds were characterized as inhibitors in a phosphatase assay and as
ligands in NMR chemical shift perturbation experiments. Based on a promising lead
compound, additional chemicals were identified using cheminformatics and subjected to
the same experimental verification.
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Chapter I. Introduction to the Methods Used to Characterize Protein Structure, Function,
and Ligand Binding
1.1 Introduction
Characterization of protein structure and ligand binding can be a challenging
endeavor. There are many factors that play a role in the structure of a protein and how
that structure might interact with a ligand. To study these factors, we employ standard
nuclear magnetic resonance (NMR) methods to investigate protein structure and ligand
binding. NMR is uniquely positioned to study these structural effects as it can give
information on the unbound protein structure, how the protein structure changes upon
ligand binding, and how tightly the ligand is binding. Additionally, other experimental
and computational techniques can be employed to help characterize protein structure and
ligand binding.
1.1.2 NMR Solution Structure Determination
Protein structures can be solved using x-ray crystallography and NMR.
Crystallography has some drawbacks. It requires a protein crystal to be grown and the
protein is frozen in a single conformation that may or may not be representative of its
actual 3D shape while in solution. NMR structure techniques are limited chiefly by the
size of the protein in that proteins above 25 kDa are typically difficult to solve.
To calculate a protein structure using NMR, triple resonance experiments are
required to assign nuclei resonance frequencies. These experiments include the HNCO,
HN(CA)CO, CBCA(CO)NH, HNCACB, HNCA, and HN(CO)CA to obtain the
sequential backbone assignments for all hydrogens (N-H, Hα’s and H-β’s). As well as the
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amide nitrogen atom and the α- and β- carbon atoms. To perform the experiment, the
radio frequency pulses transfer magnetization between the atoms and then detects the
free-inductive decay which can then be transformed using a Fourier transform to a
frequency. Each unique frequency can be assigned to the correct atom based the transfer
of magnetization for the experiment. For example, in the HNCACB experiment,
magnetization begins on the amide proton and is transferred to the α- and β- carbon atoms
through the amide nitrogen. Using this information in concert with the other experiments
allows one to assign the atoms in the backbone. Additionally, a program called TALOS1
predicts the ϕ and ψ angles for the protein backbone. These angles are then used as
restraints during the calculation of the 3D models.
Additonally, the other atoms in the residue, commonly called the side chains,
need to be assigned. Experiments to obtain these assignments include the CC(CO)NH,
CBCA(CO)NH, HBHA(CO)NH, HCC(CO)NH, and the HCCH-TOCSY. These
assignments are important as they form the basis on which distance restraints are made to
generate a 3D structure. The 13C-NOESY, aromatic and aliphatic, and the 15N-NOESY
experiments are 3D experiments based on the Nuclear Overhauser Effect for which cross
peaks are observed if atoms are within 5 Å.
Using the distance restraints from the NOESY spectra and the angle restraints
from the TALOS prediction, the program Cyana2-4 is used to sort through these restraints
and construct 3D models for the protein. After sufficient refinement using Cyana,
additional refinement is performed using a simulated annealing protocol with the
AMBER5 molecular force field. This step considers the energentic effects of
intermolecular forces. This simulated annealing procedure creates an ensemble of
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structures that are characterized by the root-mean-squared difference (RMSD) between
atoms.
1.1.3 Molecular Docking
Docking is the computational process of positioning a ligand into the binding site
of a protein to identify the preferred pose of the ligand. Using this pose, a binding affinity
for the ligand-protein complex can be calculated using a force field.6 Docking plays a
role in the design and discovery of drugs as drug candidates are docked against protein
targets to predict their affinity to the target. This process is called virtual screening. 7
Though there are many docking programs available, we use Autodock4.2.8, 9 Autodock
uses a genetic algorithm to sample multiple conformations of a ligand when binding to a
protein. Using these coordinates, Autodock will adjust a degree of freedom on the ligand
(ie. rotatable bond or translational motion) and calculate if the movement is favorable to
predicted binding. Unfavorable adjustments are discarded while favorable adjustments
are subjected to further iterations of this process.
Autodock uses the following Gibbs free energy equation to quantify ligand
protein binding.
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The first four terms describe the van Der Waals forces hydrogen bonding, electrostatics,
and deviations from covalent geometry. The final two terms describe the internal entropy
(ligand torsions) and desolvation energy.
This process is an excellent way to being studying ligand binding on a new
protein. Quickly, a prioritized list of chemicals can be obtained to be tested
experimentally on a new protein. This virtual screening process allows the testing of
many more compounds to be tested that would otherwise be possible due to time and
resource constraints.
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Chapter II. Solution Structures of Mycobacterium tuberculosis Thioredoxin C and
Models of the Intact Thioredoxin System Suggest New Approaches to
Inhibitor and Drug Design
2.1 Introduction
Mycobacterium tuberculosis (M. tuberculosis) is the causative agent of
tuberculosis, which has a mortality rate of 1.3 million people in 2008.10 It is estimated
that a third of the world population is infected with a latent form of M. tuberculosis.11
The M. tuberculosis pathogen resides in the alveolar phagocytes of the host and can resist
the oxidative killing of these immune cells, but the exact mechanism of this resistance is
remains unclear.12 Disrupting this defense could be an effective means by which that
pathogen could be killed, so the proteins involved in this defense are being pursued as
potential targets for new anti-mycobacterial drugs. The method by which host phagocytes
attempt to kill the invading M. tuberculosis pathogen is via production of reactive oxygen
and nitrogen species, including superoxides and hydrogen peroxide, which can be toxic to
the microbe.13 One method that M. tuberculosis uses to resist this oxidative attack is via
the same process that eukaryotic cells use to combat oxidative stress, using the thiol
reductants of the thioredoxin system (in addition to other enzymatic anti-oxidant
systems). In other prokaryotic organisms, the thioredoxin system keeps cellular proteins
in a reduced state, along with glutathione (mycothiol is used in M. tuberculosis).14-16
Thioredoxins are well-studied proteins, found in all organisms.17 They share
common features such as a conserved catalytic motif of WCXXC, and have a low
molecular weight of about 12 kDa.18 Thioredoxins catalyze thiol-disulfide exchange
reactions using redox active cysteine thiols to reduce oxidized disulfide cysteines of
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proteins, including metabolically essential enzymes.19-21 The oxidized thioredoxins are
then reduced by thioredoxin reductase (TrxR) in an NADPH-dependent reaction, via
redox active cysteine or selenocysteine thiols, depending on the host organism.22-24 In
plants, fungi and bacteria, the disulfide reductions in TrxR (~35 kDa) occur via a
sequence of reactions that begins with hydride transfer from NADPH to a bound FAD
cofactor, followed by electron transfer from FADH2 to the redox-active cysteines, to the
thioredoxin, which forms a mixed disulfide with TrxR before the thioredoxin cysteines
are fully oxidized. In higher organisms, such as mammals, the TrxR (~55 kDa) transfers
the hydride from the NADPH to FAD, then from FADH2 to an amino-terminal TrxR
active site, then to a carboxy-terminal active site of the TrxR/Trx dimer pair. This
TrxR/Trx dimer contains a cysteine-selenocysteine redox-active pair, which then
transfers electrons to the thioredoxin in a disulfide exchange reaction.23 Thus, the
microbial and human thioredoxin mechanisms diverge significantly in the steps involving
Trx binding and reduction. Disruption of this process, by selectively targeting the
microbe over the host, could be used to kill the M. tuberculosis pathogen. Selective
targeting should be possible since the Trx binding site is in a different region of the TrxR.
Furthermore, the M. tuberculosis thioredoxins are only 35% identical to the human Trx,
and the M. tuberculosis TrxR is only 28% identical to human TrxR. While these proteins
are functionally related from microbe to man, the TrxR’s are structurally and
mechanistically quite different.25, 26
The catalytic cycle of the thioredoxin system from various prokaryotic sources
has been extensively studied, with the best characterized being that from E. coli. The first
E. coli Trx solution structures were reported over 20 years ago.27-31 Building on this rich
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literature, a comprehensive study from the Ludwig lab32 determined structures for the
various steps in the E. coli thioredoxin system catalytic cycle, providing a structural
complement to the mechanistic knowledgebase surrounding the microbial thioredoxin
system. While the thioredoxin system from E. coli is well characterized, that of M.
tuberculosis is not.12 Because the E. coli thioredoxin system is so similar to that of M.
tuberculosis. (TrxR 45% identity, 63% homology, and Trx 50% identity and 64%
homology), the structural studies presented herein build on what has been learned about
the E. coli system, to provide a foundation for future structure-based design of inhibitors
that disrupt the M. tuberculosis thioredoxin system, either as chemical probes of function,
or as potential anti-mycobacterial agents. Analysis of structures and models for various
steps in the M. tuberculosis thioredoxin catalytic cycle, as opposed to individual static
snapshots of single proteins (ex. TrxR), may suggest novel strategies for inhibition.
The thioredoxin system in M. tuberculosis is comprised of three thioredoxins
(TrxA, TrxB, and TrxC) and one thioredoxin reductase (TrxR).12, 33, 34 It has been shown
that M. tuberculosis TrxB and TrxC behave as general disulfide reductases with near
equal reduction potential (-262 mV vs. -269 mV), while TrxA is observed to have only a
weak capacity to act as a disulfide reductase, and was found to not be a substrate for
TrxR under the assay conditions tested.12 It has also been shown that the ability of M.
tuberculosis to survive redox stress, while dependent on TrxR, is not dependent on the
expression of just one thioredoxin. This suggests that having multiple thioredoxins in M.
tuberculosis may provide a “redundant system” to ensure survival under oxidative
conditions.12 The thioredoxin system of M. tuberculosis is increasingly viewed as a viable
drug target for novel anti-mycobacterials, as long as a drug can be designed that knocks
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out the entire M. tuberculosis thioredoxin system (ex. inhibit TrxR catalytic turnover with
all Trx’s).35 Of particular interest would be inhibitors that remain effective at high levels
of competing substrate, either Trx or NADPH; this would be uncompetitive inhibition.
Cells cannot achieve resistance to such uncompetitive inhibitors by increasing levels of
substrates; but, design of such inhibitors requires structural information that enables more
than just simple targeting the NADPH or Trx pockets on TrxR, as has been the focus to
date.26 Design of uncompetitive inhibitors requires a knowledge of potential pockets that
exist during the catalytic cycle and that could be occupied by inhibitors (in the presence
of Trx substrate), and that stabilize reaction intermediates, thereby stopping catalytic
turnover in a manner that cannot be overcome at high substrate. Studies presented herein
will provide structures and models for various steps in the catalytic cycle of the M.
tuberculosis thioredoxin system to facilitate design of such inhibitors.
Structural studies presented herein focus initially on M. tuberculosis TrxC (Figure
2.2), and modeling of its interactions with TrxR throughout the catalytic cycle, based on
NMR chemical shift perturbation studies (Figure 2.2). While the crystal structure of
TrxC in the oxidized state had been solved, there is no structure of TrxC in the reduced
state, and no structural studies of interactions between TrxR and TrxC.34 Furthermore, it
was previously suggested (but never proven) that the crystal structure of TrxC may have
had distortions due to crystal packing forces that affect the C-terminal helix.34 Studies
presented herein establish that this is in fact the case. Previous studies of the different
redox states of prokaryotic thioredoxins have shown that there are subtle changes in
structure in going from the oxidized to the reduced state.30, 36, 37 Most of the changes
occur in the active site near the redox active cysteines, with some conformational
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flexibility observed in the active site loop.34, 38 Whether this is also true in M. tuberculosis
TrxC is not known, since there is no structure of reduced TrxC. Studies presented herein
will provide an analysis of differences between reduced and oxidized TrxC. Beyond this,
studies will address how these forms of TrxC may interact with TrxR at different steps in
the catalytic cycle (building on the E. coli work from the Ludwig lab), and whether these
intermediates suggest unique opportunities for the design of uncompetitive inhibitors.
2.2 Materials and Methods
2.2.1 Protein Expression and Purification
The plasmids containing the Rv3914 gene (TrxC) in the pET22b vector and the
Rv3913 gene (TrxR) in the pET23a vector were obtained from Tuberculosis Vaccine
Testing and Research Materials at Colorado State University and from Dr. Mande from
the Center for DNA Fingerprinting and Diagnostics in Hyderabad, India. Both expression
constructs produced protein with a C-terminal poly-histidine tag (Figure 2.1); plasmids
were transformed into E. coli BL21-(DE3) Rosetta cells from Novagen and grown
overnight at 37° C, then inoculated into 2 L of LB (Luria Bertani) media supplemented
with a vitamin mix that included riboflavin (needed for TrxR flavin production).
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Figure 2.1. Structure of TrxC showing location of last contiguously assigned residue,
Asn116. The C-terminal histidine tag was present after Asn116 (some residues in the
histidine tag were assigned as well). Data provided by Andrew Olson.
Cells containing the TrxR gene were grown until O.D. 600 nm reached 0.7, at
which point cells were induced for 4 hours with 1 mM IPTG. For expression of TrxC
protein cells were grown to 0.7 at O.D. 600 at which point the cells were spun down at
7000 rpm and washed with M9 minimal media salts (pH 7.0). Cell pellets were
transferred to 0.5 L of M9 minimal media containing 0.5 grams 15NH4Cl and 2.0 grams of
13

C-glucose as the only sources of nitrogen and carbon, to yield uniformly labeled

protein.39 The cells were allowed to acclimate for 1 hour and then induced with 1 mM
IPTG for an additional 4 hours at 37° C, then harvested. The bacterial pellet was
resuspended in lysis buffer consisting of 50 mM Tris base, 300 mM NaCl, 5 mM
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imidazole, and 10% glycerol at pH of 7.8, and lysed using sonication. The lysate was
clarified by centrifugation at 15,000 RPM for 30 minutes and the supernatant loaded onto
1 mL of nickel-Sepharose (Amersham Sciences) resin at 1 mL/minute. The bound
protein (TrxC or TrxR) was then washed with lysate buffer, then with lysate buffer
containing 25 mM imidazole, and then eluted using lysate buffer containing 300 mM
imidazole. The eluted protein was than dialyzed with 40 mM potassium phosphate buffer
at pH of 6.3 (for NMR structure studies) and pH of 7.0 (for TrxC/TrxR binding
experiments) and concentrated to 1 mM using Amicon Ultra-4 centrifugal device
(Millipore) with protein concentration determined by the absorbance at 280 nm using
extinction coefficients of 11,000 and 14,440 L/mol-cm for TrxC and TrxR respectively,
based on ProtParam calculations (http://expasy.org/tools/protparam.html). While
estimation of protein concentration in this manner may slightly overestimate TrxR
concentration (the FAD has some absorbance at 280 nm), exact stoichiometry is not
required for titration of TrxC with TrxR, because we see complete disappearance of
crosspeaks at < 1:1 stoichiometry due to exchange broadening. The purpose of the
TrxR/TrxC titration is simply to identify interface crosspeaks, and the residues
corresponding to those crosspeaks. Flavin incorporation into TrxR was verified using
UV-Visible spectroscopy (Figure 2.4). For studies of reduced protein, 5 mM DTT was
added.
2.2.2 NMR Spectroscopy and Structure Calculation
All NMR experiments were performed on a 600 MHz Varian NMR System at
599.515 MHz using a triple resonance cryoprobe with z-axis gradients at 25 °C.
Backbone assignments were obtained using 2D 1H-15N HSQC, and 3D HNCO,
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HN(CA)CO, HNCA, HN(CO)CA, CBCA(CO)NH, and HNCACB spectra. Side chains
were assigned using CC(CO)NH, HBHA(CO)NH, HCC(CO)NH, and HCCH-TOCSY
spectra. Distance restraints were obtained from 3-D 15N-NOESY, 13C aliphatic NOESY,
and 13C aromatic NOESY experiments, which were obtained using 150 ms mixing times.
Structures were calculated using these distance restraints with the program CYANA2-4, in
conjunction with backbone phi and psi angle restraints as predicted from TALOS1 based
on chemical shifts of Cα, Cβ, Hα, Hβ, HN, and CO atoms. Initial structures were
obtained using the noeassign macro of CYANA4, followed by manual refinement using
the calibration of peaklists by the CYANA function caliba, with the disulfide bond added
as a restraint for the oxidized structure. A final ensemble of 500 structures was
calculated, and the 100 conformers with the lowest target function were then selected for
water refinement using AMBER.5 Using implicit solvent, a 500 step energy
minimization was first performed on the 100 structures (no restraints) followed by two
cycles of 30 ps simulated annealing from 1000K to 0K, with distance and dihedral
restraints applied. After the MD simulated annealing, a 2000 step minimization with
restraints was applied in implicit solvent and analyzed for distance and dihedral penalties
and rank ordered by lowest AMBER energy. The 20 lowest energy structures were then
selected for the final ensemble (Figure 2.2), and were analyzed using the Protein
Structure Validation Software suite.40 NMR spectra were processed using NMRPipe41
and analyzed using NMRView42 and Sparky.43 Processing was performed with a cosine
bell window function in the direct and indirect dimensions.

2.2.3 Structural Modeling of Intermediates in the M. tuberculosis Thioredoxin
Reductase Catalytic Cycle
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The M. tuberculosis thioredoxin reductase crystal structure (pdb code 2A87)26 had
previously been solved in the oxidized state (in what is referred to as the FO
conformation). To create a model of TrxR in the reduced state, where the disulfide is
converted to surface free thiols (available to react with and reduce thioredoxins), the
coordinates of the E. coli homolog of TrxR bound to a thioredoxin (pdb code 1F6M)44
were used as template. Specifically, the M. tuberculosis TrxR (oxidized) structure was
superimposed on the E. coli TrxR (reduced) structure. But, since the reduced E. coli TrxR
is known to have a 66° domain rotation relative to the oxidized TrxR26, 44, this same
rotation was created in the M. tuberculosis structure. To do this, the pdb file of M.
tuberculosis TrxR was split at amino acids 117 and 241 so that the FAD and NADPH
domains could be separated. The separated NADPH and FAD domain coordinates were
then superimposed onto the coordinates of the E. coli NADPH and FAD domain using
Pymol45, then rejoined and then minimized using AMBER.5 This yielded what is
referred to as the FR conformation. To model the various oxidation states of the
TrxR/TrxC complexes, including the mixed disulfide between TrxR and TrxC, structures
were minimized with a restrained disulfide bond between the cysteines (oxidized) or left
with no restraint (reduced). All AMBER minimizations were performed with 2000 steps
in implicit solvent.

2.2.4 Thioredoxin System NMR Binding Experiments
In order to establish which redox states of TrxC, TrxR and NADPH/NADP+
interact, and where interacts occur, chemical shift perturbations were monitored using
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N-labeled TrxC (reduced or oxidized) (Figure 2.3). If binding occurs, based upon

observation of chemical shift changes in HSQC spectra, chemical shifts are mapped onto
the surface of TrxC to guide and confirm modeling of the TrxC/TrxR complexes,
described in the previous section. These data were used, in part, to construct the models
in Figure 2.3, as described in Figure 2.9 and Figure 2.7. TrxC and TrxR solutions were
exchanged into 50 mM potassium phosphate buffer at pH 7.0, then concentrated to 1 mM
each. TrxC was diluted to 320 µM in the absence of DTT, so that it was in the oxidized
state. TrxR was then added to the TrxC NMR sample, so that both proteins were at equal
concentrations of 250 µM. NADPH was then added to the sample at 1 mM so that TrxR
would reduce the disulfide of TrxC. As a control to test for binding in the presence of the
different redox states of the cofactor, NADP+ was added to the sample at 1 mM.

1

H-15N

HSQC experiments were acquired after every addition, and pH was measured to ensure
that it remained at 7.0. As a control for the reduced state, 1H-15N HSQC spectra were
acquired for TrxC in the oxidized state, and then reduced by DTT at pH 7.0.

2.2.5 Thioredoxin System Interface Inhibition Docking and Titration Experiments
An in-house collection of 10,000 drug-like chemicals was docked into open
spaces at the interface of the TrxC-TrxR complex using Autodock 4.2.8, 9 The grid box
was centered at the interface and was 24.75 Å x 25.5 Å x 29.25 Å. Autodock 4.2 docked
each ligand 50 times, scored the pose based on the program’s force field, and clustered
each pose based on a root-mean-squared difference from the other poses. NMR
screening of individual chemicals was prioritized by the cluster’s mean binding energy
and population. Compounds that scored favorably were then dissolved in DMSO to a
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concnetration of 5 mM. Binding studies were performed by combining 200 µM TrxC,
250 µM TrxR, and 0.80 mM NADPH in the NMR buffer described above. Compounds
were added at 200 µM (DMSO ~4% by volume) and HSQC spectra acquired before and
after compound addition, and analyzed for any chemical shift perturbations.
2.3 Results and Discussion
2.3.1 NMR Solution Structures of Oxidized and Reduced Thioredoxin C
The solution structures of M. tuberculosis thioredoxin C were solved by NMR
(Figure 2.2), with 2036 NOE derived restraints and 168 angle restraints in the oxidized
state and 2114 NOE restraints in the reduced state with 169 angle restraints. Statistics
describing the restraints used in calculation, precision, and quality of the structures are
summarized in Table 2.1. The ensemble of structures for oxidized TrxC (PDB entry
2L59 and BMRB entry 17268) has a backbone RMSD of 0.54 Å, and 0.50 Å for the
reduced state (PDB entry 2L4Q and BMRB entry 17242), shown in Figure 2.2A and
2.2B. To ensure that the cysteines were reduced, 5 mM DTT was added to the protein
sample and chemical shifts were monitored before and after each experiment, using a 1H15

N HSQC (Figure 2.2A and 2.2B) spectrum. Reduction of the active site cysteines

results in a decrease in the 13Cβ chemical shifts from 44.6 to 26.9 ppm and 35.1 to 27.6
ppm for C37 and C40 respectively, consistent with the additional shielding that is present
with the electron rich thiol, compare to the disulfide. After addition of DTT to oxidized
TrxC, those residues that are affected the most are located along the active site loop,
including F32, A34, T35, C37, G38, and C40.
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Table 2.1. NMR and water refinement statistics and analysis for solution structures of
both redox states of M. tuberculosis. Data provided by the Sem lab.
NMR Distance and Dihedral Constraints
TrxCox
TrxCred
distance constraints
total NOEs
2036
2114
intra-residue
207
257
inter-residue
sequential (|i-j|=1)
509
540
medium-range (|i-j|<4)
510
555
long-range (|i-j|>5)
810
762
dihedral angle constraints
φ
84
85
ψ
84
84
Water Refinement and Structure Statistics
Mean AMBER energy (kcal/mol)
-3943
-3940
distance constraints (>0.3 Å)
0
0
dihedral angle constraints (>5.0°)
1
1
Ramachandran statistics
residues in most favored regions (%)
92.2
90.5
residues in additionally allowed regions (%)
7.8
9.2
residues in generously allowed regions (%)
0
0.2
residues in disallowed regions (%)
0
0.1
average pairwise RMSD (Å) 7-110
backbone
0.541
0.501
heavy
0.942
0.875
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Figure 2.2. Solution NMR structures of TrxC: (a) the ensemble for oxidized TrxC with a
backbone RMSD of 0.54 Å, (b) the ensemble for the reduced state of TrxC with a
backbone RMSD of 0.50 Å, and (c) overlay of the median structures for both redox
states, colored as in panels (a) and (b). Note: disordered N- and C-terminal residues 1-6
and 113-116 have been omitted for clarity in panels (a) and (b). (d) Overlay of the
median NMR solution structure for the oxidized TrxC (red) and the crystal structure of
oxidized TrxC (gray), with the active site disulfides shown in yellow. The only
significant deviation is in the C-terminal helix, a4, which in the crystal structure
participated in an interaction with another TrxC in the asymmetric unit. Data provided by
Andrew Olson.
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Analogous to the situation with the E. coli thioredoxin solution structures27-29, 31,
the oxidized and reduced forms of TrxC are very similar to each other, showing only
small differences between oxidized and reduced states, with a pairwise RMSD of only
0.53 Å between the ensembles (Figure 2.2C). Consistent with other thioredoxins, TrxC
in both states has the characteristic-folding pattern of 4 α-helices surrounding a 5stranded beta sheet core, consisting of three parallel strands and two antiparallel strands.
The redox active cysteine residues C37 and C40 are located in the conserved active site
loop (C37-G-P-C40) that leads into the α2 helix, which in both redox states is a bent helix.
The active site of TrxC includes a predominately hydrophobic core including two Ala (34
and 44), two Pro (39 and 81), an Ile (80), and a Val (43) residue. Both Trp (33 and 36)
indole rings are within 6 Å of the two Cys’s, with W36 also forming the interface surface
that interacts with TrxR (Figure 2.9). The disulfide in the oxidized state has the typical
90° χss angle for the C-S-S-C linkage. Interestingly, roughly the same geometry with the
same χss angle is present in the reduced state. The most dramatic change in going from
oxidized to reduced state is the distance between the Cys residue sidechains, with the S-S
distance in the oxidized state of the median structure in the ensemble having a distance of
2.0 Å, compared with 3.5 Å in the reduced state (Figure 2.2C). That is, overall geometry
is roughly the same before and after S-S bond formation; but, the thiols move 1.5 Å
closer together as the bond forms.
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Figure 2.3. 2D 1H-15N HSQC spectra of (a) the oxidized state of TrxC (red) with all the
backbone N-H chemical shifts assigned, and (b) the oxidized (red) and reduced (black)
states of TrxC, with the large chemical shift changes associated with disulfide reduction
labeled. Data provided by Andrew Olson.
The N-terminal (α1) helix is somewhat irregular, but is nearly identical between
the two redox states, and is the same as in the crystal structure of M. tuberculosis
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TrxCox34 as well as both E. coli Trx solution structures. The α4 helix spans residues 101111, but begins to show fraying at L108. There are some differences between the two
redox states in the turn region linking the α1 helix to the β3 sheet (residues 22-26), and
the α3 helix connecting to the β4 sheet (residues 75-81). The latter region closely
contacts the active site region. These regions are probably dynamic in nature, and show
similar effects in the E. coli solution structures of the different redox states (Figure 2.4).

Figure 2.4. Absorbance spectrum of a TrxR sample (28 µM) at 25 degrees in a 50 mM
phosphate buffer at pH 7.6, obtained using an HP 8452 diode array UV-Vis
spectrophotometer. Relative band intensity and shape matches that which was previously
reported for the E. coli thioredoxins (Prongay, A.J., Engelke, D.R., and Williams, C.H.,
Jr. (1989) J. Biol. Chem. 264, 2656-2664). Data provided by Elise Span.
2.3.2 Comparison to the M. tuberculosis TrxC Crystal Structure

The M. tuberculosis TrxC crystal structure (pdb code 2i1u)34 was solved in the
oxidized state, and is nearly identical in secondary structure to our solution structure,
with a pairwise RMSD of 0.83 Å between the crystal structure and the median structure

21	
  
	
  
from the ensemble (Figure 2.2D). But, there is one significant difference – and that is
with regard to the orientation of the C-terminal a4 helix. It was noted in the crystal
structure study that the protein crystals packed such that the C-terminus (residues 110114) in the a4 helix rested in the active site groove of an adjacent protein in the crystal
lattice, which the authors noted could cause a structural perturbation. Based on our
solution structure of oxidized TrxC, this crystal packing effect does in fact seem to have
caused the α4 helix to be pushed up 2.7 Å towards the β5 strand, and rotated in towards
the β4 strand (Figure 2.2D). Residues 108-115 in the crystal structure are disordered,
perhaps so that those residues can occupy the active site of a neighboring TrxC protein.
However, residues 108-111 still retain helical shape (as mentioned above) before
becoming disordered at residues 112-115 in our solution structure. Although it is
possible that some difference in the a4 helix may stem from the C-terminal histidine tag,
we believe this is unlikely since the solution structure maintains the characteristic
thioredoxin folding pattern, and is more compact than the crystal structure (Figure 2.5).
Even though the distortion of the a4 helix and its ability to participate in a protein-protein
interaction may be an artifact of crystal packing, its ability to participate in this
interaction may also hint of a biologically relevant role. That is, since a4 is flexible, it is
possible that it plays a role in protein-protein interactions with TrxR, which may require
motion of this helix. In this regard, we have also performed calculations of generalized
order parameter of TrxC, based on the “Random Coil Index”46, and found that several
active site loop regions are predicted to have low order parameters (S2 < 0.8), including
the loop that leads into the a4 helix (Figure 2.6). Flexibility in these loops may indicate
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they can function as hinges that enable motion of the N- and C-terminal helices a1 and
a4, to optimally fit into the binding site presented by TrxR.

Figure 2.5. Overlays of both redox states of solution structures from E. coli Trx and M.
tuberculosis TrxC, where A) is the overlay for the oxidized states, with blue being from
M. tuberculosis and green from E. coli and B) is the overlay for the reduced states, with
wheat being from M. tuberculosis and purple from E. coli. Data provided by the Sem lab.
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Figure 2.6. Top panel: Calculated order parameters, based on the Random Coil Index
(RCI), from the Wishart group. Bottom panel: structure of TrxC (reduced) showing those
segments (in red) with the greatest disorder, predicted to be random coil. The a1 and a4
helices are shown on the left and right sides, respectively, in the above representation.
2.3.3 Structures and Models of M. tuberculosis Thioredoxin C (oxidized and
reduced) and Thioredoxin Reductase throughout the Thioredoxin Catalytic Cycle
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After having reduced other proteins in the cell, the oxidized TrxC must be regenerated to
the reduced state by the enzyme thioredoxin reductase (TrxR). This process had been
thoroughly studied in E. coli, culminating in a structural characterization of the various
steps in the TrxR catalytic cycle.44 Figure 2.3 presents the corresponding structures and
structural models for the M. tuberculosis TrxR/TrxC system in different redox states,
depicting the complete redox cycle between TrxR and TrxC, using the M. tuberculosis
TrxR crystal structure26, our TrxC structures (oxidized and reduced), and the various E.
coli structures44 as templates, with protein complexes created or confirmed based on
chemical shift (and line-width) perturbation studies. Chemical shift mapping studies used
to create these complexes are summarized in Figure 2.9 and Figure 2.7. M. tuberculosis.
TrxR is known to undergo a large domain rearrangement, to position the reactive
cysteines so that they are able to react with the disulfide on the thioredoxin substrate.
The crystal structure of the M. tuberculosis TrxR is in the oxidized conformation (FO),
with its disulfide buried in the protein interior, near the isoalloxazine ring of FADH2;
FADH2 provides the electrons to reduce this disulfide (step B to C in Figure 2.3). The
reduced state of M. tuberculosis TrxR (FR), with its cysteines now at the surface, and the
NADPH close to the FAD (D in Figure 2.3), was modeled using the E. coli thioredoxin
reductase structure as a template (pdb code 1f6m).44 This structure was used to guide
initial positioning of the M. tuberculosis TrxR FAD and NADPH domains. In this
manner, structural models have been created for all the steps in the thioredoxin reaction
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sequence (Figure 2.3), using chemical shift perturbation data to define the TrxR and TrxC
interface (see below).
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Figure 2.7. 2D 1H-15N HSQC spectra where the black cross peaks in all panels are for
oxidized/reduced TrxC and A) TrxR has been added to the sample (red), B) TrxR has
been added to the sample and the redox activity initiated by addition of with NADPH to
reduce TrxC (green), and C) DTT is added to the sample to fully reduce TrxC as a control
experiment (blue). Protein concentration is 250 µM for TrxC and TrxR is slightly less
than 250 µM. Data provided by Andrew Olson.
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Figure 2.7 continued. 2D 1H-15N HSQC spectra where D) black cross peaks are for
oxidized/reduced TrxC and TrxR is added to the sample along with the oxidized cofactor
NADP+. E) The overlay of the DTT reduced sample (blue) and the NADPH reduced
sample (green), and F) is the same as panel E with the oxidized sample from panel D and
DTT added to it (orange). Data provided by Andrew Olson.
2.3.4 NMR Data Defining the Binding Interface between M. tuberculosis TrxC and
TrxR
It has previously been proposed that the E. coli TrxR exists in a dynamic
equilibrium between two conformations (FO and FR)32, irrespective of the state of
oxidation for the flavin or cysteines. It is hypothesized that changing redox state or
binding to the thioredoxin (Trx) substrate merely shifts the FO/FR equilibrium. To
determine what oxidation state the proteins (TrxC and TrxR) must be in for binding to
occur, a series of 1H-15N HSQC titration experiments were performed so that changes to
the state of the proteins in different oxidative states could be monitored (Figure 2.9;
Figure 2.7). Chemical shift changes could be due to binding or to
conformational/structural changes induced by redox changes; the latter effects are known
from DTT titrations of isolated TrxC (Figure 2.2B). When oxidized TrxR, in the absence
of NADPH, was added to TrxC, there were no chemical shift changes to TrxC (Figure
2.7), indicating that oxidized TrxR (that has no NADP(H) cofactor bound) cannot bind to
TrxC. Interestingly, a small amount of TrxC that was present in a reduced state was
converted to a fully oxidized state, indicating that even though the oxidized TrxC cannot
bind, the reduced TrxC can bind to oxidized TrxR (lacking NADP(H)) and react in what
would be the reverse of the biologically relevant direction (high NADPH concentrations
ensure the reductive reaction is favored in vivo). When the reducing agent (NADPH) for
the thioredoxin system was added in excess (4-fold), all of the oxidized TrxC was
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converted to the reduced state in the presence of TrxR, via the TrxR-catalyzed reduction
(Figure 2.7); this is consistent with the reduced TrxR/NADPH being able to bind TrxC.
While there were no chemical shift differences in comparing the TrxR/NADPH-reduced
TrxC (TrxR present) with the DTT-reduced TrxC (TrxR absent), the presence of TrxR
did cause disappearance of some TrxC crosspeaks due to exchange broadening (see
below). This exchange broadening identifies residues at the TrxR/TrxC interface, thereby
facilitating construction of properly docked TrxR/TrxC models (Figure 2.3).
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Figure 2.8. The complete redox and catalytic cycle for the M. tuberculosis thioredoxin
system, modeled after the E. coli thioredoxin catalytic cycle. The cycle begins with free
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TrxR (colored red) in the oxidized state, with bound NADP+, with the first step being
release of NADP+ and a simple domain rotation to produce the FO conformation. FR and
FO refer to the reduced or oxidized conformations (not the redox state) of TrxR, which
are related by a 66° rotation of the NADPH and flavin domains. TrxC (ox and red)
structures are those reported herein (colored blue), TrxR (FO) is the previously reported
crystal structure, while models for the various complexes were constructed based on
structural and functional data for the E. coli thioredoxin system, and chemical shift
perturbation studies. Expansions show the redox state of relevant thiols or disulfides.
Each modeled complex was minimized with AMBER. This cycle can also be visualized
via a molecular animation and structure models are available to be used in docking or
structure-based drug design efforts. Data provided by Andrew Olson.
When the spectra for the TrxC/TrxR mixture, which has been reduced using
NADPH or DTT (+ NADP+), were overlaid (Figure 2.9), there were again no
distinguishable chemical shift changes. When compared to the spectrum for unbound
TrxC (reduced), there are a number of residues that disappear due to exchange
broadening, due to binding interactions between TrxC and TrxR. The residues that
showed exchange broadening were mapped onto the reduced state solution structure of
TrxC in Figure 2.9. The majority of these residues are in the active site region of the
protein (F32, A34, T35, W36, C37, T67, V78), and these residues create a hydrophobic
surface that interacts with TrxR, and that was used to define the protein-protein interface
region for constructing the structural models in Figure 2.8. Based on these results,
although TrxR may be sampling both FO and FR states, TrxC will only bind to the
reduced (free thiol) form of TrxR with cofactor (NADPH) bound, not to the FO state that
is lacking NADPH cofactor.

2.3.5 Analysis of the M. tuberculosis Thioredoxin Cycle Models
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As illustrated in Figure 5.3, and by analogy to the E. coli system, the catalytic
cycle for the M. tuberculosis thioredoxin system is shown starting in the conformation
described as “FR” (intermediate A in Figure 5.3), so that the active site cysteines have just
finished reducing TrxC (which was released in the previous step), and there are bound
NADP+ and FADH2 cofactors. It is called the FR state because of the relative orientation
of the NADPH and FAD domains such that the NADPH binding site is close to the FAD
(and the thiol/disulfide is distal). Assuming M. tuberculosis TrxR behaves as the E. coli
reductase, it will then undergo a 66° rotation around the NADPH binding domain to bring
the disulfide bonded cysteines (C145 and C148) proximal to the isoalloxazine ring of
FADH2, while the NADPH binding pocket moves away from the FADH2, thereby
allowing NADP+ to be released (this creates intermediate B). This also positions the
isoalloxazine ring of FADH2 to within 3.7 Å of the S atom of C148 (now TrxR is in the
“FO” state), which permits electron transfer from flavin to the disulfide (transfer will most
likely be to the more proximal cysteine, C148). After the FADH2 reduces the disulfide,
the sulfur inter-atomic distance increases from 2.0 Å to 3.7 Å, giving a slightly smaller χ
angle across what was the disulfide. After reduction, a general base (likely to be D149,
which is 5.3 Å from the thiol of C148) abstracts a proton from C148 to produce a thiolate
that is ready to attack the disulfide of the thioredoxin (intermediate C converted to D).47
NADPH then binds to TrxR, and the NADPH domain undergoes another 66° rotation to
bring the reduced active site cysteines away from the FAD isoalloxazine ring, and back to
the surface (back to the FR conformation) of the protein, core that defines the TrxC
binding pocket (the concave pocket on the bottom of intermediate D in Figure 2.8).
Elsewhere in the protein in intermediate D, the NADPH nicotinamide ring comes to

34	
  
	
  
within 3.4 Å of the isoalloxazine ring of FAD so that it can reduce the N5 position of
FAD, again producing FADH2. The FADH2 can once again reduce the disulfide of
TrxR, later in the catalytic cycle.
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Figure 2.9. Definition of the TrxR/TrxC interface using chemical shift perturbation
studies. (a) Several HSQC spectra were overlaid, with blue crosspeaks corresponding to
free reduced TrxC (in presence of 1 mM DTT). Green crosspeaks correspond to a ~1:1
complex between TrxC/TrxR at 250 µM (TrxC in slight excess over TrxR), with a fourfold excess of NADPH added. In cases where there was exchange broadening due to
TrxR binding to TrxC, green peaks are no longer visible; so, the presence of blue
identifies residues that are likely to be at the TrxC/TrxR interface. Orange crosspeaks
correspond also to the complex between TrxC/TrxR at 250 µM, but now with a four-fold
excess of NADP+ added in addition to 1 mM DTT. The exact match between green and
orange crosspeaks suggests these two ternary complexes are similar, if not identical, and
would correspond somewhat to intermediate F (but possibly with the mixed disulfide
reduced) in Fig. 3. All spectra were acquired at pH 7.0. (b) Interface residues, which are
largely hydrophobic, are shown as a surface rendering (white). This is the interface that
forms when TrxR binds to and reduces an oxidized TrxC, and includes F142 and F143 on
TrxR. (c) Residues on TrxC that show chemical shift perturbations or line broadening
(from panel (a)) upon binding to TrxR have been mapped on the TrxC solution structure
as blue Van der Waals spheres. These residues define the binding interface with TrxR (in
panel (b)). Data provided by Andrew Olson.
The TrxR is now in a conformation that can bind and then reduce TrxC
(intermediate E). Inspection of this TrxC/TrxR structural model reveals that helix a4 is in
contact with the mobile NADP(H) domain of TrxR (the a4 helix is on the far left side of
the blue TrxC, as shown in Figure 2.8, intermediates E-G). This same a4 helix was
distorted in the crystal structure of TrxC, and is attached to the core TrxC structure via a
flexible linker (predicted S2 < 0.8; Figure 2.6) based on our solution NMR studies. It
appears that this mobile a4 helix permits binding of TrxC to the TrxR FR state (the FO
state can’t bind Trx, because it has this TrxR interface rotated 66o away). Also of interest
is that the a1 helix, which is likewise attached to the TrxC core via a flexible linker,
makes contact on the opposite side of the TrxR pocket; and, the distortion (kink) in helix
a1 creates a somewhat convex surface that may be essential for matching the concave
shape of the TrxR pocket (the far right side of the blue TrxC structure in intermediate E
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of Figure 2.8). Thus, a majority of the TrxR/TrxC binding interface is comprised of the
a1 and a2 helices, which form a convex recognition surface on TrxC.
In addition to TrxR interactions with the TrxC a1 and a4 helices, the complex
appears to be stabilized by a hydrophobic interface produced in the FR state by TrxR
residues F142 and F143, which interacts with TrxC residues A34, P39, V43, A44, A72,
V78, I80, and P81. Figure 2.9 shows a view of the binding interface between TrxR and
TrxC, identified using chemical shift mapping, with surface rendering showing the
hydrophobic pocket. Of particular interest is that W36 of TrxC, which is conserved in all
thioredoxins. W36 has its indole ring situated in this hydrophobic pocket, with the ring
NH hydrogen bonding to the carboxyl group of Asp66, at a distance of 1.9 Å. This
interaction is likely to be important for proper positioning of the TrxC C37, for reaction
with the TrxR thiol/disulfide (C145, C148). The thiolate of C148 in TrxR is 4.9 Å from
the disulfide-linked cysteine thiol (C37) of TrxC (intermediate E). Attack of C37 on
C148 (disulfide) would produce the mixed disulfide between the two proteins
(intermediate F), which is analogous to the mixed disulfide structure of E. coli TrxR/Trx
that was structurally characterized by the Ludwig group.44 The free thiolate in TrxR
(C145) then attacks C148 of the mixed disulfide, thereby producing fully reduced TrxC
in the thiol reduced state (intermediate G). The newly reduced TrxC is released from the
now oxidized TrxR, which is in the same state as Figure 2.9A, thereby completing the
thioredoxin catalytic cycle. This series of thiol/disulfide exchanges is distinct from, and
occurs in a different active site region, in the mammalian thioredoxin system.
Accordingly, targeting this active site region in drug design efforts could provide
compounds that are specific for microbial over mammalian enzymes.
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2.4 Conclusion

Developing an inhibitor that targets the M. tuberculosis. thioredoxin system rather
than the human thioredoxin system would provide a novel route to anti-mycobacterial
drugs. The function of the thioredoxin system, from microbe to man, is to maintain redox
homeostasis by keeping cellular proteins reduced; and, in doing this, Trx becomes
oxidized, so must be reduced by TrxR. The M. tuberculosis TrxR undergoes a domain
rotation in to move the NADPH and FAD(H2) in proximity to each other, and to move
the reduced active site cysteines proximal to bound Trx.26 The human thioredoxin
reductase instead uses a cysteine-selenocysteine active site on a flexible carboxy-terminal
tail that is absent in the microbial enzyme, to shuttle FAD(H2) electrons to its bound
thioredoxin (Figure 2.10B).23 In comparing the models from M. tuberculosis., described
herein, and the recently published human thioredoxin system25, it becomes clear that
there are significance structural differences (Figure 2.10), along with the mechanistic
differences, that can be exploited for selective inhibition of the microbial system. The
human thioredoxin reductase has an additional domain that interacts with Trx (Figure
2.11, interface domain, Figure 2.10B and 2.10C), which is absent in the microbial system.
Furthermore, the active site cysteines (that receive electrons from FADH2) are not
directly exposed to the bound Trx, as they are in the microbial system. Of particular
importance is the absence of the binding pocket between the Trx and TrxR that was
observed in M. tuberculosis complex (compare Figures 2.8B and 2.10B), because the
human system uses the C-terminal domain for the final electron transfer step to bound
Trx.
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Figure 2.10. Comparison of the M. tuberculosis. and human Trx-TrxR complex. (a) M.
tuberculosis. Trx (blue)-TrxR (red) mixed disulfide. (b) Human Trx (orange)-TrxR
(teal) mixed disulfide. Note the carboxy-terminus of the dimer pair is highlighted in
violet and forms the mixed disulfide. (c) Overlay of the M. tuberculosis. and human
thioredoxin systems. (d) Close up of M. tuberculosis thioredoxin complex disulfide from
Figure 5(c). (e) Close up of the human thioredoxin complex disulfide from Figure 5(c).
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Figure 2.11. Comparison of the three thioredoxin reductases discussed in this study.
The M. tuberculosis TrxR shows 45% identity and 63% homology to the E. coli TrxR
and 14% identity and 22% homology to human TrxR1. ¢ denotes active site cysteines. x
denotes cysteines that form mixed disulfides between the thioredoxin and thioredoxin
reductase. ¤ denotes the selenocysteine from human thioredoxin reductase.
Besides providing insights into mechanism, and providing structural hypotheses
that can be tested with future mechanistic studies (ex. using site-directed mutagenesis),
the models presented herein (Figure 2.8) can be used to facilitate structure-based design
of inhibitors that selectively block the M. tuberculosis thioredoxin catalytic cycle, by
targeting the Trx/TrxR interface. While inhibitors could be designed to block either the
NADP(H) or TrxC substrate pockets on TrxR, the former class would yield inhibitors that
might not be selective for the microbial system and which would be competitive versus
cofactor. The latter approach is attractive, but suffers from the usual challenge of finding
inhibitors that bind to broad protein-protein recognition surfaces; and, competitive
inhibition can be overcome by the pathogen increasing expression levels of TrxC. A third
approach might be to design inhibitors that occupy pockets that appear in the catalytic
cycle at the Trx/TrxR interface, and are present even when Trx substrate is bound, so that
binding of an inhibitor might stabilize that intermediate in the presence of substrate and
thereby block catalytic turnover. This is the general concept behind uncompetitive
inhibition. To illustrate the feasibility of the strategy of targeting interface pockets, a
library of 10,000 compounds was docked into a pocket that is present in intermediates E,
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F and G (Figure 2.8), at the interface of TrxR and TrxC. Compounds with reasonable
drug-like appearance and properties (ex. adherence to Lipinski Rule of 5) are found that
fit into this pocket (Figure 2.12). Initial characterization of one of these compounds, by
titrating onto the TrxR/TrxC complex, has shown some cross-peak perturbations,
including the NH of interface residue W33. This result suggests feasibility of identifying
compounds that bind at the TrxR/TrxC interface. More in-depth studies are needed to
fully characterize the potential druggability of this binding site, by identifying and
characterizing multiple inhibitors and establishing structure-activity relationships for
binding at the TrxR/TrxC interface. These studies should include verification of binding
by multiple techniques (direct binding and enzyme activity measurements), as well as
MIC measurements, first in a model organism (ex. M. smegmatis) and ultimately in M.
tuberculosis. Such structure-based drug design efforts are enabled by the results we have
presented here, and are currently underway.
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Figure 2.12. (a) Result of docking into one of the intermediates in the thioredoxin
catalytic cycle, to demonstrate the presence of potential binding pockets at the Trx/TrxR
interface of sufficient size to accommodate potential inhibitors or drug leads. After
docking 10,000 compounds, the best scoring (lowest energy) docked structure (shown in
green, compound number CSDDD_6702) occupied a site at the interface of TrxR (red)
and TrxC (blue) in Panels A and B, with energy = -10 kcal/mol using AutoDock4. (b)
Expansion that shows the docking pose for CSDDD_6702. (c) Expansion showing the
crosspeak perturbations in a section of the 15N-1H HSQC upon addition of 200 µM of
compound CSDDD_6702 (blue) to a sample containing 200 µM TrxC, 250 µM TrxR,
and 0.80 mM NADPH (black). Interface residue W33(HE1) is represented by the
crosspeak at 10.2 ppm, which has been shifted upon binding CSDDD-6702.
In summary, we have determined high-resolution solution structures for both
redox states of TrxC from M. tuberculosis using NMR (backbone RMSD of 0.54 and
0.50 Å for TrxCox and TrxCred, respectively). The secondary structure and folding of the
oxidized and reduced states of TrxC are nearly identical, with only subtle changes around
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the active site cysteines, and with some changes in loop regions. In the presence of the
TrxR from M. tuberculosis, it appears that TrxC binds to TrxR only when TrxR has a
reduced disulfide and cofactor (NADP(H)) bound. This was demonstrated by the
disappearance of cross peaks for residues in the active site of TrxC, due to exchange
broadening. The lack of other chemical shift changes (or peak shape changes) suggests
that there are no significant structural changes to TrxC upon binding to TrxR. Using our
structures and chemical shift perturbation data, along with the previously reported TrxR
structure and structures for the thioredoxin system from E. coli44, we constructed
structural models for all the steps of the catalytic cycle of the M. tuberculosis thioredoxin
system (Figure 2.8). These structures, significantly different from the human thioredoxin
system, should facilitate future mechanistic studies of the M. tuberculosis thioredoxin
system, and aid in the design of inhibitors as potential drug leads. Indeed, initial analysis
of these structures have identified at least one potential binding pocket, which is distinct
from both substrate pockets, that could be pursued in structure-based drug design efforts.
Inhibitors of the M. tuberculosis thioredoxin system may serve as chemical probes to
study this pathogen’s ability to survive intracellular redox stress, in addition to providing
a new class of anti-mycobacterial agents.
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Chapter III. Solution Structures of Mycobacterium tuberculosis Thioredoxin A and B
3.1 Introduction

Further investigation into the structure of the thioredoxins (Trx’s) of
Mycobacterium tuberculosis (M. tuberculosis) build upon the previous chapter of this
thesis. The Trx’s are strikingly similar in primary amino acid sequence as seen by the
sequence alignment in Figure 3.1 and the resulting statistics in Table 3.1.

Figure 3.1. Amino acid sequence alignment of three thioredoxins, A, B, and C, from M.
tuberculosis. Sequence identity statistics are shown in Table 3.1. The conserved
thioredoxin motif (CXXC, shown in red) is observed for all three thioredoxins.
Table 3.1. Alignment statistics comparing the thioredoxins from M. tuberculosis. The
percent identity, or residues shown in the same sequence are shown. Percent homology
or area where similar amino acids are show in the alignment are in parenthesis. For
comparison, the statistics comparing the M. tuberculosis thioredoxins to Homo sapien
thioredoxin is also given.
TrxA
TrxB
TrxC

TrxA
--55% (71%)
33% (54%)

TrxB
----43% (60%)

Trx (H. sapien)
34% (58%)
35% (64%)
36% (61%)
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Since the three proteins are so similar, it is interesting to consider the evolutionary reason
the Mycobacteria would need three different thioredoxins. Considering that E. coli and
humans have a single thioredoxin while Arabidopsis thaliana has at least five48 has points
to the possibility that each thioredoxin has a specialized function.
Previous work12, showed that the three thioredoxins showed different redox
potentials with TrxA having the least redox potential. Additionally, an assay which used
TrxR to reduce the oxidized Trx’s was performed. While TrxB and TrxC were able to be
reduced by TrxR, no reaction was observed between TrxA and TrxR. The authors
postulated that the gene for TrxA could be cryptic and the protein would not be wellfolded.12

Table 3.2. Comparison of the redox potential and the Michaelis constant for the
reduction of the Trx by TrxR. Trx’s included TrxA, TrxB, TrxC and the E. coli Trx.
Adapted from Akif and coworkers.12
Redox Potential (mV)
Km (µM)
TrxA
-248
ND
TrxB
-262
2.65
TrxC
-269
2.05
Trx (H. sapien)
-233
2.8
To investigate the structures of these thioredoxins, we aim to calculate the
structures of TrxA and TrxB in oxidized and reduced states in order to compare them to
the published TrxC structures.49 Structural characterization of these proteins could lead
to insights into the evolutionary need for M. tuberculosis to have of these three similar
proteins.
3.2 Materials and Methods
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3.2.1. Protein Expression and Purification

The plasmids containing the Rv1470 gene (TrxA) in the pET22b vector and the
Rv1471 gene (TrxB) in the pET23a vector were obtained from Dr. Mande at the Center
for DNA Fingerprinting and Diagnostics in Hyderabad, India. Both expression constructs
produced protein with a C-terminal poly-histidine tag.

Figure 3.2. DNA sequence for the TrxA plasmid including C-terminal poly-histidine
tag.

Figure 3.3. DNA sequence for the TrxB plasmid including C-terminal poly-histidine tag.
Plasmids were transformed into BL21(DE3) from Invitrogen and grown in overnight
cultures at 37° C. These cultures were used to inoculate into 2 L of Luria Bertani (LB)
media supplemented. Cells were grown to an OD600 of 0.7 at which point the cells were
harvested and washed with M9 minimal media salts (pH 7.0). Cell pellets were
transferred to 0.5 L of M9 minimal media containing 6.4 g Na2HPO4, 1.5g KH2PO4, 0.5 g
NaCl, 1 mL 1 M MgSO4, 5 mL Basal Eagle Medium Vitamins (Sigma), 0.050 mL metal
mix, 0.5 g 15NH4Cl and 2.0 g of 13C-glucose as the only sources of nitrogen and carbon,
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to yield uniformly labeled protein.39 The cells were allowed to acclimate for 1 hour and
then induced with 1 mM IPTG for an additional 4 hours at 37° C, after which, the cells
were harvested. The bacterial pellet was resuspended in lysis buffer consisting of 50 mM
Tris base, 300 mM NaCl, 5 mM imidazole, and 10% glycerol at pH of 7.8, and lysed via
sonication. The lysate was clarified by centrifugation at 10,000 rpm for 30 minutes and
the supernatant loaded onto 1 mL of Ni-Sepharose Fast Flow resin (GE Heathcare). The
bound protein to the resin was then washed with lysate buffer, then with lysate buffer
spiked with 25 mM imidazole, and then eluted using lysate buffer containing 300 mM
imidazole. The eluted protein was than dialyzed with 50 mM potassium phosphate buffer
at pH of 6.3 (for NMR structure studies) and concentrated to 1 mM using Amicon Ultra-4
centrifugal device (Millipore) with protein concentration determined by the absorbance at
280 nm using extinction coefficients of 14,400 and 13,980 L/mol-cm for TrxA and TrxB
respectively.12 For studies of reduced protein, 5 mM DTT was added.

3.2.2. NMR Spectroscopy and Structure Calculation.

All NMR experiments were performed on a 600 MHz Varian NMR System at
599.515 MHz using a triple resonance cryoprobe with z-axis gradients at 25° C with the
exception of the HCCH TOCSY for TrxA which was performed at the Medical College
of Wisconsin on a Bruker 600 MHz instrument with triple resonance cyroprobe at 25° C.
Backbone assignments were obtained using 2D 1H-15N HSQC, and 3D HNCO,
HN(CA)CO, HNCA, HN(CO)CA, CBCA(CO)NH, and HNCACB spectra. Side chains
were assigned using CC(CO)NH, HBHA(CO)NH, HCC(CO)NH, and HCCH-TOCSY
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spectra. Distance restraints were obtained from 3-D 15N-NOESY, 13C aliphatic NOESY,
and 13C aromatic NOESY experiments, which were obtained using 150 ms mixing times.
Typical experimental parameters were as follows: sw1=6200, sw2=2700, ni=80, ni2=40.
Structures were calculated using these distance restraints with the program CYANA,2-4 in
conjunction with backbone phi and psi angle restraints as predicted from TALOS1 based
on chemical shifts of Cα, Cβ, Hα, Hβ, HN, and CO atoms. Initial structures were
obtained using the noeassign macro of CYANA.4 NMR spectra were processed using
NMRPipe41 and analyzed using NMRView42 and Sparky.43
Spectra to compare the 2D 1H-15N HSQC for oxidized and reduced forms of TrxA
were also obtained. For these studies, 1 mM protein was used for the oxidized protein. A
second 1H-15N HSQC spectrum was collected using 5 mM DTT to ensure the protein was
fully reduced.

3.3 Results and Discussion

An ensemble of solution structures for the oxidized form of TrxA were calculated
(Figure 3.4). This structure has 1535 NOE derived restraints, 170 angle restraints, and
92.5% of all hydrogen atom resonances assigned. The ensemble of 20 structures
calculated by Cyana produced an atom to atom root-mean-square difference (RMSD) of
1.08 Å. Additional statistics are seen in Table 3.3. Due to flexibility in the C-terminus,
amino acids 110-124 were seen as disordered in the models calculated by Cyana.2-4
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Figure 3.4. Ensemble of solution NMR structures of TrxA calculated using Cyana.2-4
Amino acids 110-124 were omitted for clarity as they appear to not be structured. The
ensemble for oxidized TrxA had a backbone RMSD of 1.08 Å. Panel B reflects a 90°
rotation of the protein from panel A.
Table 3.3. NMR constraints for the solution structure of oxidized form of TrxA.
NMR Distance and Dihedral Constraints
TrxA
distance constraints
total NOEs
intra-residue
inter-residue
sequential (|i-j|=1)
medium-range (|i-j|<4)
long-range (|i-j|>5)
dihedral angle constraints
φ
ψ

1535

806
308
421
85
85

To compare the calculated oxidized TrxA with the published oxidized TrxC (PDB
code 2L59)49, the median structures of the ensembles were overlaid. These structures
exhibited similar shapes and an atom-to-atom RMSD of 3.06 Å was calculated. Figure
3.5 shows these two structures overlaid for comparison. Comparing the active site of the
Trx’s, the cysteines for TrxA (C30) and TrxC (C37) lie on opposite sides of their
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respective helices. For TrxA, this could be due to the inclusion of a proline (P28) residue
preceding the active site. TrxA also lacks a well-conserved tryptophan immediately
preceding the active site. The tryptophan is replaced by a leucine residue. Thus why the
backbone shows general similarity between the Trx’s, there are important differences
near the active site.

Figure 3.5. The oxidized NMR solution structures of TrxA (blue) and TrxC (wheat,
PDB code 2L59)6 are shown, overlaid, below (A) with a backbone RMSD of 3.06 Å.
Based on the published TrxC-TrxR binding models6, the TrxR binds to the face of TrxC
including residues F32, A34, T35, W36, C37, T67 and V78. Based on sequence
alignment, the corresponding TrxA residues would be F25, A27, P28, L29, C30, T59, and
K70. B) Stick representation showing TrxC T35 and W36 with corresponding TrxA P28
and L29. Models, C) TrxA and D)TrxC, showing all important residues are shown below.
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Additionally, the three thioredoxins secondary structure can be compared. Figure 3.6
shows an alignment of the predicted secondary structure elements for the three proteins.
All three seem to fold similarly; each forms five helicies and five distinct regions for βsheets.

Figure 3.6. Comparison of Trx secondary structure elements from TALOS+1 backbone
angle prediction. The y-axis depicts a predicted order parameter (S2) value. Positive
values are regions predicted to be β-sheet regions and negative values are predicted to be
α-helicies. Trx’s are aligned such the amino acid sequence alignment from Figure 3.1 is
matched. Data for TrxB and TrxC were provided by Sheng Cai, Sarata Sahu, and
Andrew Olson.
Experiments are ongoing to calculate the oxidized form of TrxB as well as the
reduced forms of TrxA and TrxB. To that end, 1H-15N HSQC spectra were collected in
the absence, for oxidized protein, and presence, for reduced protein, of 5 mM DTT.
Figure 3.7 shows the overlay of these spectra. Addition of DTT perturbed the 1H-15N
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crosspeaks, likely causing some minor changes in the protein structure, similar to what
was observed for TrxC.49

Figure 3.7. 1H-15N HSQC spectra overlay comparing the oxidized (black) to reduced
(red) cross peaks for A) TrxA and B) TrxB. Spectra were collected using a 50 mM
phosphate buffer at pH 6.3. Spectra for reduced protein were collected
3.5 Conclusions

A structural model for TrxA has been observed for the first time. Contrary to
previous speculation12, TrxA is a well-folded protein with defined 3D structure.
Additional experiments will investigate TrxA’s ability to bind to TrxR from M.
tuberculosis. Progress has been reported on the development of structures for the
reduced form of TrxA as well as the oxidized and reduced forms of TrxB. The three
Trx’s appear to have similar overall 3D structures. Yet, there appears to be important
differences based on residues near the proteins’ active sites.
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Chapter IV. Dual Specificity Protein Phosphatase 5 Expression and Discovery of Small
Molecule Inhibitors Using Molecular Docking
4.1 Introduction

Dual-specificity phosphatase 5 (DUSP5) is part of a class of proteins that
dephosphorylate phospho-serine/threonine and phospho-tyrosine substrates (DSPs) on
proteins called mitogen-activated protein kinases (MAPKs).50 MAPKs are involved in
the mediation of cell signaling that is directly involved in diseases such as cancer,
diabetes, and autoimmune disorders.51-53 MAPKs are fully activated when the tyrosine
and threonine in their active loops are both phosphorylated. As such, DSPs counteract
activity and if over expressed or the activity of DSPs were to increase, the cell signaling
brought on by the activated MAP would cease. In effect, the phosphorylation state of
protein’s such as MAPKs acts as an on/off switch for the proteins signaling activity.
DUSP5 specifically dephosphrylates a MAPK called extracellular signal regulated kinase
(ERK). It has also been shown that over expression of DUSP5 suppresses the growth of
several types of human cancer cells, by “shutting off” ERK (i.e. dephosphorylation).50
There is also some interest in inhibition of DUSP5, which would lead to increased
levels of phosphorylated ERK (pERK), leading to angiogenesis (growth of blood
vessels). Inhibition of DUSP5 could, for example, be used to treat peripheral arterial
disease associated with diabetes and retinal diseases. Further, a DUSP5 mutation was
identified in patients with vascular anomalies, which implicate the importance of the
protein in human diseases.54
DUSP5 consists of two domains. The N-terminal domain (DUSP5EBD) functions
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as a regulatory domain, binding ERK. DUSP5EBD could function to properly position
ERK relative to the C-terminal phosphatase domain (DUPS5PD) to undergo
dephosophorylation.55 DUSP5 also contains a linker region of about 30 amino acids,
which connects these two domains and does not have a defined structure.54 A
representation is shown in Figure 4.1.
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Figure 4.1. A) Molecular model of DUSP5. This model was constructed using a
homology model for the DUSP5EBD based on the solution structure (21% identity and
35% homology) of the human MKP-3 protein [PDB:1HZM].56 The DUSP5PD is from
the crystal structure [PDB:2G6Z].55 The linker region connecting the two domains was
done manually. The ERK binding domain, DUSP5EBD, is shown at right connected via a
30 amino acid linker to the phosphatase domain (DUSP5PD). As yet the linker region is
not known to be structured. The S147P mutation present in patients with vascular
anamolies is shown in green. B) DUSP5 and ERK2 binding model. DUSP5 is
positioned similarly in respects to panel A with the EBD to the left and PD to the right.
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Here the linker region is modeled with the first 11 amino acids as being helical based on
predicted secondary structure.57-59 ERK2 [PDB:3I60] was positioned between DUSP5
domains.
Due to the importance of DUSP5 in vascular anomalies, it would be beneficial to
develop chemical probes that could help elucidate DUSP5 cellular function. To this end,
we have screened chemicals using docking techniques in search of inhibitors for the
DUSP5PD. To facilitate these studies, a phosphatase assay was developed for use with
DUSP5PD to test inhibition on potency for chemicals identified via docking and other
computational methods.

4.2 Materials and Methods

4.2.1 Molecular Docking and Rapid Overlay of Chemicals

The Center for Structure-based Drug Design and Development (CSD3) chemical
library consisting of 11,500 drug-like chemicals was prepared in electronic format as 2D
SDF files. Using Pipeline Pilot60, the protonation state of all compounds was adjusted to
reflect the most prevalent form at a pH of 7.4. CORINA61 was used to convert these files
to 3D PDB coordinate files, which resulted in low energy 3D structures. The files were
then processed with the python script prepare_ligand4.py, which comes with the
Autodock8 molecular modeling package. This script generates a pdbqt file, and adds
partial charges to the ligand, sets all torsions in the ligand to active (to permit rotation), as
well as merging all non-polar hydrogen atoms.
The DUSP5PD [PDB:2G6Z] was downloaded55 and prepared using the Autodock
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Tools Suite.8 Grid maps are used in the energy calculations performed by Autodock.
Partial charges were added and all non-polar hydrogen atoms were merged resulting in a
pdbqt file. The 13 different grid maps, one needed for each of the different atoms in the
chemical libraries (ex. C, H, F, Cl, etc.), were generated using Autogrid4. The grid box,
the site used to dock the ligands, was positioned to cover the entire protein in a blind
docking experiment.
The docking parameter file (dpf), which contains the parameters that Autodock4
uses to dock the ligand into the protein, was prepared using the python script
prepare_dpf4.py, and default docking parameters were used, except that 50 separate
docking calculations were performed with each calculation consisting of 1,750,000
energy evaluations and a root mean square deviation (rmsd) tolerance set to 2.0
angstroms (to define entry of structure into a given cluster). The dpf files were then
automatically docked using the MUGrid Cluster (Marquette University) with
HTCondor62, 63 and AutoDock4,8, 64 using the Lamarckian genetic algorithm local search
method to perform the optimization of docking poses. The docking results were then
clustered on the basis of the rmsd between the coordinates of the atoms in a given ligand,
and were ranked on the basis of calculated free energy of binding. The docking log files
were then analyzed using the python script summarize_results4.py contained in the shell
script sumresults_48, which rank orders all the dockings, by binding energy. The results
were then analyzed to find the best-clustered compounds with lowest free energy of
binding as determined by Autodock4.2. Additional docking of all experimentally tested
chemicals occurred as described above but with 100 dockings trials.
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As previously described, the CSD3 chemical library was electronically prepared
and protonation state adjusted using Pipeline Pilot.60 Using Openeye Scientific
Software’s Omega265, three dimensional coordinates were calculated and stored in
Openeye Scientific Software’s preferred file, .oeb.gz, for subsequent overlay evaluation.
Openeye Scientific Software’s Rapid Overlay of Chemical (ROCS) matches a chemical
query to a database of chemicals in search of hits. ROCS was used to rank-order hits
based on overlay and optimal matching of electrostatics and molecular shape. ROCS was
used to query against promising chemical hits from docking to identify related analogs.
In this way, we were able to prioritize a larger number of chemicals for subsequent
experimental screening.
The ZINC66 library of 13 million commercially available chemicals were obtained
as 2D SDF files and prepared similarly to the CSD3 chemical library for use with
Openeye Scientific Software’s ROCS. This further expanded the availability of chemical
analogs available for experimental screening.

4.2.2 Protein Production

The DUSP5PD gene was synthesized by Blue Heron (Bothell, WA) in both an
active, wild type (DUSP5PD-WT) form and inactive form, where the catalytic cysteine
was mutated to a serine residue (DUSP5PD-C263S). The genes were inserted into
Origene pEX plasmids with ampicillin resistance and N-terminal hexa-histidine tag for
protein purification. These plasmids were transformed in to BL21(DE3) cells
(Invitrogen) for expression.
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For unlabeled DUSP5PD-WT preparation, LB media was inoculated for an
overnight culture; which was subsequently used to inoculate 500 mL of LB media
supplemented with 50 µg/mL of ampicillin. Cells were grown at 37° C to an OD600 of
0.7 and then induced with 0.6 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). Cells
were harvested after 4h at 37° C then frozen before purification. Thawed cells were lysed
in a buffer containing 50 mM Tris, 300 mM NaCl, 5 mM imidzole, and 10% glycerol at
pH 7.8. Lysate was centrifuged at 10,000 g for 30 min. The supernatant was loaded on
to Ni-Sepharose Fast Flow resin (GE Healthcare) and washed with 5 column volumes of
lysis buffer and then with lysis buffer containing 25 mM imidazole. To elute the protein,
the lysis buffer was spiked with 300 mM imidazole. Protein was dialyzed in a buffer
containing 50 mM potassium phosphate and 2 mM dithiothreitol (DTT) at pH 6.8.
For 15N-labeled DUSP5PD-C263S preparation, LB media was inoculated for an
overnight culture, which was subsequently used to inoculate 2 L of LB media
supplemented with 50 µg/mL of ampicillin. Cells were grown to an OD600 of 0.7 at 37°
C , then harvested, and washed with M9 minimal media (pH 7.0).39 Cells were
resuspended in 500mL M9 minimal media containing 0.5 g 15NH4Cl, 2 g D-glucose, 5
mL Basal Vitamins Eagle Media (Sigma), 1.0 mL 1M MgSO4, and 0.5 mL 1 M CaCl2
(pH 7.2).39 Cells were allowed to acclimate for 30 min at 37° C, then induced with 1 mM
IPTG for an additional 4h at 37° C.

15

N-labeled protein was purified as described before.

NMR samples were prepared to observe the 1H-15N HSQC spectrum of
DUSP5PD. The 15N-labeled protein was concentrated using an Amicon Ultra-4
centrifugal device (Millipore) to 500 µM. NMR samples were prepared with the
following conditions: 250 µM DUSP5PD, 10% D2O, 5 mM DTT at pH 6.8.

60	
  
	
  
Additionally, to investigate small molecule binding, a second sample was prepared as
above with the addition of 250 µM inhibitor (RR505).

4.2.3 Assay Development and Chemical Screening

To assess enzymatic activity of DUSP5PD and the inhibitory capacity of selected
molecules, an in vitro phosphatase assay was developed based on previous work (Scheme
4.1).67 In this scheme, DUSP5PD will dephosphorylate the substrate p-nitrophenyl
phosphate (pNPP, Sigma Aldrich) yielding p-nitrophenol, which absorbs light at 405 nm.
Thus an increase in absorbance at 405 nm corresponds to the turnover of pNPP to pnitrophenol. The assay was initially tested in a cuvette, then was subsequently designed
for and validated in a 96-well plate format. IC50 values were obtained via a 96-well plate
assay.

Scheme 4.1. Chemical representation of the phosphatase assay. p-nitrophenolphosphate
(pNPP) is hydrolyzed by DUSP5 to form p-nitrophenolate, which absorbs light at 405 nm
and has a molar extinction coefficient of 18,000 M-1 cm-1.
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The assay buffer contained 100 mM Tris, 100 mM sodium chloride, 5mM
magnesium chloride, and 1mM dithiothreitol at pH 7.5. The substrate was prepared as a
50 mM stock by dissolving the solid substrate in assay buffer. The DUSP5PD and pNPP
were assayed initially in a cuvette (1 mL total volume) and initial velocities were fitted to
the Michaelis-Menten equation:
(1)
where v is the initial velocity, Vmax is the maximum velocity, Km is the Michaelis
constant, and [S] is the concentration of pNPP. Dimethyl sulfoxide (DMSO) was tested
as an enzyme effector using the above assay, but with additional aliquots of DMSO as
shown in Figure 4.7.
For the plate validation assay, sodium orthovanadate (Sigma Aldrich), a known
phosphatase inhibitor, was utilized as a positive control for inhibition,68 at a final
concentration of 10 µM in the assay. A high concentration of sodium orthovanadate was
used to completely block activity, ensuring full inhibition. Enzyme was stored at a
concentration of 2.5 mg/mL in a buffer containing 50 mM potassium phosphate and 2
mM DTT at pH 6.8. For the assay, a DUSP5PD stock was prepared as a 1/3 dilution of
the concentrated enzyme stock by adding the appropriate volume of assay buffer to an
aliquot of concentrated DUSP5PD. All plate assays were performed in standard 96-well
clear bottom plates (Nunc) with the total assay volume per well being 200 µL. A 0.83
mg/mL stock of DUSP5PD enzyme in a buffer containing 50 mM potassium phosphate
and 2 mM DTT at pH 6.8 was used.
The plate validation assay setup included replicate rows of positive control wells,
negative control wells and blank wells and is depicted in Figure 4.2. Rows 1, 4, 7 and 10
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contained only buffer and pNPP and were utilized as blanks. Rows 2, 5, 8 and 11
contained buffer, pNPP, and DUSP5PD, reflecting full (uninhibited) enzymatic activity.
Rows 3, 6, 9 and 12 contained buffer, pNPP, DUSP5PD, and 1 µM sodium
orthovanadate. The plate was then shaken and allowed to equilibrate in the
spectrophotometer at 25°C for 30 minutes. Post-incubation, 4 µL of enzyme stock was
dispensed into appropriate wells utilizing a single-channel pipette and reverse pipetting
technique. Errors in dispensing time were minimized by hanging the enzyme aliquot on
the side of each well, directly above the meniscus of the solution. The reaction was
initiated by gently tapping the plate on the bench top, causing the enzyme to fall into
solution and resulting in a uniform reaction start time. Before a read was taken, the plate
was again shaken for five seconds to ensure even distribution of enzyme throughout the
solution. The initial rate for the DUSP5PD reaction is linear for approximately 90 min;
and, the plate was kept in the spectrophotometer at 25° C for an additional 80 min after
the kinetic read. The endpoint reading was subsequently taken at 90 min after initiation.
Slopes from the kinetic read, as well as single-point absorbance values at the 90minute endpoint read, were then averaged. For blank wells and positive control wells,
both slope values and single point absorbance values were approximately zero, as a lack
of enzyme in blank wells and the presence of inhibitor in positive control wells resulted
in no enzymatic activity and therefore a lack of formation of p-nitrophenol. Standard
error was calculated and a Z’ value69 subsequently determined using the following
equation
(2)
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where σp is the standard deviation for the positive control, σn is the standard deviation for
the negative control, µp is the mean for the positive control, and µn is the mean for the
negative control. The Z’ value is a coefficient denoting the quality of a high throughput
screening assay, reflecting both the variation in data and signal dynamic range. A good
assay exhibits a high signal to background ratio. A Z-factor of 1.0 reflects an ideal assay.
For an assay to be considered reliable, the Z-factor must exceed 0.5.69

Figure 4.2. Plate setup for validation of the phosphatase assay to determine Z’ as
described by equation 2.
Upon validation of the high throughput screen, chemicals identified by docking,
ROCS, and through synthesis were tested and IC50 values were obtained. Six, eight, and
ten-point IC50 assays were performed. The maximum concentration screened in any plate
was 300 mM and the minimum concentration was1.5 µM. The IC50 plate was designed so
that the first row of wells served as a plate blank, with wells containing only buffer and
substrate. The second row of wells functioned as the plate positive control, with each well
containing buffer, substrate and enzyme. The remaining wells in the plate contained
buffer, substrate, enzyme, and varying amounts of inhibitor, with inhibitor concentration
increasing from left to right across the plate. Data points were collected in triplicate, and
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each set of three wells was approximately a one to three dilution of the concentration of
inhibitor in the previous set of wells. The composition of buffer and the concentrations of
substrate and enzyme utilized were identical to those in the plate validation assay and
similarly constructed with inhibitor aliquots added after the buffer but before the enzyme.
After initiation and shaking, a ten-minute kinetic read was immediately taken.
For each plate assayed, the slope values for all negative control wells were
averaged and the measured value considered representative of full enzymatic activity.
Fractional activity was then calculated by dividing the slope of each inhibitor well by this
value, determining the relative amount of enzyme activity observed at each concentration
of inhibitor. Values were then plotted as percent activity versus the log of the
concentration of inhibitor, and fitted using GraphPad Prism using the following equation
(3)
where Top and Bottom are plateaus in the experimental initial velocity (rate) uninhibited
and fully inhibited DUSP5PD, as fitted in GraphPad.70

4.2.4 Aggregation and Nephelometry

Nephelometry is a technique for measuring the relative aggregation of particles in
solution, based on the light-scattering properties of molecular aggregates.71 To explore
the ability of the chemicals studied herein to form aggregates which can lead to
artifactual inhibition effects, nephelometry was performed. Compounds listed in Table
4.2 were tested for aggregation in 96-well plates using a buffer containing 100 mM Tris
base, 100 mM sodium chloride, 5 mM magnesium chloride and 1 mM dithiothreitol at a
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pH of 7.5. Each compound analyzed in these experiments contained concentrations of
compound ranging from 10-100 µM and were recorded in quadruplet. Each plate was
analyzed at two separate gains, 52 and 72. Data were collected using a BMG
NEPHELOStar Plus, equipped with a 635 nm laser.

4.2.5. Cellular Assays

Inhibitors were also tested in human umbilical vein endothelial cells (HUVECs),
where pERK and ERK levels were quantified using antibodies. This particular assay
detects changes in pERK and ERK levels in cells. Sodium orthovanadate was used as a
positive control at 200 µM, and RR505, RR056, NTS, and suramin were tested at various
concentrations. This assay was performed in the Ramchandran lab at Medical College of
Wisconsin.

4.3 Results and Discussion

4.3.1. Docking

Docking of the in house collection of 11,500 chemicals produced a rank-ordered
list of chemicals that were tested using the phosphatase assay (discussed below). One
promising compound, SM1842 displayed attributes associated with lead-like chemicals.72
The docking pose from the lowest energy cluster, with calculated binding energy of -9.69
kcal/mol, is shown in Figure 4.3A. 1H NMR analysis of the SM1842 (Figure 4.4B)
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sample did not match the expected 1H NMR spectrum (Figure 4.4A) when compared to
the compound that was resynthesized by the Rathore lab at Marquette University. This
chemical, RR505 (Table 4.2) displayed the expected 1H NMR spectrum. Additional
synthesis of a tetra-sulfonated carbazole, RR506 (Table 4.2) and 1H NMR experiments
(Figure 4.4C) showed that the commercial SM1842 sample was likely a mixture of
RR505 and R506, the tri- and tetrasulfonated carbazoles. Further experimental analysis
focused on the single component pure samples, RR505 and RR506.

Figure 4.3. A) Predicted docking pose of SM1842/RR505 (gold) in DUSP5PD (blue)
using Autodock 4.2. The inset image shows predicted binding position relative to the rest
of the protein. The side chains around the bound ligand (mostly arginine guanido groups)
are delineated in light turquoise and the catalytic cysteine is displayed in yellow. Threearginine residues are observed around one sulfonate group of SM1842/RR505. The
predicted binding energy for this pose was -9.69 kcal/mol. B) Overlay of SM1842/RR505
(gold) and naphthalene trisulfonate (NTS, moss green) using OpenEye Scientific
Software ROCs v. 3.0.
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Figure 4.4. NMR analysis of commercial SM1842 and subsequent resynthesized
compound indicates that commercial SM1842 was a mixture of at least two compounds.
Proton NMR spectra for RR505 (A), SM1842 (B), and RR506 (C) are shown.
Experiments were performed by the Rathore lab.
Using the chemical structure of RR505 as a template, additional chemical libraries
were computationally searched to identify related structures that could also be tested.
One such compound, naphthalene trisulfonate (Table 4.2, NTS), was identified from the
in house collection of chemicals and from the ZINC collection66 of commercially
available chemicals. This compound was identified using Openeye Scientific Software’s
ROCS which matches chemical queries to compounds in chemical libraries based on
molecular shape and electrostatics. Figure 4.3B shows the overlay of RR505 and NTS
identified by ROCS.
RR506 and NTS docked similarly to SM1842/RR505 into the DUSP5PD active
site pocket. Figure 4.5 shows the predicted binding poses associated with each ligand for
the two lowest energy clusters. Interestingly, the lowest energy poses for NTS and
RR505 show a flipped binding mode relative to each other. One would speculate that
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since the ROCS alignment (Figure 4.3B) matched so well, the docking algorithm would
position the ligands similarly. While this is not the case for the lowest energy cluster, it
is the case for the second lowest energy cluster. Similarly, RR506 was flipped relative to
the lowest energy cluster pose of RR505. And again, the second lowest energy cluster
pose matched that of the lowest energy pose of RR505.
Drugbank73, 74, a chemical library containing structures of FDA approved drugs,
was also searched. By using ROCS to query against the RR505 and NTS structures,
suramin was found as a match to the NTS structure. Suramin (Table 4.2) is a
superstructure of NTS comprised of two NTS substructures connected with a rigid linker.
Suramin is an FDA approved drug that is used to treat African sleeping sickness.75
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Figure 4.5. A) Lowest energy binding pose as predicted by docking of NTS (moss
green) in DUSP5PD (blue) using Autodock 4.2. The predicted binding energy for this
pose was -8.48 kcal/mol. B) Second lowest energy binding pose for NTS (seafoam) as
predicted by docking using Autodock 4.2. The predicted binding energy for this pose
was -8.21 kcal/mol. C) Predicted docking of RR506 (pink) in DUSP5PD (blue) using
Autodock 4.2. The predicted binding energy for this pose was -9.89 kcal/mol. D) Second
lowest energy binding pose for RR506 (puce) as predicted by docking using Autodock
4.2. The predicted binding energy for this pose was -9.35 kcal/mol. The inset images
show the predicted binding position relative to the rest of the protein.
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4.3.2. Protein Production of DUSP5PD
Structural studies will be performed on DUSP5PD, to structure-based drug
design, and to perform NMR-based fragment assembly. To facilitate these NMR studies,
DUSP5PD-C263S expressed in E. coli in M9 minimal media (15N labeled), and purified.
Figure 4.6A shows the SDS-PAGE gel for the purification of DUSP5PD-C263S. This gel
is representative of the purification quality that was also obtained for DUSP5PD-WT for
activity assay studies. Figure 4.6B shows the 2D 1H-15N HSQC NMR spectrum for a
sample of the DUSP5PD-C263S protein. The spectrum’s crosspeaks, essentially
representing a single N-H bond in the amide backbone, show good chemical shift
dispersion, indicating suitability for further NMR structural characterization, as well as
NMR-based screening.
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Figure 4.6. DUSP5PD-C263S 15N-labeled protein production. The DUSP5PD construct
containing amino acids 178-320 (i.e. the phosphatase domain) was purified using it’s Nterminal hexa-histidine tag. A) SDS-PAGE gel of the DUSP5PD purification. Molecular
weights of standards (column 1) are shown at left in kDa. Lanes are delineated as
follows: 2-lysate, 3-flow through from nickel column, 4-first wash with 5 mM imidazole,
5,6, & 7-second wash with 30 mM imidazole, 8-elution with 300 mM imidazole, 9-1:10
dilution of lane 8. B) 1H-15N HSQC of 15N labeled DUSP5PD (250 µM, pH 6.3, 50 mM
potassium phosphate). C) Overlaid 1H-15N HSQC spectra of DUSP5PD: spectrum of 250
µM DUSP5PDin the absence (black) and presence (red) of 250 µM RR505 (trisulfonated
carbazole contained in SM1842). Note the visibility of a black crosspeaks, which
indicates there was shifting or broadening of a red crosspeak due to binding; several
black crosspeaks are visible, indicating that RR505 binds to DUSP5PD.
4.3.3. Phosphatase assay

To assess the ability of the chemicals identified via docking to inhibit DUSP5
activity, a phosphatase assay was developed based on previously published assays.67, 68, 76
The substrate, p-nitrophenolphosphate (pNPP), has been shown to react with a wide

72	
  
	
  
variety of phosphatases. Scheme 4.1 shows the assay reaction scheme used in the
DUSP5PD phosphatase assay.
As a proof of concept, the assay was performed in a cuvette as described
previously. The experimental data were fitted to the Michalelis-Menten equation (Figure
4.7A) and resulted in a Vmax of 1.35 ± 0.02 x 10-3 (µmol/min) and a Km of 7.63 ± 0.45
mM. Since some of the inhibitors to be screened will be dissolved in DMSO, the effect
of 1%, 2%, and 4% DMSO was investigated by substituting appropriate quantities of
DMSO for some of the buffer mixture. Relative rates with and without DMSO were
compared and plotted in Figure 4.7B. DMSO appears to activate the DUSP5PD reaction.
Thus, assays done on compounds dissolved in DMSO must be done such that DMSO
concentration is kept constant.
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Figure 4.7. A) Michaelis-Menten kinetics (equation 1) for the phosphatase assay
represented in Scheme 1. B) Effect of dimethyl sulfoxide (DMSO) on reaction kinetics.
DMSO acts as an activator. Experiments were performed in the Sem lab by Kelsey
Kalous and Elise Span.
To show this DUSP5PD assay can detect inhibition, the assay was performed with
the addition of a known broad-spectrum inhibitor of phosphatases, sodium orthovanadate
(vanadate).68 Initial experiments were performed in a cuvette and concentrations of
vanadate were varied. Slopes from a kinetic read were plotted as a function of the log of
vanadate concentration and fitted to equation 3 to find the IC50. Figure 4.8 shows this
plot with vanadate having a fitted IC50 of 88 ± 8 nM.
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Figure 4.8. Inhibition assay validation using sodium orthovanadate as a positive control
for enzyme inhibition. Data were fitted to equation 3, and in the absence of Triton X-100
the IC50 was 88 ± 8 nM. Experiments were performed by Kelsey Kalous and Elise Span
in the Sem lab.
This assay was also performed in a plate format to increase throughput by which
inhibitors could be screened. To validate this setup, the Z’ factor69 was determined using
the plate arrangement in Figure 4.2, and described as above. The absorbances for the
end-point assay and the slopes for the kinetic assay were averaged and Z’ was calculated
using equation 2. Both the end point assay (Z’ = 0.73) and the kinetic assay (Z’ = 0.74)
formats resulted in Z’ factors in the acceptable range for an HTS assay. Table 4.1
summarizes the plate validation.
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Table 4.1. Validation of the phosphatase assay by Z’ determination. Means and standard
deviations for the positive and negative controls were obtained and used to determine Z’
as in equation 2. Assays were performed in two ways: A) An end-point assay with
absorbances collected after 90 min yielded a Z’ of 0.73. B) A kinetic assay measuring
slopes over 5 min yielded a Z’ of 0.74. Experiments were performed in the Sem lab by
Kelsey Kalous and Elise Span.
A) End-point assay after 90 min
Positive control
Negative control
Mean
0.006
0.269
Standard deviation
0.004
0.02
B) Kinetic assay over 5 min
Mean
Standard deviation

Positive control
-0.035
0.091

Negative control
3.28
0.193

Chemicals identified by docking and ROCS overlays were tested using the plate
assay validated above by measuring slopes over 5 min. Slopes were plotted (Figure 4.9)
and the fitted to equation 3 to determine the IC50’s, and reported in Table 4.2. Note that
SM1842 is a mixture of two components, likely RR505 and RR506. Triton X-100 was
used in this assay (0.1%) to break up aggregates that could be formed by the small
molecules. This aggregation phenomenon is studied in depth later.
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Table 4.2. Docking and kinetic phosphatase inhibition assay results for chemicals
investigated in this study. The kinetic phosphatase assay was enzyme initiated and
absorbances were measured over 5 min. To limit aggregation, experiments were
performed in the presence of 0.1% Triton X-100. Assay experiments were by the Elise
Span and Kelsey Kalous.
Lowest
Kinetic
Predicted
Phosphatase
Chemical
Binding
Assay IC50
Energy
(kcal/mol)
SM1842
-9.69
5.1 ± 1.9 mM

-9.69

26 ± 3 mM

-9.89

16 ± 2 mM

-8.48

6.4 ± 0.8mM*

RR505

RR506

Napthalene trisulfonate (NTS)
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NA

Suramin
*Obtained in absence of Triton X-100.

44 ± 6 µM
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Figure 4.9. Graphical representation of chemical screening for the kinetic phosphatase
assay. IC50 values were obtained by fitting data to equation 3. The kinetic phosphatase
assay was enzyme initiated and absorbances measured over 5 min. To limit aggregation,
experiments occurred in the presence of 0.1% Triton X-100. A) Plots for suramin,
RR505, RR506, and SM1842, a mixture of RR505 and RR506, are shown. B) Plot
comparing the inhibition of suramin and naphthalene trisulfonate (NTS) in the absence of
Triton X-100. Experiments were performed in the Sem lab by Kelsey Kalous and Elise
Span.
Suramin displayed the best inhibition profile in the phoshpatase assay. But,
literature on suramin75, 77, 78 shows that suramin can bind to many protein targets, so it
could be binding non-specifically to DUSP5PD. To further investigate, a competitive
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inhibition profile of suramin was measure by fitting the Micaelis-Menten kinetic model
(equation 4) to assays with varying concentrations of suramin (Figure 4.10). Equation 4
is as follows
(4) v =

Vmax [S]
" [I] %
$1+ ' + [S]
# Ki &

€ initial velocity, Vmax is the maximum velocity, Km is the Michaelis
where v is the
€

constant, and [S] is the concentration of pNPP.The data fit cleanly to the equation for
competitive inhibition, with a Ki of 24.6 ± 5.2 µM, suggesting that inhibition was
occurring via specific blockage of the phosphatase active site (suramin competes for
pNPP binding in the phosphatase active site).

Figure 4.10. Competitive inhibition profile of suramin. Fitting data to equation 4
resulted in a Km of 6.4 ± 0.8 mM, Ki of 24.6 ± 5.2 µM, and Vmax of 0.00124 ± 0.00004
µmol/min. Results were obtained in the absence of Triton X-100. Experiments were
performed in the Sem lab by Kelsey Kalous and Elise Span.
It is possible that suramin in addition to specific inhibition, inhibits DUSP5PD
aggregating in solution, leading to non-specific binding from these aggregates. Triton X-
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100 is a detergent that is able to break up aggregates, while not significantly interfering
with the assay.79 NTS and suramin were compared under identical conditions in the
absence and presence of this detergent. Figure 4.11 shows the results of these
experiments. Suramin inhibition is decreased while NTS is not, indicating that at least
some of suramin’s inhibition is due to aggregation.

Figure 4.11. Triton X-100 effects on NTS and suramin inhibition of DUSP5PD enzyme
activity. A) Kinetic assay inhibition results for NTS in the absence (16.0 mM ± 3.4 mM)
and presence (14.0 mM ± 2.5 mM) of Triton X-100, indicating NTS does not inhibit via
aggregation. B) Kinetic assay inhibition results for suramin in the absence (7.6 µM ± 2.9
µM) and presence (212 µM ± 83 µM) of Triton X-100, suggesting that at least some of
the suramin inhibition is due to aggregation effects (of either suramin, or of DUSP5PD).
C) Effect of Triton X-100 on reaction kinetics based on relative activity in the presenceof
suramin inhibitor, at 100 µM. Triton X-100 acts as a detergent, breaking up aggregates.
Experiments were performed in the Sem lab by Kelsey Kalous and Elise Span.
Further investigation into the potential aggregating effects of suramin, were
performed using nephelometry. When an inflection occurs in the Relative Nephelometry
Units as a function of concentration, this indicates that the particle size in solution starts
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to increase, due to aggregating effects. RR505, RR506, NTS, and suramin were
subjected to the nephelometry (Figure 4.12). Suramin appears to start forming aggregates
around 25 µM, while RR505, RR506 and NTS do not seem to form similar aggregates.
This is consistent with the Triton X-100 studies that suggest that suramin inhibition is at
least partially due to aggregation effects.
The above-mentioned competitive inhibition versus pNPP binding suggests that –
while suramin may aggregate – it can also competitively block the phosphatase active
site, and apparently with higher affinity than NTS. Since suramin is effectively a tethered
NTS, one can ask whether there is an additional NTS binding site outside of the
phosphatase active site pocket, that results in higher affinity for the bivalent (tethered)
NTS. But, structural analysis suggests that suramin is unlikely to bind both NTS
substructures to the same DUSP5PD protein, since there are not two potential NTS
pockets within adequate proximity. In Figure 4.13, all 100 docking poses of NTS are
displayed on an electrostatically colored map of DUSP5PD, indicating that there are only
three general areas in which the NTS is predicted to bind. The main secondary pocket is
31 Å, while another secondary pocket that is 11 Å away lacks any density of positively
charged sidechains, as would be expected for binding the negatively-charged NTS. The
distance between the two NTS substructures in suramin is 8Å and the linker is
sufficiently rigid as to prevent optimal alignment for binding both NTS substructures to
the active site, and either of these potential secondary pockets. Thus, if the two NTS
molecules contained in suramin are both binding to DUSP5PD pockets, it can only be via
two separate DUSP5PD molecules, as in a protein dimer or in a DUSP5PD aggregate.
The latter possibility would be consistent with the observed ability of suramin to cause
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aggregation of DUSP5PD (in NMR HSQC titrations). The former possibility is consistent
with literature reports that DUSP5 forms dimers.80 Future studies will be directed to
distinguishing these possibilities; but, it is clear that the suramin inhibition mechanism is
complex, and includes a combination of aggregation (of suramin and of DUSP5PD) as
well as direct blockage of the phosphatase active site.

Figure 4.12. Nephelometry of various DUSP5PD inhibitors. Aggregating compounds
are identified based on an inflection in the Relative Nephelometry unit versus compound
concentration (i.e. data is best fit by two lines). The intersection of these lines shows the
concentration at which the compound begins to form aggregates. Two gain values were
used, to observe trends that might have been masked by detector saturation. A)
Nephelometry of chemicals using a gain of 52. Only suramin produced aggregates above
25 µM. B) Nephelometry of chemicals using a gain of 92. Only suramin, again,
produced aggregates above 25 µM. Experiments were performed in the Sem lab by
Kelsey Kalous, Elise Span and Rachel Lange.
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Figure 4.13. Binding site location prediction for 100 dockings of NTS mapped onto an
electrostatic surface of DUSP5PD. Poses were observed in three clusters. Clusters are
observed at distances that suggest binding of suramin so that both NTS substructures
would fit into defined binding pockets on the same DUSP5PD protein molecule seems
unlikely.
4.3.4. HUVEC Cellular Assay
An assay to detect pERK levels in HUVEC cells was performed by the
Ramchandran lab. In this assay, chemicals were tested to see if they would affect the
levels of pERK (Figures 4.14 and 4.15). Interestingly, suramin showed that it lowered
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pERK levels at 50 and 100 µM concentrations. Likely, this is due to suramin being able
to target multiple steps in the VEGF pathway.81 As expected, vanadate, used as a positive
control in the phosphatase assay, shows an increased level of pERK in the HUVEC cells.
Likely, this is due to vanadate being able to inhibit the DUSP5 phosphatase activity.
SM1842, RR505, and RR506 show no effect at 100 µ, consistent with their high IC50
values.

Figure 4.14. Chemical modulation of pERK levels in HUVEC cells from suramin (A),
SM1842 (B), RR505 (C), and RR506 (D). Suramin had the greatest effect on pERK but
resulted in decreased levels. 200 µM Na3VO4 was used as a positive control.
Experiments were preformed by the Ramachandran lab.
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Figure 4.15. Chemical modulation of pERK levels in HUVEC cells from suramin,
SM1842, RR505, and RR506 correlating to the relative activity in Figure 4.14. Suramin
had the greatest effect on pERK levels. 200 µM Na3VO4 was used as a positive control.
Experiments were preformed by the Ramachandran lab.
4.5 Conclusion

Docking studies and the development of a DUSP5 phosphatase assay have
facilitated the identification and characterization of inhibitors of DUSP5PD. The assay
developed herein is suitable for HTS, with a Z’ value > 0.7. Our initial studies of
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compounds identified by docking and subsequent enzymatic inhibition have identified
weak poly-sulfonated inhibitors that could be used as scaffolds off of which more potent
lead molecules could be developed by rational drug design or by fragment-based drug
design techniques, if proximal binding pockets can be identified.82, 83 We have also
employed a novel approach, to transition from an initial lead molecule (SM1842/RR505)
to an advanced clinical candidate, by screening for FDA approved compounds that match
the shape and electronic properties of a lead molecule, by using ROCS. In this manner,
suramin, a drug used to treat African sleeping sickness, was identified. While initially
promising, suramin does not exhibit properties of a good drug lead molecule.
HUVEC cellular assays do not show biologically useful levels of potency for the
sulfonated inhibitors RR505 and RR506 consistent with enzyme inhibition with IC50’s in
the mM range. HUVEC studies with suramin show an effect in cells (decreased pERK
levels) that is opposite to that which was expected, probably due to its binding to other
protein(s) in the VEGF pathway other than DUSP5. Control inhibition with vanadate
gave the expected increase in pERK levels due to DUSP5 inhibition.
Based on DUSP5PD assays performed with and without detergent, along with
nephelometry studies, we conclude that, suramin forms aggregates in vitro, which can
lead to non-specific protein inhibition effects. This raises more global concerns regarding
the current clinical use of suramin, and may in part explain some of the known toxicity
associated with suramin.84
Competitive inhibition studies do indicate that suramin (i.e. the NTS group of
suramin) can bind in the phosphatase active site and – importantly - that the linker
attached to NTS, in making suramin, does not disrupt binding to the NTS fragment. Thus,
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future studies could be directed toward using NTS with a linker attachment like that in
suramin, but with different chemical composition in the linker, and tethered to a different
fragment (NTS-(linker)-(new fragment)), such that inhibition occurs without any
aggregation artifacts. This new fragment will be identified using NMR fragment-based
screening methods, which are now possible since we have obtained high quality 2D 1H15N HSQC spectra. Such methods will be used to design analogs of our initial
sulfonated lead molecules, NTS, RR505, and R506.
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Chapter V. Design of a Fragment Based Drug Design Library Considering Toxicity,
Druglikeness, and Synthetic Access
5.1 Introduction

Drug discovery is a long, expensive, and ever-changing endeavor. Discovery of
new chemical entities (NCE) can take upwards of 12 years and cost in excess of $1.4
billion to move a chemical from discovery through clinical trials to approval.85 Recently,
the number of drugs advancing through the Food and Drug Administration (FDA)
approval process has even decreased.86 Some studies suggest that increased safe1ty
concerns arising from drug candidates are the cause of the depressed NCE success rate.87,
88

Also, many drugs (ex. Vioxx)89 have been removed from the market post-approval,

due to safety concerns that only become apparent in larger populations.90 Thus, it is
increasingly important to produce safe, high quality drug leads, such that safety concerns
can be minimized earlier in the drug discovery and development process.
Traditionally, novel drugs were discovered by screening for activity in biological
assays. Protein crystallography91 and NMR experiments92 have afforded structural views
of drug targets alone or in complexes, to facilitate structure-based drug design. With the
advent of increasingly powerful computers, it has become easier to investigate
relationships between molecules and their biological activities through Quantitative
Structure-Activity/Property Relationships (QSAR/QSPR)93, similarity/dissimilarity
measures94, varying drug-like measures95, and virtual screening.96 These techniques have
formed a basis for structure-based drug design.
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5.2 Fragment Based Drug Design

Over a decade ago, methods were developed to merge traditional assays with
rational drug design techniques through the use of NMR spectroscopy, by using NMR
screening to identify proximal binding chemical fragments.97, 98 This approach, termed
fragment based drug design (FBDD), was developed to quickly screen libraries of
chemicals that are typically only low molecular weight (MW) molecules or functional
groups, to find weak interacting ligands for a protein target.99, 100 These fragments can be
linked and/or chemically modified, to convert them into higher affinity drug leads (ie.
protein inhibitors).101 The fragments that are screened are carefully chosen to be “druglike” and are inspired by existing drug chemical substructures.102 Fragment screening has
evolved to include X-ray crystallography detection and optimization of fragment leads.103
Other techniques, such as surface plasmon resonance, have been utilized for the detection
of protein-fragment binding.104
A recent example of a successful drug lead being derived from a FBDD project
and being developed into a clinical candidate is the Bcl-Xl inhibitor designed by Petros,
et al.105 Bcl-Xl is a protein in the B-cell lymphoma family of proteins that plays a role in
apoptosis, or programmed cell death. An overexpression of Bcl-Xl can lead to cancer in
some tissues and can play a role in drug resistance for certain cancers. To design an
inhibitor for this protein, the investigators, using a NMR screen, screened Abbott
Laboratories’ 10,000 chemical fragment library, which produced a weak binding fluoro
biaryl acid hit (Figure 5.1) with a Kd of 300 µM. Further NMR experiments and
structure comparison of the Bcl-Xl complexed with the native ligand and the fluoro biaryl
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acid hit indicated there was a second site binding pocket, proximal to the site the fluoro
biaryl acid binding site. A second site NMR screen was performed using a 3500
chemical library in the presence of an excess of the fluoro biaryl acid. This NMR screen
produced hits that bound more weakly than the first site hits, with Kd’s in the millimolar
range, and contained napthol and biaryl phenol analogues. After structurally
characterizing the binding sites to help guide linking of the two fragments, a trans-olefin
linker was designed to link the fluoro biaryl acid and biphenyl together. This bi-fragment
compound then bound to Bcl-Xl much more tightly, with a Kd of 0.714 (Ki 1.4 ± 0.4 µM).
That is, tethering the two fragments produced a 200-fold better inhibitor than the fluoro
biaryl acid alone. Parallel synthesis and adjustments to make the inhibitor more soluble
and bound less tightly to human serum albumin, to improve bioavailability, yielded a lead
with a Kd of 28 µM (Ki of 36 ± 2 nM).105 This lead was further developed into ABT-737
with a Ki < 1 nM.106 ABT-737 represents one of many examples of drugs in clinical trials
that have been developed, at least in part, using FBDD methods.

91	
  
	
  

A)

B)

C)
Figure 5.1. A) Chemical fragment identified from a 10,000 compound library using an
NMR screen against the protein Bcl-XL. This chemical fragment was determined to bind
to the protein with a Kd of 300 µM. B) Chemical fragment identified from a 3500
compound library using a second site NMR screen (excess of fragment A). This
chemical fragment had a Kd of 6000 ± 2000 µM. C) Drug lead after linking fragments A
and B together, giving a Kd of 28 µM (Ki of 1.4 ± 0.2 µM).
FBDD has evolved into a widely-used technique in the drug design toolbox. As
of 2006, 23 companies used fragment screening as a portion of their drug discovery
efforts.107 Abbott Laboratories alone h108 as developed 14 potent inhibitors (IC50 < 100
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nM) for various protein targets.107 The Bcl-Xl inhibitor mentioned above, ABT-737, is
currently in Phase II clinical trials for treatment of ovarian tumors.106, 109 Astex
Therapeutics has an Aurora kinase inhibitor, AT9283110, and Cyclin-dependent kinase
inhibitor, AT7519, in Phase II for treatment of multiple myeloma.109 More than 49 potent
inhibitors from13 different institutions have been developed using FBDD principles.107
Although there are as yet no approved drugs that were discovered using FBDD
methods, it is likely only a matter of time before this next milestone of success will be
reached – presuming the existing drugs in the clinical pipeline do not fail because of lack
of efficacy, bioavailability, or toxicity. As is the case in any drug discovery and
development project, potential for toxicity and adverse effects remains a concern not only
throughout clinical trials, but even after approval. Thus, it is always germane to ask
whether enough precautions have been taken to minimize the potential for toxicity, as
early as possible in the drug discovery and development process. Ideally, a minimization
of the potential for toxicity would be designed into the process itself; this could be
viewed as safety-by-design (SbD), by analogy to the widely used quality-by-design
(QbD) concepts that are revolutionizing drug development procedures.

5.3 Toxicological Considerations in Drug Discovery

Toxicity is among the leading causes of attrition during later stages of drug
discovery and development.111 To improve the efficiency of advancing drug leads and
clinical candidates, drug discovery programs have increased the usage of toxicological
studies throughout the drug discovery process, even earlier in the process in order to drop
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potentially problematic compounds before they enter costly clinical trials.112 Limiting the
effectiveness of these earlier studies are a number of factors. For example, in vivo studies
require large quantities of compound. In vitro assays, such as the Ames’ test, can be
unreliable, and the time and resource commitment to such studies can be significant.113
Accordingly, such studies cannot, in a practical sense, be applied to large numbers of hits
and preclinical leads. In silico tools such as TOPKAT with models constructed based on
animal and human data, relate chemical structure to biological end points.114, 115 This
allows toxicity screening of large numbers of chemicals to be done quickly,
inexpensively, and before time is committed in synthesizing and characterizing a
potentially toxic chemical.116 For example, such in silico screens are routinely done on
contaminants that are found in APIs (active pharmaceutical ingredients), and these
flagged compounds are then submitted for AMES testing. In general, these methods are
ligand-based, because they rely on comparisons to other small molecules, correlating
structures with potential for adverse effects.
Protein target-based methods can also be used to predict adverse effects or drug-drug
interactions, by computationally predicting which drugs might bind to an anti-target
protein, or to certain cytochromes P450 (CYP450s). In the latter case, the drug candidate
can either be metabolized by the CYP450, or can inhibit it and potentially produce drugdrug interactions with other drugs that are metabolized by the CYP450 that is inhibited.
To this end, we have recently used docking and neural network methods to score large
numbers of molecules (>4000) for their likelihood of binding to CYP2D6, which would
lead to poor ADME properties and/or drug-drug interactions.117, 118 These cheminformatic
methods for predicting toxicological problems have been useful, but have not yet been
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widely applied to the design of fragment libraries. Use of such techniques in the design of
fragment libraries would decrease the likelihood of potential adverse effects, poor ADME
properties, and toxicity in drugs developed using fragment assembly methods. Better
integration and deployment of such in silico techniques, earlier in the discovery and
development process, is essential to the successful implementation of a SbD strategy.

5.4 Library Design Considerations

5.4.1 Traditional Considerations in Designing a Fragment Library

Choosing what chemicals to put into a fragment library presents unique
challenges. Typically, fragment libraries have been developed based on scaffolds or
collections of heterocyclic of rings with the acyclic atomic arrays stripped away.119 In an
attempt to address potential toxicological or bioavailability problems of library
fragments, albeit indirectly, ring combinations and functional groups are typically chosen
based on known drugs.99 Since FBDD has become a powerful and widely used
technique, there has been significant work performed by our lab and others in designing
such fragment libraries.82, 98, 101, 107, 120-125 Fragment libraries range in size from 100 to
over 1,000 chemical structures, and can be designed using various criteria. Since there
has been so much work done, only an overview will be presented herein. The chemical
logic used to design a fragment library is typically based on a systematic analysis of
existing drugs. This type of analysis, calculating properties for large collections of
chemical structures, is the focus of the cheminformatics field.126
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One widely used set of criteria used in design of fragment libraries is the “Rule of
3.” The “Rule of 3” methodology has been proposed, as a variation on “Lipinski’s Rule
of 5,” to increase the likelihood that a fragment will be bioavailable and therefore leadlike.95, 101 The Rule of 3 requires the following conditions.
Molecular Weight < 300 Da.
Number of hydrogen-bond donors ≤ 3
Number of hydrogen-bond acceptors ≤ 3
The “Rule of 3” is really just a trimming of the “Rule of 5”, to accommodate the fact that
final drug leads will only result from the chemical tethering of two fragments, so that the
tethered molecule will satisfy the Rule of 5.” A drug lead is defined as a chemical that
has been shown to inhibit its protein target, has had multiple analogs synthesized and
tested to improve potency, and is likely to be “bioavailable” (ex. cross the intestinal
mucosa and make it into the circulatory system).127
To minimize false-positive hits in high throughput screens for protein inhibitors, it
is necessary to also filter for and remove chemicals (ex. electrophiles)128 that could react
covalently and nonspecifically with proteins. So, another set of criteria used in the design
of a drug fragment library is used to identify and eliminate chemicals that contain
functional groups or reactive regions that are likely to bind to proteins covalently.
Covalent bonding, for example due to a Michael reaction with a protein electrophile, is
less specific for the desired protein target, so could lead to toxic side-effects.128 Other
reactive groups including anhydrides, epoxides, alkyl halides, acyl halides, imines,
aldehydes, or aliphatic ketones are also groups that can covalently link ligands containing
these funcational groups to proteins. Table 5.1 shows examples of these functional
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groups. The above-described methods of filtering compounds that go into a chemical
library are used routinely, and were also used in the library described herein.

Table 5.1. Examples of functional groups that could covalently bind or nonspecifically
bind to protein targets. Chemicals containing these fuctional groups were not considered
for addition to the fragment library.
Functional Group
Example
Michael acceptor

Acid anhydride

Epoxide

Alkyl halide

Acyl halide

Imine

Aldehyde
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Aliphatic ketone

Ester

5.4.2 Framework Frequency Analysis in Drug and Toxic Chemical Libraries

Just as certain chemical fragments appear more frequently in drugs (and are
therefore called “druglike”), some fragments may also occur more frequently in toxic and
carcinogenic compounds. So, just as one can enrich a fragment library with fragments
found to be present frequently in drugs, one can attempt to avoid fragments that appear
frequently in chemicals known to cause adverse effects. This is a strategy to design
potential for drug safety, earlier into the process. Any such innovation in design of a
fragment library should consider and build upon past previous research and successes,
such as the fragment libraries prepared at Abbott and Vertex.
Chemical libraries were computationally screened to determine how many
chemical structures were present that contained frameworks from the Abbott structureactivity relationship (SAR) by NMR129 and the Vertex SHAPES frameworks98 libraries,
to quantify the relative population of each framework in a given library. The Abbott and
Vertex libraries are considered high-quality and validated fragment libraries, which have
resulted in drugs that have entered clinical trials. The library presented herein builds
upon these and extends these, adding considerations of potential toxicity. Also considered
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was synthetic accessibility, in terms of ability to chemically tether fragments into bifragment drug leads. This comparative analysis of frameworks was done to investigate
whether a library contained larger percentages of any particular framework. For
example, enrichment of a framework in a library, where that framework is associated
with chemical carcinogenesis (ex. Ames positive) is cause for concern. A range of
chemical libraries (in addition to the Abbott and Vertex libraries) were screened
computationally, in this manner, to determine which fragments are more associated with
drug-like behavior, and which with potential for toxicity. Computational screening for
scaffolds (chemical motifs) using Pipeline Pilot software was performed of libraries of
known drugs73, 74, 130-134 and “toxic chemical” libraries: libraries that contain chemicals
that tested positive for mutagenicity in the Ames test135, toxic compounds listed in
DSSTox library136, and the Carcinogenic Potency Database (CPDB).137, 138 The
DrugBank database contains detailed information of the Food and Drug Administration
(FDA) approved small molecule theraputics. The Physicians’ Desk Reference (PDR) is a
collection of information provided by manufacturers regarding the prescribing
information. The top 200 drug collection captures the therapeutics that lead the
pharmaceutical industry in sales during 2008. The Ames dataset was derived from a set
of 4337 chemicals of which 2401 were identified as mutagens by an Ames test. The
DSSTox library contains environmental chemicals and drugs tested by various cellular
and biochemical assays under the United States Tox21 Initiative. The CPDB database is
the results from 6540 long term animal cancer tests of 1547 chemicals. Any framework
that showed up at a higher frequency in the drug libraries versus the “toxic chemical”
libraries (ex. carcinogens), was viewed as a potentially safer starting molecule for a drug
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design project. Likewise, frameworks appearing at a higher relative frequency in the
“toxic chemical libraries” compared to those of the “drug libraries” could be considered
more harmful, and we would therefore avoid including them in a fragment library. This
strategy of biasing a library of fragments away from fragments known to be associated
with toxic effects, is central to the concept of safety by design (SbD) in building fragment
libraries.

5.4.3 Molecular Diversity in Chemical Library Design

The above design constraints still allow for an overwhelming number of
possibilities in terms of chemicals that could go into a fragment library. How does one
decide which chemicals should go into the library, to produce a library of manageable
size? The decision as to which fragments to actually include can be further limited by
choosing to include the subset of possible fragments that are as different or as diverse as
possible.139, 140 There is obviously greater value in screening a library of 1,000 very
different chemical structure, that of nearly identical chemical motifs that represent
marginal variations. This chemical diversity is, of course, hard to quantify. One method
of viewing the diversity of the library is to compare it to another library, using principal
component-based measures of diversity, where those principal components are comprised
of calculated chemical properties (see below). An extremely diverse virtual library (i.e.
built only on a computer) has recently been reported. This library, termed the Generated
Database (GDB), is comprised of 26.4 million structures containing all possible
compounds comprised of 11 atoms that include the following atom types: carbon,
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nitrogen, oxygen, or fluorine. The goal of this library was to have all possible structures
of fragments in a single library, in an attempt to completely cover what could be called
“chemical fragment space”; chemical structures are represented as points in that space,
with axes defined by principal components that are themselves linear combinations of
molecular properties that are calculated for each molecule. While this is not a perfect
description of the possible chemical diversity for fragments, due to the absence of other
atom types that occur in drugs (ex. chlorine, bromine, sulfur, etc), it does provide a
description of chemical diversity, against which an actual fragment library can be
compared, to assess its “chemical diversity”.140 The principal component axes that
disperse these 26.4 million compounds most effectively can also be used to quantify and
visualize the diversity of actual fragment libraries that are being planned.
While developing this collection, the investigators used a principal component
model consisting of the descriptors that are used in the “Rule of 3” filter, including
molecular weight, logP, number of hydrogen bond donors and acceptors, molecular polar
surface area, and the number of rotatable bonds123, to describe the chemical space of this
collection.140 A principal component (PC) analysis reduces a complex data set to a lower
dimension, in this case reducing six parameters (the Lipinski properties) to two
parameters (each some linear combination of the six), which helps in visualizing the
chemical diversity space.139 This is accomplished through the use of linear algebra by
finding the leading eigenvalues of the data matrix for the first PC. In the published study
by Fink and Reymond140, the first PC accounts for as much of the variability of the data
set as possible (i.e. the variance is maximized). The second PC was found after an
orthogonal transformation was done on the data matrix, so that the second PC is

101	
  
	
  
independent of the first, and then the variance for the first and second PCs are
maximized.111 This model accounted for almost 70% of the variance of the library. This
PC model was applied to the chemicals under consideration for inclusion in the library
and were plotted to visualize the spatial distribution. To facilitate chemical selection for
the fragment library, the investigators placed the chemicals in up to nine subgroups
equally dividing the range of each PC. The equations for their PC analysis are listed
below:

(1)

PC1= Molecular_Weight*.014+ AlogP*-0.302 + Num_H_Donors*0.282
+Num_H_Acceptors*.259 + Molecular_PolarSurfaceArea*0.311
+Num_RotatableBonds*-.092

(2)

PC2= Molecular_Weight*.609 + AlogP*.147 + Num_H_Donors*-.05
+Num_H_Acceptors*-.016 +Molecular_PolarSurfaceArea*-.015
+Num_RotatableBonds*.647

Given that these two principal components have demonstrated their utility in visualizing
the universe of all possible chemical fragments, they can also be used to quantify and
visualize the diversity of a fragment library that is being designed. That is, the fragment
library should be designed to maximally cover the diversity space defined by these two
principal components.

5.4.4 Solubility and it’s Importance in Screening
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Solubility plays an important and practical role in chemical selection for a
fragment library, due to the obvious need to experimentally screen the library against
protein targets in an aqueous environment.141 By maximizing the (predicted) solubility of
the chemical fragments in the library, it will be easier to assay for binding. Also, since
the end goal of this project is to design inhibitors (and ultimately drugs), it is necessary to
consider the ability of the fragments to dissolve and be available in the circulatory system
(blood).142 This parameter inherently affects the likelihood for uptake, distribution, and
transport of the chemical in the body.143 And, since subsequent chemical modifications
typically lead to decreases in polarity, it is good to start with a very soluble fragment.107
Solubility can be measured or estimated in many ways.142 One such method
rapidly estimates the solubility using only structural information. This method uses
atom121, 122, 144 type electro-topological keys, or a way to encode algorithmically the
topological environment and electronic interactions for an atom due to all other atoms in
the molecule.143 These keys were used by Tetko, et. al. to estimate, using an Artificial
Neural Network (ANN), the aqueous solubility of a diverse set of 1291 organic
compounds. An ANN is a computational method that tries to simulate biological neural
networks by employing simple processing units (neurons) which when combined together
function in a complex manner. This ANN model was used to estimate solubility for the
library being designed in that study143, and is applicable to any fragment library design
effort.

5.5 Library Design Guidelines
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This review, with exemplary proof of concept library design example, focuses on
the cheminformatic-based design of a fragment library for use in FBDD. All of the design
criteria and constraints described in the previous sections should be employed, with
particular focus on the potential for adverse and toxic effects. Additional consideration of
synthetic accessibility, and ability to tether two fragments, should also be considered as a
pragmatic matter. To this end, the following criteria are set forth to guide the design of a
fragment library:
1. Chemicals to be included in the fragment library, as well as multiple analogs of
each chemical, should be available from a reliable source, so that it can be
restocked as needed and so that additional SAR work can be done. Sigma Aldrich
maintains a consistent chemical catalog, thus their collection was used to develop
the initial version of this library. We have found it to be generally true that when
there are multiple analogs of a compound that are commercially available, that
compound tends to be synthetically accessible. While there is no good metric for
synthetic accessibility, this – in practice – serves as a reasonable surrogate metric.
2. Chemicals were selected such that they do not contain known functional groups
known to react with proteins (ex. electrophilic groups). Groups that were
excluded include: anhydrides, epoxides, alkyl halides, acyl halides, imines,
aldehydes, or aliphatic ketones and are listed in Table 5.1.
3. Chemicals that do not satisfy the rule of 3 will not be allowed into this library, to
increase chances of obtaining drug leads that are bioavailable.
4. Chemicals were prioritized based on substructure searching against drug
databases, to ensure the fragments are “druglike”.
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5. Chemicals that have substructures (ie. frameworks) that were shown to be more
prevalent in libraries of known toxic compounds (which we refer to as toxic
libraries), than in drug libraries, will not be considered for inclusion in this
library. This strategy of identifying potentially toxic fragments is a unique feature
of this fragment library design strategy, and exemplifies the SbD philosophy.
6. So that we are building off of current best practices, fragment selection also
considers established and “validated” libraries, the Abbott SAR by NMR, the
Vertex SHAPES frameworks, and additional frameworks based on rules that
generated the SHAPES scaffolds, to further parse the Sigma Aldrich collection.97,
98

7. Fragments were ultimately chosen to ensure that the resulting library will be
diverse and cover the fragment space, as defined by the principal components that
were used to measure diversity of the GDB library; diversity of the fragment
library is then compared against the maximum possible diversity, as defined by
the in silico GDB library.
8. The ability to tether two fragments should be considered by ensuring that robust
and reliable chemical reactions are available that allow the fragments to be
chemically linked together.

These library design criteria are summarized in Scheme 1. It is hypothesized that a
relatively small number of chemicals (approximately 100-1000) can be purchased that
will satisfy these criteria, and provide a generally useful fragment library for FBDD
projects, to ultimately produce potent drug-like inhibitors when two adjacent-binding
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fragment are tethered. The number of potential tethered fragments that could be derived
from this small library is 10,000 (100 x 100) – 1,000,000 (1,000 x 1,000).

5.6 Results of Applying Fragment Filters in a Test Case

5.6.1 Application of Traditional Design Considerations

PipelinePilot cheminformatic software was used for the analyses and chemical
filters used in this study.126 This software permits one to write programs that perform
manipulations and calculations on large collections of molecules, as is required in the
design of a fragment library.143
A fragment library is typically obtained by searching databases of commercially
available compounds, using criteria such as those described above. As mentioned above,
our initial studies relied on Sigma Aldrich as a commercial source of compounds. To
increase the likelihood of bioavailability for each fragment, the commercial compound
collection145 was filtered using a “Rule of 3” methodology.123 The “Rule of 3” is similar
to the widely used “Lipinski’s rule of 5”95 for “drug-like” compounds, however, it takes
into account that two or more fragments will be connected, and the new bi-fragment
molecule will still need to satisfy Lipinski’s rule of 5. In order to satisfy the rule of 5, the
filter requirements for the Rule of 3 are lower. The requirements for the rule of 3 are:
MW < 300 g/mol, logP ≤ 3, where
(3)
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hydrogen bond donors (HBD) ≤ 3, hydrogen bond acceptors (HBA) ≤ 3, and number of
rotatable bonds ≤ 3.
A number of additional filters are typically used, to remove inorganic compounds
as well as chemically reactively compounds that would lablel proteins in a nonspecific
manner. To this end, the commercial collection of compounds was filtered to remove
compounds with atoms other than C, O, H, N, S, P, F, Cl, Br, or I (Figure 5.2).100 The
filter to remove compounds with functional groups that are reactive with proteins was
designed to identify then remove compounds that contained Michael acceptors,
anhydrides, epoxides, alkyl halides, acyl halides, imines, aldehydes, or aliphatic ketones
(Figure 5.3).146 This prescreening avoids compounds that are likely to show false positive
biological activity due to nonspecific covalent bond formation with protein nucleophiles.

A)

B)
Figure 5.2. A) Pipeline Pilot script used to remove chemicals from the Sigma Aldrich
screening collection that contained metals (Organic Filter), duplicate molecules, and that
did not satisfy the rule of three. Molecules were also ionized to a physiological pH of 7.4.
B) Expansion of the subroutine for the rule of 3 implementation (molecular weight < 300,
ALogP ≤ 3, number of hydrogen bond acceptors ≤ 3, number of hydrogen bond donors ≤
3, number of rotatable bonds ≤ 3, molecular polar surface area ≤ 60). Individual Pipeline
Pilot modules are customizable and can be manipulated in a Pipeline Pilot program so
that the results of one module flows to the input of the next.
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Figure 5.3. Pipeline Pilot script to remove known functional groups that react with
proteins. This script utilized many substructure searches based on reactive functional
groups (i.e. esters, anhydrides, and imines) that are known to react with proteins, as
described by Hann, et. al.146
5.6.2 Framework Analysis of Drug Libraries: Comparing to State of the Art

The previously published Abbott SAR by NMR fragment library97 and Vertex
SHAPES fragment library98 were computationally screened to determine which chemical
frameworks are present in these established fragment libraries. Then, these scaffolds and
fragments were used to identify commercially available fragments that contained the
same substructures. While these libraries are considered validated and state of the art,
they may still be missing chemical substructures that could be valuable sources of drug
leads. To this end, we attempted to add commercially available compounds that contain
substructures that are present in current collections of drugs and drug-like molecules.
Most of these are likely to have been present in the Abbott and Vertex libraries, so it is
merely a precautionary measure – and, it may identify substructures that were not known
when those fragment libraries were developed. To determine if the Abbott and Vertex
libraries may be missing such valuable substructures, we screened the DrugBank
library73, 74, a library comprised of chemicals from the Physician’s Desk Reference130-132,
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and a listing of the top 200 drugs based on 2008 sales134 using the SAR by NMR
fragment library and SHAPES fragment library scaffolds. This computational screen
yielded information on the scaffolds that are present in the existing fragment libraries, as
well as those that are most likely to be found in a drug and that are available from SigmaAldrich. Table 5.2 lists the 20 most prominent ring structures (scaffolds) from the SAR
by NMR and SHAPES libraries and the frequency in which they occur in DrugBank.
The benzene ring was ignored, as it is ubiquitous across all investigated libraries. Table
5.3 shows examples of five drugs from the listing of the top 200 drugs (based on 2008
sales)133 that contained five of these scaffolds. Cymbalta, containing a thiophene
framework, is used to treat depression through uptake regulation of serotonin and
norepinephrine. Imitrex Oral, used to treat migraines, contains an indoleine framework.
Keppra, an anticonvulsant, contains pyrrolidine as a substructure. Actonel, based on
diphenylmethane, is used to treat osteoporosis. Benicar HCT, containing an imidazole
framework, is used to treat hypertension.

Table 5.2. The top 20 drug-like frameworks, excluding benzene, based on a relative
frequency analysis, for occurrence in the drug library, DrugBank. 73, 74
Rank
Framework
Rank
Framework
1

11

2

12
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3

13

4

14

5

15

6

16

7

17

8

18

9

19

10

20
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Table 5.3. Five examples of drugs containing frameworks in the top 20 druglike
frameworks.134
Framework
Drug Structure
Drug Name
Cymbalta

Imitrex Oral

Keppra

Actonel
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Benicar HCT

5.6.3 Framework Analysis of Toxic Chemical Libraries: Safety by Design (SbD).

An analysis similar to the drug framework substructure search described above
was performed using various “toxic chemical libraries” in place of the drug libraries.
These toxic chemical libraries contain mutagens identified using an Ames mutagenicity
test135, and include toxic compounds that are listed in the DSSTox library136 and the
CPDB.137, 138 The top 10 chemical frameworks and ring structures that appeared in these
toxic chemical libraries are listed in Table 5.4. Table 5.5 shows three examples of known
carcinogens containing substructures that were listed in Table 5.4. For example, 7chlorobenz[a]anthracene has been shown to cause liver tumors in mice.147 A naphthalene
derived compound, 2-naphthyl amine, has been shown to cause bladder cancer in
humans.148 A chemical containing the substructure of framework 4, 3-2’-dimethyl-4nitrosobiphenyl, has been shown to contribute to bladder cancer.149 This listing of
chemical frameworks should be used only as a rough guide to potential for toxicity, and
must be interpreted with consideration of other factors – because, potential for toxicity
will depend very much on the molecular context of the framework (i.e. substituents on
the ring, and other ring systems in the molecule). For example, while it is not surprising
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that polycylic aromatic hydrocarbons like anthracene have a high potential for toxicity,
there are a large number of drugs that contain the pyridine ring. The computational
filtering methods discussed herein address this concern by considering the relative
frequency of occurrence of these chemical frameworks in drug versus toxic compound
databases.

Table 5.4. Top 10 frameworks, based on frequency of occurrence (excluding benzene) in
the libraries that contain chemicals that tested positive for mutagenicity in the Ames
test135, toxic compounds listed in DSSTox library136 and the CPDB.137, 138
Rank
Framework
Rank
Framework

1

6

2

7

3

8

4

9
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5

10

Table 5.5. Four examples of toxic chemicals containing the frameworks from Table 5.3.
Framework
Known carcinogen
Toxic effect
Mouse Liver Carcinoma150

Human Bladder Carcinogen151

Hamster Spindle Cell
Carcinoma149
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Mouse Liver Carcinoma152

To easily visualize the relative frequencies of the scaffolds in drug libraries versus
the toxic chemical libraries, three histograms were constructed (Figures 5.4A-C). Figure
5.4A shows two frameworks that occur much more frequently in the toxic libraries
relative to the drug libraries: biphenyl and naphthalene. Similarly, anthracene appears in
a disproportionate number of compounds in the toxic chemical libraries compared to the
drug libraries (Figure 5.4B). Diphenyl methane had the next highest proportion of
relative frequencies in the toxic chemical libraries relative to the drug library (Figure
5.4C); but, since this ratio was not above 2:1, this framework could arguably be kept for
consideration in a library; in the fragment library constructed herein, it has been included
(Figures 5.4C).
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A)

B)

116	
  
	
  

C)
Figure 5.4. A) Histogram showing the relative frequency of occurrence of 55 in the drug
libraries (shown in blue) DrugBank library73, 74, a library comprised of chemicals from
the Physician’s Desk Reference130-132, and a listing of the top 200 drugs based on 2008
sales133 and the average relative frequencies for toxic chemical libraries (shown in red)
mutagens found through an Ames mutagenicity test134,toxic compound listed in DSSTox
library136 and the CPDB.137, 138 B) Relative frequency histogram of the 55 more
frameworks in the drug libraries and toxic chemical libraries. C) Relative frequency
histogram of the remaining frameworks in the drug libraries and toxic chemical libraries.
One practical consideration for a fragment library is that one typically needs to
have access to many analogs of a fragment, once it is determined that a fragment binds to
a protein drug target. Ideally, these analogs should be commercially available. But, in
many cases one needs to synthesize analogs – which means it is important that the
fragment be synthetically accessible. There is no easy and reliable computational filter
for synthetic accessibility; although, it is likely that if there are many commercially
available analogs of a fragment, that synthesis of that fragment should not be too
difficult. So, to be included in the test case fragment library presented herein, a fragment
(framework) needs to be present in a minimum of four commercially available chemicals.
So, once it is established that a fragment binds to a protein, it will then be possible to
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purchase and test analogs of that fragment to establish an initial SAR. And, presence of
the analogs is a surrogate indicator of synthetic accessibility.153 Examples of
commercially available analogs of frameworks that meet these criteria are given in Table
5.6.

Population

Table 5.6. Examples of commercially available chemicals that contain each framework,
and that have a population of 4 or more chemical analogs available from Sigma Aldrich’s
collection, as an indication of synthetic accessibility. The chemicals listed in this table
represents scaffolds passing the SbD filter and also meet the chemical tethering
requirements.
Framework
Variant 1
Variant 2
Variant 3

218

53

51
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48

29

40

9

23
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47

18

13

31

58
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73

2

10

215

10
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64

2

26

29

112
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25

6

8

25

4
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40

4

4

48

4

14

6
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4

7

20

4

5.6.4 Chemical Tethering: Two Methods.
Ultimately, chemical fragments that are found to bind proximally to each other in
a fragment screening assay will need to be chemically linked to produce a bi-fragment
inhibitor. Often, the synthetic chemistry skills needed to link two fragment is significant,
so tethering ends up being a bottleneck in any fragment-based drug design (FBDD)
effort. This problem is further compounded by the fact that FBDD research teams often
do not have access to significant resources in synthetic organic chemistry. But, even if
they do, it is helpful if the chemistry needed to link fragments is well-established and
robust. To this end, fragments were selected based on the availability of simple chemical
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reactions that could be used to join them; reactions that can even be done in a
biochemistry laboratory. Many types of established linking chemistries could be used,
such as Suzuki and Heck couplings. Even simpler are SN2 reactions, as well as amide
couplings. The first method presented herein relies on fragments with methyl and primary
amine groups. The second method requires allylic and benzylic methyl groups. Examples
of fragments in each of these categories are provided in Table 5.7.

Table 5.7. Examples of commercially available chemical fragments containing methyl
groups, primary amines, or allylic (benzylic) methyl groups, showing representative
compounds that were included in the final fragment library.
Structure
Element
Allylic methyl

Methyl

Primary
Amine

Variant 1

Variant 2

Variant 3
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5.6.4.1. Methyl and Primary Amines

The commercial collection was parsed as described above based on frameworks
that are more prevalent in drugs than in toxic compounds, in addition to using other filters
(removing reactive groups; Rule of 3). The compound collection was then further filtered
for commercial availability and then for presence of functional groups that permit
tethering using simple chemistries. One such computational screen ensured that every
chemical considered for inclusion in the fragment library would have either a methyl
group or a primary amine. This filter is meant to address practical issues in NMR
screening as well as the chemistry of fragment tethering. Methyl groups are excellent
NMR probes for interligand nuclear Overhauser effect (NOE) studies, which are
performed to detect if another fragment binds proximally to it.154 Three identical
hydrogen atoms increase sensitivity, and rapid spinning of the methyl group produces
narrow linewidths, even when bound to a large protein. Methyls groups can be
substituted with halogens via free radical reactions (ex. Br2 + hν); they can also be
oxidized to carboxylic acids (ex. permanganate oxidation, or convert to the alcohol, then
oxidize). Amines were chosen because they are easily linked to carboxylic acids (once
activated or converted to an acid chloride). If two such fragments are found to bind near
to each other, they could then be easily joined together via an amide linkage. Analogs of
fragments that meet these criteria have been listed in Table 5.7 (along with a listing of the
number of commercially available analogs in each framework category).

5.4.2. Allylic and Benzylic Methyls
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In parallel, the pre-filtered commercial collection was also computationally
screened to include chemicals that contained either an allylic or benzylic methyl group.
Not only would this give a characteristic signal with good signal-to-noise in NMR spectra
(as described above), but it builds in the ability to join fragments together. Allylic and
benzylic bromination using N-bromosuccinimide (NBS) is more selective, and would
create a position (R-CH2-Br) for an SN2 reaction to be performed later with a nucleophile,
as a way to tether adjacent-binding fragments.155 An existing, in house thiol fragment
library could be used to join fragments together from any library member in this manner.
Or, the methyl halide (R-CH2-Br) could be converted to a sulfide (R-CH2-S-), and used
for linkage to another methyl halide (R-CH2-Br). Accordingly, any combination of
benzylic or allylic methyl-containing fragments could be tethered, simply by converting
one to an alkyl halide (R-CH2-Br), and the other to the corresponding sulfide (R’-CH2-S), and then reacting to form R-S-R’ bi-fragment (or R-O-R’ if an alcohol is used instead).
Importantly, linking is done through the same methyl groups that would have given the
NOE, so are known to be proximal (within 5 Å). Since this rather stringent filter (allylic
and benzylic methyls) eliminated many chemicals in the computational screen of the
commercial collection, all chemicals passing this filter were included in the library.

5.4.3. Additional Filters to Decrease Library Size – a Diverse Subset with Optimal
Solubility.
While the allylic and benzylic filters decreased the fragment library to a
manageable size, this might not be the case if we had started with a larger collection of
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commercially available compounds. That is, our computational filtering began with
206,674 commercially available compounds from Sigma-Aldrich. A search of the ZINC
database of 14 million compounds, on the other hand, would produce a fragment library
that is too large for the needs of most FBDD laboratories. But, a softer filter – like our
first screen for amines and methyl groups – produces a fragment library that is too large,
even starting with the smaller Sigma-Aldrich collection. So, how should the fragment
library be decreased to a manageable size? Normally what is done is to select a diverse
subset of chemicals from the list of possible candidates to include in a chemical library.
The approach we use is to choose a diverse subset of possible variants of each framework
category (ex. for each that is listed in Table 5.6). For example, we initially chose to
include 9 commercially available fragments in the fragment library, for each framework
category. But, how should chemical diversity be defined to facilitate this process?
Fink and Reymond recently presented a PC (principal component) analysis of
diversity for fragment-like chemical libraries, and that analysis is well-suited to the
problem at hand. Accordingly, their approach was used herein as a basis for assessing
chemical diversity of our library, and then ultimately choosing a diverse subset of this
library to create the fragment collection.140 Their GDB in silico library established an
estimate of the theoretically possible fragment space, based on the PCs that they
developed (Figure 5.5, unfilled and filled ovals). For this analysis, they enumerated
every possible chemical structure comprised of up to 11 atoms; they also extracted every
possible chemical structure comsprised of up to 11 atoms from five large chemical
libraries (PubChem, ChemACX, ChemSCX, National Cancer Institute (NCI) open
databases, Merck Index), and overlayed their PC plot (or actual chemicals) on their GDB
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PC plot (of theroetically possible structures) as a way to assess whether currently
available compound collections sample chemical diversity space (Figure 5.5). It is of
course possible that their GDB library also contains chemically unrealistic structures, so
it represents a kind of upper limit on chemical diversity, for compounds of this size.
Indeed, this analysis showed that not all of the GDB fragment space is chemically
revelant, as there are no currently available compounds that reside outside of the red oval,
to the right along the PC1 axis in Figure 5.5.140

Figure 5.5. Representation of the fragment space established by the principal component
analysis of the GDB of 26.4 million chemical strucutres. This fragment space includes
all the space inside the outlined oval, which includes the red colored area; this represents
all of chemical diversity space, which is covered by the componds in the GDB. The Red
colored area represents the area of fragment space covered by all known chemicals of up
to 11 atoms from PubChem, ChemACX, ChemSCX, NCI open databases, and the Merck
Index.140 PC1 and PC2 are as defined in equations 1 and 2, respectively.
This same type of PC analysis can be used to visualize chemical diversity of a
potential fragment library, in a scatter-plot format where each data point represents a
chemical structure with calculated values of PC1 and PC2 (Figure 5.6D). This type of
analysis was performed on the fragments selected for our fragment chemical library,
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implemented with a program that we wrote using Pipeline Pilot (Figure 5.6A), and
considering that some of the GDB diversity space may not be useful (Figure 5.5). There
are some caveats that should be noted with this analysis. For example, the Fink and
Reymond PCs are being applied to chemicals that are somewhat larger than the 11 atoms
used in their GDB study, with more types of atoms (ex. sulfur, chlorine, and bromine).
But, we argue that the PC1 and PC2 diversity metrics should apply reasonably well on
this somewhat larger dataset. Also, it should be noted that some compounds may fall
outside of the ranges discussed in the previous paragraph for those reasons (ex. molecular
weight is larger, and molecular weight is an element of PC1 and PC2).

A)

B)
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C)

D)
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E)
Figure 5.6. A) Compound selection script to aid in subdividing chemicals into the nine
diversity subgroups. Visualizing of the chemical diversity aided in selecting compounds
for each framework. B) Chemical structure of a representative framework scaffold,
pyrimidine, which was used as a substructure filter. C) Partial output from application of
the script in panel A, showing some chemical structures from Sigma-Aldrich that passed
this filter. Note: The 973 chemical fragments are what resulted from all the previous
cheminformatic screens (Rule of 3, Hahn’s filter, Abbott and Vertex frameworks,
Potential toxic frameworks) of an initial set of 206,674 chemicals from Sigma-Aldrich.
D) Segmentation of fragment space for the pyrimidine scaffold into nine diversity
subgroups. Based on these nine subgroups, one chemical was selected from within each
subgroup (when present) basing selection on that chemical fragment with the highest
calculated solubility. Compounds were then purchased from Sigma Aldrich. Principal
components (PC1 and PC2) are described by equations 1 and 2 respectively. E) Three
representative chemical structures for chemical fragments that were to be included in the
fragment library.
Chemical fragments being considered for inclusion in the fragment library in each
framework class (after application of all the previously described filters) can be
visualized in diversity plots like that in Figure 5.6D. Such a diversity plot is created for
each framework (ex. each framework in Figures 5.6 and 5.7). This chemical diversity
space can then be broken up into a grid (ex. a 3x3 grid), as in Figure 5.6D, and a
fragment can be selected from each segment of the grid. In this manner, a compound
subset of maximum diversity is selected for each framework. Since each fragment was
chosen from one of the nine subgroups, which are uniformally distributed across
fragment space for each framework, a diverse subset of 9 compounds is selected for each
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framework. If more than 9 in each fragment category are desired, then larger grids (i.e.
with more granularity) can be chosen.
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A)

B)
Figure 5.7. A) Normalized chemical space for the selection of chemicals based on the
first method (chemicals containing methyl or primary amine groups). B) Normalized
chemical space for the selection of fragments based on the second method (chemicals
containing allylic or benzylic methyl groups).
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When multiple compounds are seen in one of the nine fragment subgroups, a
decision needs to be made in terms of which one to include in the fragment library. We
decided to choose the fragment with the best predicted solubility, since solubility is
important in drug screening experiments. This is because screening is done at relatively
high concentrations of fragment, often at 1 mM or higher. An example of this selection
process is illustrated in Table 5.8. The eight chemicals in this table were all in the same
subgroup based on the framework PCs, and thus are structurally similar based on that
diversity metric (i.e. similar PC1 and PC2 values). The chemical fragment that is
selected for inclusion in the final fragment library is that fragment with highest predicted
solubility, which in this case is 7 mM for the 2-iodo-3-hydroxy-pyridine.

Table 5.8. Predicted solubility for eight chemicals in a subgroup of the pyridine
framework for which only the top scoring chemical fragment was selected for inclusion
in the initial library.
Chemical

Solubility
(mol/L)

7.41 x 10-3

7.76 x 10-5
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1.91 x 10-5

5.37 x 10-5

4.17 x 10-4

1.70 x 10-4

1.12 x 10-4

7.76 x 10-5

As a practical matter, it should be noted that an additional and useful filter
(beyond solubility) is price. Once it comes to deciding on the final list of compounds to
include in the fragment library (as described above), the most expensive chemicals (top
20%) were removed, and the remaining chemicals were purchased. As needed, substitutes
in other areas of the same segment of diversity space (Figure 5.6) can be used in place of
the more expensive fragment analog.
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Once the final fragment library has been designed, using the various
computational filtering methods described above (summarized in Scheme 1), a final
diversity analysis is performed to determine if the fragment library adequately samples
chemical diversity space (as defined using the Fink and Reymond PC1 and PC2
values139). Diversity analysis of the amine & methyl fragment library (Figure 5.7A) and
of the benzylic & allylic methyl fragment library (Figure 5.7B) indicates that the
fragment libraries do in fact sample chemical space quite broadly and evenly This is a
visual confirmation of the chemical diversity for the two fragment libraries designed in
this study, according to the various computational filters and selections that are
summarized in Scheme 5.1.
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Scheme 5.1. Summary of the cheminformatic filtering process for the inclusion of
chemical fragments in the chemical library. Steps are outlined, showing the number of
chemicals passing each filter listed.
5.7 Conclusions
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This review and trial fragment library design study presents the various
considerations and associated cheminformatic analyses that are used to guide the design
of a fragment library, to be used in FBDD projects. The six criteria used to define this
fragment library led to the initial selection of 125 chemicals (chemical structures shown
in Tables 5.9 and 5.10); the selection process summarizing the cheminformatic filtering
strategy is shown in Scheme 1. One of the most important and novel filters that was used
relied on comparative template analysis of drug libraries versus toxic compound libraries,
to ensure that the templates used were those with higher frequency of occurance in drug
versus toxic compound libraries. This safety by design (SbD) strategy was also
complemented with traditional filters (ex. Rule of 3; chemical reactivity; solubility), as
well as a novel consideration of synthetic accessibility of fragments, and of the tethered
bi-fragment itself.

Diversity analysis, using a recently reported analysis of diversity

space for fragments, ensures maximum coverage of chemical diversity by the library.
Additional libraries could be designed using this same strategy, to incorporate more
chemicals (i.e. additional vendors could be searched) or some filters could be relaxed.
While a library of 125 enables access to 125x125 potential tethered bi-fragments, a
library of 1,000 or more may be ideal, because it would allow access to over 1 million
potential bi-ligands.
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Table 5.9. Fragments purchased with methyl and/or primary amines.
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Table 5.10. Fragments purchased with allylic or benzylic methyls.
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Appendix I. Sulfonates: A Viable Source of Drug Leads and Chemical Genomic Probes
A1.1 Introduction
In 1935, Gerhard Domagk reported that the dye prontosil protected mice from
Streptococci.156 This discovery led to the development of the sulfonamide drugs, initially
used as antimicrobials, and to development of a plethora of related drugs, the so-called
sulfa or “wonder drugs” which predated the penicillin class of antibiotics. Sulfa drugs
have since been used for other indications, including as diuretics and anticonvulsants. A
close cousin of the sulfonamides are the sulfonates, which have the sulfur-bonded NH
replaced with an oxygen. Aryl-sulfonates have long been used as food, drug, and
cosmetic (FDC) dyes, and frequently contain bridging azo groups as well (Figure
A1.1).157
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Figure A1.1. Examples of widely used FDC dyes that contain an aryl-sulfonate
functional group, with some also containing a bridging azo (-N=N-) group.
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There are six approved drugs that contain the sulfonate functional group as the active
ingredient of the drug (Figure A1.2). One of these, polystyrene sulfonate, is a cation
exchange resin that is used to bind potassium in patients with renal failure due to
hyperkalemia, though its safety and efficacy have recently been questioned.158
Acamprosate is used in the treatment of alcohol dependence and is thought to activate γaminobutyric acid type A receptors and block glutaminergic N-methyl-D-aspartate
receptors.159 Cefonicid is a broad-spectrum antibiotic.160 Ecabet is used to treat dry eyes
in the United States161 and has been used to treat chronic gastritis in South Korea.162
Colistimethate has been used to treat multidrug resistant infections.163 The remaining
drug, suramin, is a polysulfonated drug used to treat trypanosomiasis and oncocerciasis.75
More recently, suramin has shown promise for treating cancer and HIV infection.77 Also,
suramin is known to bind to a wide range of biologically important molecules (ex.
fibroblast growth factor), which may be due to a somewhat non-specific mode of binding
to charged pockets.78 Three other FDA approved drugs that contain the sulfonate
functionality, cisatracurium besylate, hydroxystilbamidine isethioate, and
dihydroergotoxine, contain the sulfonate only as a counterion for the active ingredient.
The fact that sulfonates are present in some drugs as an active or inactive ingredient,
combined with the fact that sulfonates are present in and have long been used as food
dyes, suggests that the sulfonate functionality is not inherently toxic. The sulfonate’s
utility as a biomimetic of negatively charged groups, in drug discovery and optimization
projects, is a topic of this study.
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Figure A1.2. Examples of drugs containing the sulfonate group.
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Herein is presented a docking-based identification of inhibitors6 for two protein
drug targets that have highly basic binding sites, and normally bind negatively charged
substrates with phosphate, sulfate or carboxylate groups. Virtual screening of a large
compound collection (10,000 compounds) was used to identify inhibitors against two
protein targets that bind charged substrates. Virtual screening is the process of
automating the docking of an entire chemical library into a protein active site, with the
goal of discovering those chemicals that bind with highest affinity for the protein target.7
Virtual screening is used in the early phase of drug discovery, since it can substantially
reduce the resources needed to identify lead molecules, relative to experimental
screening.6 Zanamivir, an influenza therapeutic, is one example of a drug that was
developed in part using docking.164 The virtual screening process is most efficient if
physical compounds are available to permit rapid experimental verification of
computational predictions.6 The study presented herein uses an in-house physical
collection of 10,000 compounds that contain drug-like molecules, and also includes
chemical dyes such as aryl-sulfonates. This is an in-house drug screening library,
constructed over many years based on >10 different drug discovery projects pursuing
dehydrogenase and kinase drug targets (both classes bind negatively charged substrates).
Herein is presented a docking-based virtual screen of this library against two protein
targets that also bind negatively charged substrates, resulting in the identification of arylsulfonate inhibitors for phosphomevalonate kinase (PMK) and CXCL12 (also known as
stromal cell derived factor 1 or SDF-1). Indeed, the best predicted inhibitors for both
targets were consistently aryl-sulfonates, which led to our interest in exploring the current
and historical utility of aryl-sulfonates as drugs and drug leads.
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PMK is in the mevalonate biosynthetic pathway, downstream of HMG-CoA
reductase, and is a potential drug target for cardiovascular disease. This pathway is the
only biosynthetic route to steroids and isoprenoids, including cholesterol, in mammals.165,
166

There has been much research in the inhibition of this pathway, with prominent

successes using statin drugs, which target the HMG-CoA reductase enzyme.167 In
contrast, much less research has been reported on PMK. A crystal structure has been
reported for apo human PMK51, and a model has been presented with both substrates
(ATP and mevalonate-5-phosphate (M5P)) bound (Figure A1.3). Notably, PMK
substrates have unusually high negative charge density, due to the presence of four
phosphate groups; these are involved in a large number of hydrogen bonding and ionic
interactions with arginine sidechains (Figure A1.3).168, 169

Figure A1.3. Crystal structure of PMK (pdb code 3ch4)51 with natural substrates, ATP
and M5P, docked into the active site.168, 169 Nearby interactions from ligands to basic
residues are shown in the yellow box, which represents the docking box used for
AutoDock calculations.
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The other protein being targeted in this study is CXCL12, which is a chemokine, a
small secreted protein that promotes directed cell migration by activating its G proteincoupled receptor, CXCR4. CXCL12 is crucial for fetal development, since deletion of
the gene for CXCL12 causes mice to die in utero due to a defect in hematopoiesis.170 In
adulthood, CXCL12 plays an important role in angiogenesis (blood vessel growth)171,
and is therefore important in the initial creation of tumor cells and formation of networks
of blood vessels, which permits tumor progression.172 CXCL12 binds the extracellular
N-terminal domain of CXCR4 with posttranslational sulfation at Y7, Y12, and Y21,
which promotes CXCL12 dimer formation.173 Figure A1.4 shows the recently reported
solution structure of the CXCL12 dimer.174 CXCL12 normally binds to negatively
charged sulfotyrosines on the CXCR4 receptor, and R47 of the chemokine plays an
important role in stabilizing this interaction.173
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Figure A1.4. One of the structures in the ensemble of solution structures of CXCL12
(pdb code 2k05)174. Relevant side chains (R47 and V49) are shown, and the box shows
the site into which the in-house chemical library was docked.
Both protein drug targets (PMK and CXCL12) chosen for this study have highly
basic binding sites, rich in arginines, since they typically bind negatively charged ligands.
Aryl-sulonate inhibitors were identified for both targets. This study also explores the
current and historical utility of aryl-sulfonates as a potential source of inhibitors, and
perhaps drugs leads.

A1.2. Results

A1.2.1. Docking
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An in-house collection of 10,000 compounds was docked into PMK (Figure A1.3)
and CXCL12 (Figure A1.4) using Autodock 4.2, to identify those coumpounds with
highest predicted binding affinity (Figures A1.5-A1.8). In most cases, compounds with
the highest predicted binding affinity were those containing sulfonate groups, especially
aryl-sulfonates (Table A1.3). For each protein target (PMK and CXCL12) docking
studies were followed by an experimental verification of binding, and titration to obtain a
Kd for the compound (Figures A1.5-A1.8).

A1.2.2. Identification of PMK inhibitor

Ten computationally selected compounds from the PMK docking calculations
were chosen for experimental verification using NMR titration experiments, monitoring
changes in 1H and 15N chemical shifts in heteronuclear single-quantum coherence
(HSQC) spectra as a function of inhibitor concentration (Figure A1.5). Of those ten
compounds, four were found to bind to PMK, and of these 2-[2-(2-oxo-3,6-disulfonatonaphthalen-1-ylidene)hydrazinyl]benzoate (CSDDD_1750) bound more tightly than the
others. CSDDD_1750 is a substituted naphthalene with an azo linkage to a carboxylic
acid substituted phenyl group (Table A1.3), somewhat reminiscent of FD&C Yellow #6
(Figure A1.1). Autodock predicted CSDDD_1750 to bind in the ATP – γ phosphate site
(Figure A1.5A, A1.5B), with the 8 poses in the lowest energy cluster having a mean
calculated binding energy of -9.8 kcal/mol (lowest in the cluster being -10.4 kcal/mol).
Panel B in Figure A1.5 shows all the predicted interactions (less than 3.2 Å) between
CSDDD_1750 (lowest energy docked pose) and active site residues of PMK. The
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sulfonate groups (and one carboxyl group) show hydrogen bonding (and ionic)
interactions with PMK basic residues R18, K22, and R73, along with hydrogen bonds to
the amide protons of S20, G21, and K22. By measuring and then fitting the chemical
shift changes for PMK active site residues in Figure A1.5D, a dissociation constant (Kd)
of 25.4 ± 7.3 µM was calculated.
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Figure A1.5. Docking and experimental titration data for compound CSDDD_1750
binding to PMK. Panels A and B show the lowest energy pose of CSDDD_1750, and
relevant interactions with PMK. Panel C shows the titration curve generated from the
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chemical shift changes in panel D, and used to calculate the Kd of 25.4 ± 7.3 µM for
CSDDD_1750 binding to PMK.
A1.2.3. Identification of CXCL12 inhibitor

The in house library of 10,000 compounds was also docked into the region on
CXCL12 to which the CXCR4 N-terminal extracellular domain binds. This site, in the
vicinity of R47, is normally occupied by the negatively charged sulfotyrosine 21 (sY21)
in an interaction that is essential for chemokine function (Figure A1.4).174 The top 50
scoring compounds were ranked by calculated binding energy for the lowest energy pose
in the docking cluster, and compounds were then experimentally screened for binding to
CXCL12 protein in batches of 5 compounds. For batches that showed significant
chemical shift changes in the 1H-15N HSQC NMR spectrum, each compound was
subsequently tested individually to identify which compound was indeed binding to
CXCL12. Since compounds were dissolved in d6-dimethylsulfoxide (DMSO), and
DMSO has an effect on the spectra of CXCL12, each compound titration was compared
to a spectra of CXCL12 titrated with only d6-DMSO. Thus, any net perturbations were
judged to arise from binding of a compound and not d6-DMSO. Of the 50 compounds
tested against CXCL12, three were found to bind with reasonable affinity, as shown in
Figures A1.6-A1.8.
The first compound identified in the batch screening process was 5-[[2-hydroxy3-[2-(2-oxonaphthalen-1-ylidene)hydrazinyl]-5-sulfonatophenyl]hydrazinylidene]-6oxonaphthalene-2-sulfonate (CSDDD_1452), which contains phenol sulfonate substituted
naphthalene rings, linked through an azo group (Table A1.3). This is a rather large
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molecule (770 Da) with many torsional degrees of freedom, thus explaining the poor
clustering in the docking (there were 32 different clusters from 50 docking runs).
However, the lowest energy cluster (-9.70 kcal/mol with lowest energy pose being -10.7
kcal/mol) is the most populated, and clustered with 5 poses and an RMSD of 2 Å. As the
docking was confined to the sY21 binding site, the negatively charged sulfonate groups
are predicted to interact with the positively charged R47 (Figures A1.6A and A1.6B).
There are also hydrogen bonding interactions predicted between the hydroxyl groups of
the naphthalene and phenol rings and the carbonyl of E15. From the NMR titration of
CSDDD_1452 and CXCL12, a calculated Kd of < 25 µM (Figure A1.6C and A1.6D) was
obtained. That is, affinity was too high to be measured accurately with NMR HSQC
titrations, but the dissociation constant is no higher than 25 µM. This is the most potent
inhibitor identified to date for CXCL12.
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Figure A1.6. Docking and experimental data for compound CSDDD_1452 binding to
CXCL12. Panels A and B show the lowest energy pose for CSDDD_1452 and relevant
interactions with CXCL12. Panel C shows the titration curves generated from the
chemical shift changes in panel D, and used to calculate the Kd for compound binding to
CXCL12, which was < 25 µM (note: for high affinity ligands, HSQC titrations provide an
upper limit for Kd). Panel D shows the overlay of the 2D 1H-15N HSQC spectra for the
NMR titration, with chemical shift changes going from green to red upon addition of
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CSDDD_1452. CXCL12 concentration was 50 µM in pH 6.8 perdeutero MES buffer (25
mM).
The second compound identified in the batch screening process was 3-[[9,10dioxo-4-(2,4,6-trimethyl-3-sulfonatoanilino)anthracen-1-yl]amino]-2,4,6trimethylbenzenesulfonate (CSDDD_1784), which has an anthracene core with two
amide groups stemming from it, connected to a trimethyl sulfonate phenyl group. This
compound (MW 633 Da) is relatively large but is rigid, so has fewer torsional degrees of
freedom than CSDDD_1452. Consequently, only 8 clusters were obtained, with 42 of the
poses appearing in the top two clusters with lowest predicted binding energy (-8.35
kcal/mol and -8.95 kcal/mol for the lowest energy pose of the respective clusters). The
difference between clusters was mostly due to alternative orientations of the phenyl rings.
This compound’s sulfonate groups were predicted to be located near R47, with
interactions between the sulfonate groups and R47, N47, and D22, with hydrogen
bonding between the amide and hydroxyl groups of CSDDD_1784 and the carbonyl of
E15 (Figures A1.7A and A1.7B). The binding affinity, as determined from NMR
titrations (Figures A1.7C and A1.7D) of multiple backbone residues, is again relatively
strong, with a Kd of 35 ± 12 µM. The cross peaks that show the largest perturbations are
for those residues located in the sY21 site, away from the CXCL12 dimer interface.
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Figure A1.7. Docking and experimental data for compound CSDDD_1784 binding to
CXCL12. Panels A and B show the lowest predicted energy pose for CSDDD_1784 and
relevant interactions with CXCL12. Panel C shows the titration curves generated from
the chemical shift changes in panel D, and used to calculate the Kd for compound binding
to CXCL12, which was determined to be 35 ± 12 µM. Panel D shows the overlay of the
2D 1H-15N HSQC spectra for the NMR titration, chemical shift changes from green going
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to red upon addition of CSDDD_1784. CXCL12 was at 50 µM in pH 6.8 predeutero
MES buffer (25 mM).
The last compound that was found to bind to CXCL12 was 5-dichloro-4-[3methyl-5-oxo-4-[(4-sulfonatophenyl)hydrazinylidene]pyrazol-1-yl]benzenesulfonate
(CSDDD_1661), which has a sulfonate group attached to a pyrazole ring through an azo
linkage, and is connected to a dichlorophenyl sulfonate group. This compound’s docking
had 16 clusters, with poor clustering due to significant rotational degrees of freedom due
to the groups attached at the pyrazole ring. But, the lowest energy cluster, with a
predicted binding energy of -8.62 kcal/mol (-8.92 kcal/mol for the lowest energy pose),
had 18 of the 50 docking poses clustered in it. Many of the interactions with the lowest
energy pose (Figures A1.8A and A1.8B) are predicted between the sulfonate groups and
the positively charged guanidinyl group of R47, as well as the backbone carbonyl and the
amide of the sidechain of Q48. The binding of this compound is weaker than for the
previous two compounds, with a Kd of 203 ± 36 µM (Figures A1.8C and A1.8D).
However, the chemical shift changes upon binding are significantly greater than for the
previous two compounds, with more of the changes occurring around the dimer interface.
This indicates that this compound may cause dimerization of CXCL12, which has
biological relevance since dimerization is known to occur upon binding the N-terminal
domain of CXCL12’s receptor, CXCR4.174 NMR crosspeaks showed broadening, upon
titration to higher levels of CSDDD_1661, suggestive of aggregation, perhaps beyond the
dimeric state.
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Figure A1.8. Docking and experimental data for compound CSDDD_1661 binding to
CXCL12. Panels A and B show the lowest energy pose for CSDDD_1661 and relevant
interactions with CXCL12. Panel C shows the titration curves generated from the
chemical shift changes in panel D, and used to calculate the Kd for compound binding to
CXCL12, which was determined to be 203 ± 36 µM. Panel D shows the overlay of the
2D 1H-15N HSQC spectra for the NMR titration, chemical shift changes from green going
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to red upon addition of CSDDD_1661. CXCL12 was at 50 µM in pH 6.8 predeutero
MES buffer (25 mM).
It should be noted that during experimental NMR screening for binding to
CXCL12, protein appeared to precipitate during titrations with some of the compounds.
Subsequent SDS-PAGE gel analysis of the NMR samples indicated that the precipitate
contained covalently crosslinked CXCL12 protein, with protein exposed to
CSDDD_1661, CSDDD_1784 and CSDDD_1452 all showing dimer bands, but the
covalent dimerization from CSDDD_1661 and CSDDD_1784 appears to be light
activated (Figure A1.9). A CXCL12 double mutant [CXCL12 (L35C/A65C)]174 that
forms a covalently linked dimer was also exposed to ligand and light for 24 hours as a
control (Figure A1.9), to show where the CXCL12 dimer band is expected, providing a
comparison for the light/chemically induced dimerization due to CSDDD_1661,
CSDDD_1784 and CSDDD_1452. A control experiment, exposing ubiquitin to
CSDDD_1452 and CSDDD_1661 indicates that their ability to crosslink CXCL12 is
specific, consistent with NMR chemical shift titrations that indicate binding to a unique
site on the protein
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Figure A1.9. Panel A shows the SDS PAGE gels with 50 µM wt- CXCL12 (SDF1)
exposed to 800 µM of CSDDD_1784, CSDDD_1661, or CSDDD_1452 and to light (L)
or kept in the dark (D) for 24 hours. SDF12 is a pre-dimerized form of CXCL12,
generated using mutagenesis. Panel B shows the results for a chemotaxis assay of
CXCL12 when exposed to different conditions.
A preliminary chemotaxis assay showed that CSDDD_1661-treated CXCL12
inhibited CXCL12/CXCR4-mediated cell migration (Figure A1.10), suggesting that
dimerization induced by CSDDD_1661 may convert CXCL12 from an agonist into an
antagonist.
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Figure A1.10. Chemotaxis assay results for CXCL12 with different inhibitors.
Given the line broadening that was observed in NMR titrations using
CSDDD_1661, there is some concern that CXCL12 may actually be aggregating due to
nonspecific effects that are sometimes observed with conjugated dye-like molecules
including such aryl sulfonates.79 To this end, all three NMR titrations were repeated in
the present of 0.01% Triton X100, which would be expected to eliminate any nonspecific
aggregation effects. HSQC titrations show that the most potent inhibitors (CSDDD_1452
and CSDDD_1784) still bind, but there are no significant chemical shift changes from the
CSDDD_1661 titration (Figure A1.11).
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Figure A1.11. NMR chemical shift perturbation monitoring of CXCL12 with small
molecule CSDDD_1661 with increasing concentration of TritionX 100 detergent.
This suggests that at least some of the CSDDD_1661 activity may have been due to
aggregation effects. Additionally, nephelometry was performed on these chemicals to
investigate their ability to form aggregates in solution. This data is shown in Figure
A1.12. Citrus Red, a limited use azo food dye, showed a strong tendancy to aggregate.
Chemicals CSDDD_1784 and CSDDD_1750 showed no tendancy to aggregate.
CSDDD_1485 could form aggregates, but likely causes aggregation above 25 µM which
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was the Kd for PMK observed by chemical shift perturbation. CSDDD_1661 formed
aggregates starting near 30 µM. Thus, at least some of the activity in the chemical shift
perturbation assay is likely being caused by aggregation factors. Interestingly, similar to
the chemotaxis assay, this chemical shows that light promotes aggregation.

Figure A1.12. Nephelometry data for chemicals identified by docking and studied by
NMR-15N-1H HSQC chemical shift perturbation. A gain of 72 was used to obtain this
data.
A1.2.4. Quantum chemical calculations: comparison of structure and
electrostatic
Aryl-sulfonate structures appear to be biomimetics of various charged functional
groups, based on their ability to mimic electronic and structural properties. These
similarities can be better assessed using quantum mechanical density functional theory
(DFT) calculations of charges, bond lengths, and resonance structures. A comparison of
results from DFT calculations of the sulfonate, sulfonamide, sulfate, and sulfamate
functional groups indicates that they all have nearly identical negative charge on the
terminal oxygen atoms, and the bond lengths are the same, as one would expect if bond
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order is the same (Table A1.1). The phosphate bears more negative charge on the oxygen
atoms and has a longer bond length, consistent with the lower bond order that is expected
in phosphates.

Table A1.1. Comparison of NBO charges and bond lengths for aryl-sulfonates, sulfates,
sulfonamides, phosphates, and sulfamates calculated using DFT (B3LYP/6-31G(d))
calculations.
NBO Charge
R-O Bond
on Oxygen
Structure
Electrostatic Maps
(or S, P, N)
Length (Å)
Atoms

Phenyl
Sulfonate

-1.032
-1.018
-1.032
(S) 2.439

S-O
S-O
S-O

1.49
1.49
1.49

Phenyl
Sulfate

-0.760
-0.981
-0.990
-0.990
(S) 2.540

S-O
S-O
S-O
S-O

1.77
1.47
1.48
1.48

Phenyl
Sulfonamid
e

-1.009
-1.003
(N) -1.118
(S) 2.256

S-O
S-O
S-N

1.49
1.48
1.80

Phenyl
Phosphate

-0.826
-1.207
-1.208
-1.208
(P) 2.398

P-O
P-O
P-O
P-O

2.01
1.53
1.52
1.52
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Phenyl
Sulfamate

-1.012
-1.005
-1.016
(N) -0.874
(S) 2.519

S-O
S-O
S-O
S-N

1.48
1.48
1.48
1.78

This is to be expected since traditional resonance considerations would give the
phosphate oxygen a bond order of 4/3 while the sulfate, sulfonate and sulfonamide would
have a bond order of 5/3, with only one negative charge being delocalized over three
oxygen atoms. Surprisingly, the oxygen atoms on the substituted sulfurs bears about the
same charge as those in the phosphate, due to the higher positive charge density on sulfur
(+2) versus phosphorus (+1). Even the phenyl sulfonamide, which is typically (and
incorrectly) drawn with no charge, actually bears a -1.1 charge on each oxygen and is
probably best drawn in a resonance form with positive charge on sulfur. This is
supported by our natural resonance theory (NRT) calculations for phenyl sulfonate and a
similar model compound, prop-1-ene-2-sulfonate:

Both compounds had this S2+ form as the highest populated resonance structure in the
NRT calculations, at 27% and 45% respectively. Additionally, no resonance structures
were observed from the NRT calculations with more than 4 bonds to sulfur (i.e. no S to O
double bonding is present). A second difference is in the effects of the sulfonate,
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sulfonamide, sulfate, phosphate, and sulfamate substituents on the electrostatic potential
of the aromatic ring. The phenyl sulfonates and phenyl sulfates have nearly identical
electrostatic potential maps for the aromatic ring (and similar to the phenyl sulfamate),
indicating similar electron withdrawing capability for these substituents; but, these
groups are more electron withdrawing than the sulfonamide and phosphate, which show
some negative charge on the ring (Table A1.1). Overall, the electrostatic potential maps
show that the negative charge on the oxygens is quite similar for all substituents (roughly
-1), irrespective of what formal charge is typically written on the oxygen atoms in the
commonly drawn incorrect rendering of the Lewis structures.

A1.2.5. Cheminformatic database mining

DrugBank, a database containing structures of all 1,485 FDA approved drugs and
the Open NCI Screening Collection, a chemical collection of over 250,000 drug-like
molecules often used for screening projects, were mined using Pipeline Pilot v. 7.4175,
with queries for sulfonate, sulfate, sulfonamide, phosphate, and sulfamate (Figure A1.13).
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Figure A1.13. Substructures used to search the DrugBank and NCI datasets to identify
the number of molecules containing some important negatively charged functional
groups.
Functional
Number of FDA
Group
Approved Drugs

Sulfonate

Sulfate

Sulfonamide

Phosphate

Sulfamate

The population of these functional groups in these drug and drug lead databases was
determined, with results summarized in Table A1.2. The sulfonamide occurs with highest
frequency (26 compounds) in DrugBank, with the sulfonate, sulfate and phosphate
groups present at similar levels (7-12). In contrast, the sulfonate is the most prevalent of
these functional groups – by over 10-fold – in the NCI database.
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Table A1.2. Frequency that chemicals with various functional groups appear as
approved drugs in the DrugBank database74 and in the Open NCI database.176 The total
number of FDA approved drugs from DrugBank is 1,485 and the number of chemicals in
the Open NCI dataset is 250,250.
Functional
Number of FDA
Number in the Open
Group
Approved Drugs
NCI Database
Sulfonate
7
2639
Sulfate
12
132
Sulfonamide
26
770
Phosphate
9
250
Sulfamate
4
23
A1.3. Discussion

Docking and experimental binding analyses have identified potent aryl-sulfonate
inhibitors for the drug targets screened, PMK (cardiovascular target) and CXCL12
(cancer target). These aryl-sulfonate inhibitors have high affinity for first-round hits, with
Kd values generally < 100 mM. The PMK inhibitor (Kd = 25 mM) has a disulfonated
naphthyl ring, with one sulfonate sandwiched between a lysine (K22) and an arginine
(R73), while the other is involved in a network of hydrogen bonds with backbone amides.
Interaction with two positively charged groups would be expected to further stabilize the
highly charged resonance hybrid that is thought to be most relevant, based on NBO
calculations (Table A1.1).
The highest affinity ligand identified for CXCL12 (CSDDD_1452) contains two
naphthyl rings, one of which is sulfonated. The naphthyl moiety was also present in a
previously described small molecule inhibitor of CXCL12, and was indispensible for
high-affinity binding in that case.177 Three aryl-sulfonate inhibitors of CXCL12 have
been identified (Table A1.3), which generally have interactions with a key binding site
residue, R47 (Figures A1.6-A1.8). These compounds could serve as starting points for
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additional medicinal chemistry based optimization for target selectivity and potency,
building off the initial affinity obtained by virtue of occupying the positively charged
pocket. CSDDD_1784 is binding in a defined manner (i.e. not a nonspecific labeling),
based on NMR chemical shift mapping that indicates binding in a specific region of the
chemokine protein (CXCL12). In general, aryl-sulfonates that target the highly basic
pockets in proteins like CXCL12 and PMK can be viewed as privileged scaffolds, upon
which to further engineer needed specificity for a desired target.

Table A1.3. Summary of inhibitors identified in this study.
Structure
Protein

Kd (µM)

PMK

25.4

CXCL12

< 25

CSDDD_1750

CSDDD_1452
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CXCL12

35

CXCL12

203

CSDDD_1784

CSDDD_1661
Of the compounds identified that bind to CXCL12 (Figures A1.6-A1.8; Table
A1.3), CSDDD_1661 is unique in that it appears to bind and induce dimerization at the
native dimer interface, based on NMR chemical shift perturbations. In other words,
CSDDD_1661 can induce a dimerization in CXCL12 that normally requires binding to
the CXCL12 receptor or another stabilizing ligand.178 Yet, CSDDD_1661 forms
aggregates in solutions which would lead to non-specific inhibition. Furthermore, SDS
PAGE gel analysis shows that all three identified CXCL12 inhibitors cause some
covalent dimer formation, and this reaction is light stimulated for CSDDD_1661 and
CSDDD_1784 (Figure A1.9). Interestingly, the nephelometry seems to confirm that light
promotes aggregation for CSDDD_1661. This dimer formation occurs in solution in the
absence of receptor (conditions where CXCL12 is normally a monomer), which is
distinct from the dimer formation that is induced by binding to the N-terminal domain of
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the CXCR4 receptor. The latter binding event is reported to block chemotaxis, so has
relevance for cancer. Recently, we found that CXCL12 dimerization converts CXCL12
from a CXCR4 agonist into a partial agonist that inhibits cell migration.174 An engineered
CXCL12 dimer blocks metastasis in animal models of human colorectal cancer and
metastatic melanoma (manuscript in preparation). Importantly, crosslinking by
CSDDD_1661 may convert CXCL12 into an inhibitor of CXCR4-mediated cell
migration (Figure A1.9).
Some literature suggests that aryl-sulfonates may, in certain cases, produce
artifactual inhibition by virtue of their ability to form aggregates, and this effect can be
established by repeating inhibition studies in the presence of detergent, to disrupt the
compound aggregate.79 But, the aryl-sulfonate titrations reported herein show direct
binding to protein, based on chemical shift perturbations to distinct active site regions of
protein structure. Binding is not disrupted for the more potent ligands, although the
weaker binding of CSDDD_1661 is eliminated in the presence of detergent, suggesting
that its HSQC perturbation may be due to induced dimerization, and perhaps further
aggregation. Although, even in the case of CSDDD_1661, chemical shift perturbations
were observed in distinct regions of protein structure, suggesting the interpretation may
not be quite so simplistic (i.e. perhaps it is a combination of specific and nonspecific
effects).
The effect of light on compound binding activity is intriguing, and is likely due to
the well established property of azo-bridged aromatic groups to undergo light activated
cis-trans isomerization, with exposure to light causing an isomerization from the more
stable trans isomer to the cis isomer.179 Minimally, this is a mechanism for changing
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which form of ligand is present, possibly enabling a light activated burst in concentration
of a more active form of the aryl-sulfonate ligand. It is also possible that if the arylsulfonate is bound to protein, then exposed to light (which breaks the azo double bond),
the transient radical species formed could be sterically trapped and then label the protein,
or the strain of light-induced cis-trans isomerization (in a constrained space) may lead to
homolytic bond cleavage. This could lead to the light activated covalent dimerization that
is observed in Figure A1.9. These results suggest a potential utility of aryl-sulfonates as
photo-activated cancer therapeutics, if potency, selectivity and bioavailability can be
improved. Targeted activation using light at a tumor site could alleviate concerns about
toxicity associated with off-target binding, thereby permitting usage of higher doses and a
larger therapeutic window for treatment. Such photoactivated cancer therapeutics, alone
or in combination with traditional chemotherapeutics, have found increasing acceptance
in oncology.180 For example, Photofrin is a photoactivated drug that is activated using an
optical fiber inserted to the target tumor site, after the drug has been given adequate time
(2-3 days) to reach the target.180 Azo-bridged sulfonated aromatics could likewise be
developed for similar applications, as photoactivated dye-based drugs.
The broader application of aryl-sulfonates is as biomemetics for charges
substrates, possessing functional groups such as phosphates, carboxylates, and sulfate.
What is it about the aryl-sulfonate structure that makes it such a good biomemetic?
Quantum mechanical calculations provide some answers, based on the observation of
significant charge and structural similarities (Table A1.1), that are not apparent based on
inspection of the typically drawn and incorrect Lewis structure for sulfonates:
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NBO (B3LYP/6-31G(d)) calculations indicate that aryl-sulfonates possess roughly the
same negative charges (-1) on their oxygen atoms, as do the aryl-sulfates (ex. the
sulfotyrosine that chemokines bind) and phosphates (ex. kinase and phosphatase
substrates), as summarized in Table A1.1. This makes them reasonable biomimetics for
the biologically common phosphate and sulfate groups, and comparable to the
sulfonamides (Table A1.2), which are widely-encountered in drugs. Indeed, the typical
manner of drawing sulfonate, sulfate and sulfonamide Lewis structures is misleading, as a
more significant contributing resonance structure would have full negative charges on the
oxygen atoms, and positively charged sulfur, as demonstrated by our NRT calculation.181
Furthermore, the significant positive charge on the sulfonate sulfur suggests that this
functional group is quite electron withdrawing, as evidenced by positive charge density
on the phenyl ring (Table A1.1). Since the active sites of the drug targets tested in this
study are rich in basic residues (Figures A1.3 and A1.4), it is not surprising that most of
the compounds identified using docking are rich in the very negatively charge sulfonate
groups (Table A1.3). For example, PMK has many positively charged amino acids (17
arginines and 6 lysines), with the majority of them located in the active site to neutralize
the multiple negative charges present on its substrates (Figure A1.3). Likewise, CXCL12
has 3 arginines and 5 lysines, among which R47 is known to be influential in activating
its receptor (Figure A1.4).174
The above studies demonstrate that the aryl-sulfonate is similar in structural and
electrostatic properties to the aryl-sulfates, sulfonamides, sulfamates, and phosphates
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(Table A1.1). These functional groups are present in many drugs, with examples of
sulfate drugs including: sucralfate, ceruletide, and ardeparin. Methyclothiazide,
sulfanilamide, and topiramate are examples of sulfonamides. Drugs containing
sulfamates include heparin, enoxaparin, and ardeparin. Fosamprenavir, fosphenytoin,
and pyridoxal phosphate contain the phosphate functionality and are used as
pharmaceuticals. Table A1.2 shows a survey of Food and Drug Administration (FDA)
approved drugs from the DrugBank database and chemicals from the Open National
Cancer Institute (NCI) Database, which contain sulfonate, sulfate, sulfonamide,
sulfamate, and phosphate functional groups.73, 74, 176 Analysis of the DrugBank database
shows that sulfonates are slightly under represented in drugs when compared to similar
functional group. However, this relative representation is quite different in the Open NCI
screening dataset, which shows the sulfonates as the largest population of molecules with
this class of functional group. This suggests that aryl-sulfonates have found great utility
in basic research studies as chemical genetic probes, showing promise as potential drug
leads, with at least some examples of FDA approved aryl-sulfonates.
While docking and subsequent titration studies have verified that aryl-sulfonates
occupy the highly basic pockets of PMK and CXCL12 (Figures A1.5-A1.8), and bind
with high affinity (Table A1.3), one can ask whether aryl-sulfonates are viable starting
points for drug lead optimization. It seems unlikely that they are inherently toxic, since
aryl-sulfonates (even with bridging azo groups) are present in widely used food dyes
(Figure A1.1), and are present in some drugs (vide supra).134 Recent literature has
suggested that aryl-sulfonates may inhibit only artifactually via non-specific aggregation
effects79, but that is not what is observed for the compounds discovered herein (with the
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possible exception of CSDDD_1661, where inhibition could be eliminated by addition of
detergent). The greatest liability of aryl-sulfonates as drug leads may therefore be that
they are less likely to be bioavailable, as their high negative charge density may prevent
membrane penetration in some cases (i.e. poor adsorption). But, it is noteworthy that the
aryl-sulfonamide has a charge distribution on oxygens comparable to the sulfonates
(Table A1.1), and they are commonly encountered in drugs. But, the aryl-sulfonamides
have a net charge of 0 for the entire functional group; this likely leads to better membrane
permeability, especially if there is redistribution of charge that is dependent on
environment (membrane versus water). This problem of membrane penetration by
charged groups can sometimes be addressed by masking charges as esters, which are then
hydrolyzed in the cell. However, this approach may present issues of toxicity for
sulfonates, due to the introduction of an electrophilic carbon atom in the ester (analogous
to mesylate and tosylate leaving groups), so is not generally considered viable for arylsulfonates.134 Fortunately, a survey of existing drugs (Table A1.2) indicates that some do
indeed contain sulfonates, suggesting that this net charge does not always present
insurmountable bioavailability problems.

A1.4. Conclusion

Aryl-sulfonates possess full negative charges on their oxygen atoms (Table A1.1),
making them excellent structural and electronic mimics of the biologically relevant
phosphate, carboxylate and sulfate groups, and similar to the sulfonamides that are
commonly found in drugs (Table A1.2). Computational docking of a targeted library that

194	
  
	
  
included aryl-sulfonates yielded at least one high affinity hit (with Kd < 50 µM),
confirmed using NMR titrations, for each of the two drug targets tested, both of which
contained highly basic (arginine rich) active sites (Figures A1.3-A1.4). Each of these hits
contained at least one aryl-sulfonate group (Table A1.3), with some also containing a
bridging azo group that is commonly found in food dyes (Figure A1.1). The next logical
step in developing these compounds as drug leads and for probing the importance of the
sulfonate functional group would be to perform structure-activity relationship studies,
directed to increasing affinity and selectivity for the respective target.
A subset of these aryl-sulfonate compounds, containing azo-bridged aryl groups
known to undergo light activated trans to cis isomerization, could also have utility in
photodynamic therapy. Covalent crosslinking of CXCL12 by two such compounds was
unexpected, and could have utility for facilitating therapeutically useful protein
dimerization (ex. as is common for cell surface receptors) but seems to be due to nonspecific binding caused by CSDDD_1661 aggregates formed in solution. Due to the
structural similarity of aryl-sulfonates with bridging azo groups identified herein (Table
A1.3) to analogous aryl-sulfonates found in widely used food dyes (Figure A1.1), one
could postulate that either (a) these molecules are not likely to be inherently toxic, and
could therefore be employed in photodynamic therapy, or (b) such reactions are
potentially toxic, and this unrecognized toxicity should be of broad concern whenever
food dyes are consumed. Given the long history of food dye usage, the former seems
more likely.
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Is summary, aryl-sulfonates seem to be safe and effective biomimetics for
phosphates, sulfates and carboxylates, especially when interactions with active site
arginines are needed.

A1.5. Experimental
A1.5.1. Material

IPTG, ampicillin and chloramphenicol were from Research Products International
Corp. Nickel-Sepharose was from GE Healthcare. PMK cDNA was purchased from
OriGene, and cloned into pET15b, which included an N-terminal hexa-histidine tag.
Centricon filters were from Millipore. All other compounds required for expression,
purification and assays were obtained from Sigma-Aldrich.

A1.5.2. Docking

Ligand chemical files were prepared by ionizing to the protonation state at pH 7.4 using
Pipeline Pilot.175 CORINA was then used to calculate three-dimensional structures, which
were converted to the Protein Data Bank (pdb) format. 61 The files were then processed
with the python script prepare_ligand4.py, which comes with the AutoDock molecular
modeling package. 8, 9

This script generates a file containing the atomic coordinates and

partial charges for ligand, sets all torsions in the ligand to active (to permit rotation), and
merges all non-polar hydrogen.
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The protein pdb files and grid maps were all prepared using the AutoDock Tools
suite.8

Grid maps are used in the energy calculations performed by AutoDock. The

protein was treated just as the ligands were (done manually using AutoDock Tools),
adding partial charges and merging all non-polar hydrogens and saved as a pdbqt file.
All 13 different grid maps available in AutoDock were generated using AutoGrid4 with
the grid box, the site used to dock the ligands, placed over the active sites of the proteins
(the colored boxes in Figures A1.3 and A1.4).
The docking parameter file (dpf), which contains the parameters that AutoDock
uses to dock the ligand into the protein, was prepared using the python script
prepare_dpf4.py, and default docking parameters were used, except that 50 separate
docking calculations were performed with each calculation consisting of 1,750,000
energy evaluations and a root mean square deviation (RMSD) tolerance set to 2.0 Å.
This determines the entry of a structure into a given cluster. 8 The docking results were
then clustered on the basis of the RMSD between the coordinates of the atoms in a given
ligand, and were ranked on the basis of calculated free energy of binding.182 The docking
log files were then analyzed using the python script summarize_results4.py, which rank
orders all the dockings by binding energy.8

The results were then analyzed to find the

best clustered compounds with lowest free energy of binding.

A1.5.3. PMK: protein expression

PMK is a protein with 192 amino acids, is 22.0 kDa, and was expressed and
purified as previously described 183. The expression construct used herein was a synthetic
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gene prepared by Origene, and was based on the previously described expression
construct 183, but with codon usage now optimized for expression in E. coli . The
pET15b(+) PMK construct contained an N-terminal histidine tag (24.2 kDa) to facilitate
purification. Briefly, BL21-(DE3) Rosetta cells were transformed with this PMK
construct, and cells were plated on to Luria Bertani (LB) agar plates containing ampicillin
(amp) and chloramphenicol (chl). Incubation of these plates was at 37 °C and a single
colony was picked and used to inoculate 50 mL LB-amp-chl media. This overnight
culture was then used inoculate 2 L of LB-amp-chl media. This culture was allowed to
grow until A600 ~ 0.5 and the cells were collected via centrifugation (4,000 RPM for 20
min). Cells were resuspended in 500 mL of M9 minimal media-amp-chl with 15NH4Cl as
the sole source of nitrogen.39 This culture was induced with 1 mM IPTG and was
harvested 4 h post induction using centrifugation (4,000 RPM for 20 min). Bacterial
pellets were resuspended in a 50 mM potassium phosphate buffer, 5 mM imidazole, 5%
glycerol and 300 mM NaCl (at pH 7.8) containing 1 mM phenylmethanesulfonylfluoride.
The lysate was clarified by centrifugation at ~100,000 g and the supernatant loaded onto
1 mL of Ni-Sepharose Fast-Flow resin. The column was washed with the washing buffer
until A280 < 0.005, and the protein was eluted using the same buffer supplemented with
300 mM imidazole. The eluted fractions were kept, and the concentration determined
spectrophotometrically using an extinction coefficient (ε280) of 32,290 M-1 cm-1.

A1.5.4. PMK: NMR sample preparation and NMR titration
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[U-15N]-PMK was concentrated to 500 µM using a 10 kDa cutoff centricon filter
and exchanged into a buffer containing 20 mM KH2PO4, 5 mM DTT, 100 mM KCl, 10%
glycerol, 0.02% NaN3, and 10% 2H2O at a pH of 6.5. NMR experiments for PMK were
performed on a 600 MHz Varian NMR System at 599.515 MHz using a triple resonance
cryoprobe with z-axis gradients at 25 °C. Titration experiments were performed using 50
µM increments until saturation was achieved based on 1H-15N heteronuclear singlequantum coherence (HSQC) experiment. NMR data were processed and visualized using
NMRPipe41 and analyzed with NMRview.42 Chemical shift perturbations were
quantified using equation 1.

(1)
The chemical shift changes (Δshiftobs) were plotted as a function of the concentration of
the ligand, then data were fitted to a quadratic equation, to determine the dissociation
constant Kd:

(2)
using Graphpad Prism software, where Lo is the total ligand concentration, Po is the total
protein concentration, and Δshiftmax is the maximum chemical shift change observed for
the particular crosspeak in question. Fitting to the quadratic equation was required
because [Po] > Kd. Standard deviations are from the non-linear least squares fitting
process. Note that as Kd gets very small relative to [Po], errors will become larger
because Kd becomes less well-defined in the fitting process). Thus, for very high affinity
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ligands (low Kd), one can only provide an upper limit for Kd. This was the case for
CSDDD_1452.

A1.5.5. CXCL12: Protein expression, NMR sample preparation, and NMR titrations

[U-15N]-SDF-1α was expressed and purified as previously described.178 Samples
contained 50 µM [U-15N]-SDF-1α (CXCL12) in 25mM d-MES buffer (pH 6.8), 10%
D2O, and 0.02% NaN3. Titrations of indicated compounds were monitored by 2D 1H-15N
HSQC spectroscopy experiments. NMR analysis was performed on a Bruker 600 MHz
spectrometer equipped with a TXI triple-resonance cryoprobe. Data was converted and
processed using NMRPipe.41 Previously published assignments 178 were transferred by
visual inspection and chemical shift values were tracked.184 Binding data were treated
similarly to data for PMK.

A1.5.6 CXCL12: gel electrophoresis and chemotaxis functional assay.

The gel samples (Figure A1.9) contained 800 µM of the chemical to be screened
and were mixed with 50 µM of one of the following proteins: wild type-CXCL12, a
CXCL12 double mutant [CXCL12 (L35C/A65C)]174 that forms a covalently linked
dimer, or ubiquitin. These samples were exposed to fluorescent light for 24 h, diluted 2X
in SDS loading buffer and 10 mM DTT was added, then boiled.
For the chemotaxis experiments (Figure A1.9), 50µl reactions containing 50µM
CXCL12, 800µM compound, 3.2% (v/v) DMSO, and 25mM MES (pH 6.8) were
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incubated under fluorescent light for 48h. As the compound stocks were originally
reconstituted at 25mM in DMSO, we prepared control reactions containing only 50µM
CXCL12, 3.2% (v/v) DMSO, and 25mM MES (pH 6.8). After incubation, the samples
were diluted 2000X in RPMI media + 0.2% (w/v) bovine serum albumin (BSA) to for
final CXCL12 and compound concentration of 25 and 400nM, respectively, and 600µl
was loaded into a 24 well plate. A 5µm pore size Transwell Membrane (Corning) was
placed into each well and loaded with 5x105 cells suspended in RPMI media + 0.2%
(w/v) BSA. The plate was incubated for 2.5h at 37 °C, 5% CO2. After incubation, all
Transwell Membrane inserts were removed and the cells were counted using a TC-10
Automated Cell Counter (Biorad). The chemotactic index was computed by counting the
cells that migrated in response to the chemokine divided by the number of cells counted
without the chemokine present.

A1.5.7. Quantum mechanics calculations

Model compounds compared in Table A1.1 were drawn using GaussView 5.185
Geometries were optimized using density functional theory (DFT) B3LYP/6-31G(d)
calculations in the Gaussian 09 suite of programs.186 Atomic charges were calculated
using natural population analysis at the B3LYP/6-31G(d) level.187, 188 Electrostatic maps
were generated using GaussView 5186 and the optimized checkpoint files obtained from
the earlier optimization step. Natural resonance theory (NRT) calculations were
performed with NBO ver. 5.9.188
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A1.5.8 Cheminformatic database mining

Two databases were mined searching for substructures describing sulfonate,
sulfate, sulfonamide, sulfamate, phosphate, and sulamate functional groups using
Pipeline Pilot v. 7.4175 with the query structures listed in Figure A1.12. The DrugBank
Small Molecule73, 74 set is a set of 1485 FDA approved small molecular therapeutics. The
NCI collection176 represents a collection of 250,250 drug candidate molecules often
screened in drug screening projects.

A1.5.9 Nephelometry

Nephelometry is the study of the relative aggregation of particles in solution,
based on the light-scattering properties of molecular aggregates.71 The nephelometry
experiments of the polysulfonated aromatic food dyes listed in Figure A1.1, as well as the
sulfonated aromatic MU compounds displayed in Table A1.3, were performed in 96-well
plates. The buffer utilized contained 100mM Trizma base, 100mM sodium chloride,
5mM magnesium chloride hexahydrate and 1mM dithiothreitol in deuterium oxide at a
pH of 7.5. Each compound analyzed in these experiments contained concentrations of
compound ranging from 10-100 µM and recorded in quadruplet. Each plate was
analyzed at three separate gains, 43, 69 and 72.
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Appendix II. Identification of Pollutants that Disrupt Kidney Development via
Hedgehog Protein Binding
A2.1 Introduction

Intrauterine organ development is a delicate well-organized process, but is also
susceptible to environmental interference. Maternal exposure to chemicals, including
pollutants, toxins, drugs and pharmaceuticals, can lead to developmental abnormalities.
Severe abnormalities are often not compatible with life or can be detected very early.
However, more subtle developmental defects are likely to go undetected until the third
and fourth decades of life where they manifest as organ dysfunction. Quantitative
assessment of organ development is challenging, but recent advances studies in kidney
development have been enabling. The kidney is an excellent surrogate for studies of
organ development, due to the availability of multiple quantitative measurements, as well
as an in-depth knowledge of the signaling events that control development.

203	
  
	
  

Figure A2.1. Schematic diagram of the process of nephrogenesis, depicting the
relationship between the UB (originating from the Wolffian duct) and the condensing
metanephric mesenchyme. The condensed mesenchyme go through mesenchymal to
epithelial transformation and finally form the proximal part of the nephron (adapted from
Shah et al, Development 131:1449).
The mammalian kidney develops in utero as a branching structure. The epithelial
branching morphogenesis is a fundamental biological process; which forms the
foundation for other organ development, including lung, pancreas and liver. The
signaling cascade that controls branching morphogenesis is very similar between these
organ systems, and is likely to respond in a similar fashion to environmental exposures.
Studies presented herein will be directed to developing and applying novel methods, to
identifying environmental exposures that disrupt kidney development.
Identifying potentially harmful chemicals by screening compounds in well-known
toxic datasets could point to chemicals that are problematic to developing children.
Databases such as the DSSTox databases189, 190, with special focus on the “EPA High
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Production Volume” collections, the “EPA Water Disinfection By-Products Collection”
and the “EPA Fathead Minnow Acute Toxicity Database” were virtually screened herein.
We intend for this compound collection to serve as a resource for future studies by other
researchers, who may be exploring interactions with other proteins and organ systems
using combined computational and experimental methods.
The kidney branching tree originates from the ureteric bud (UB). The UB branch tips are
essential for stimulating the formation of the nephrons (the filtration unit of the kidney
and the basic building block). Inadequate UB branching leads to a reduction in the
nephron number.191, 192 Low nephron number (Oligonephronia) is a risk factor for
development of hypertension, chronic kidney disease (CKD) and ultimately end stage
renal disease (ESRD)193-195. The consequences of being borne with low nephron number
are dependent on the severity of nephron number reduction. Severe reduction in
nephrons manifests as ESRD in infancy or childhood, while milder forms lead to
adulthood hypertension and increased susceptibility to kidney disease.196-200
Hedgehog (HH) signaling is a pivotal in organism development, with
evolutionally conserved function from fruit fly to higher mammals.201 And, HH signaling
is also regulated in part by the MAP kinase signaling cascade. Severe disruption of HH
signaling is lethal; this effect was demonstrated in multiple knock out animal models.202,
203

However, modulation of HH signaling can alter development and leads to abnormal

organ programming and adulthood disease. HH signaling plays a major part on cancer
cell survival, which made it an attractive target for therapeutic development.204 A
modulator of HH signaling, the HH interacting protein (HHIP), has been gaining
attention over the past couple of years. SNPs in this gene have been found in Genome
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Wide Association Studies (GWAS) to be linked to type II diabetes205 and lung disease.203,
206

The mechanism by which this gene could be linked to these apparently not related

diseases is not known, but it is to be noted that both pancreas and lung rely on epithelial
branching morphogenesis during development, and HH signaling controls this process
during lung and pancreatic development.
Computational tools were used to identify and prioritize compounds that are most
likely to lead to kidney developmental defects. Compounds that are likely to disrupt the
Hedgehog (HH) signaling pathway were be identified using protein docking studies using
Autodock4.28, 9. Also of interest will be compounds that are structurally related to
cyclopamine207 and Vismodegib208, 209, known disruptors of Hedgehog signaling.209, 210

Figure A2.2. Chemical structures of cyclopamine (left) and Vismodegib (right) known
to modulate HH activity.
Compounds structurally related to these (which act by disrupting Hedgehog (HH)
signaling), are possibly being released into the environment, and this would pose serious
risks to fetal development, if consumed early in pregnancy.
In vitro mouse embryonic kidney cultures provide a standardized system for
testing of molecules present in environmental exposures, which can disrupt kidney
development and epithelial branching morphogenesis. In this proposal we intend to
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examine the effect(s) of such environmental exposures on kidney development. This will
allow us to predict the environmental risk to a developing fetus. The ability to also assess
whether our computational predictions correlate with experimental observations of
developmental defects will also be key. To the extent that they do not, new computational
models will be developed.
Herein, we aim to create an environmental toxin database. Using this database,
we will use in silco tools to identify compounds likely to act as HH disruptors. We
propose these chemicals can be tested using in vitro testing methods and assays of
deleterious effects of exposure to these toxins at a concentration similar to environmental
exposures, as well as higher doses (1 pM - mM). Herein we present a novel tissue culture
assay for identifying chemicals that disrupt kidney development, by disrupting HH or
other signaling pathways. Furthermore, we combine this assay with computational tools
to identify compounds that are likely to disrupt kidney development. This computational
approach will be refined, so that it we can identify with high accuracy compounds that
are being released into the environment and pose high exposure risks for pregnant
women. Finally, we will produce a physical and computational collection of compounds,
for analogous studies by other researchers – such a physical collection is not currently
available. The methods described are widely used in the pharmaceutical industry, but we
are applying them now to the realm of environmental toxicology.

A2.2. Materials and Methods

A2.2.1. Docking prediction of compounds likely to cause kidney developmental
defects
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The DSSTox chemical library received as 2D SDF files. Using Pipeline Pilot60, the
protonation state was adjusted to reflect the most prevalent form of the molecule at a pH
of 7.4. CORINA61 was used to these files to 3D PDB coordinate files; which resulted in
low energy 3D structures. The files were then processed with the python script
prepare_ligand4.py, which comes with Autodock8 molecular modeling package. This
script generates a pdbqt file, and adds partial charges to the ligand, sets all torsions in the
ligand to active (to permit rotation), as well as merging all non-polar hydrogen atoms.
The HH-HHIP protein pdb file (Figure A2.3) was downloaded211, the HHIP protein
removed, and prepared using the Autodock Tools Suite.8 Grid maps are used in the
energy calculations performed by Autodock4.2. Partial charges were added and all nonpolar hydrogen atoms were merged resulting in a pdbqt file. The 13 different grid maps,
one needed for each of the different atoms in the chemical libraries (ex. C, H, F, Cl, etc.)
were generated using Autogrid48 with the grid box, the site used to dock the ligands, was
positioned to cover the interface region of the HH and HHIP.
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Figure A2.3. Crystal structure for human Hedgehog (HH) protein (wheat) bound to
HHIP (blue). Docking box will be at the protein-protein interface (after removing HHIP).
The docking parameter file (dpf), which contains the parameters that Autodock uses
to dock the ligand into the protein, was prepared using the python script prepare_dpf4.py,
and default docking parameters were used, except that 50 separate docking calculations
were performed with each calculation consisting of 1,750,000 energy evaluations and an
rmsd tolerance set to 2.0 angstroms (to define entry of structure into a given cluster). The
dpf files were then automatically docked using MUGrid with HTCondor62, 63 and
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AutoDock4.28, 64 using the Lamarckian genetic algorithm local search method to perform
the optimization of docking pose. The docking results were then clustered on the basis of
the root mean square deviation (rmsd) between the coordinates of the atoms in a given
ligand, and were ranked on the basis of calculated free energy of binding. The docking
log files were then analyzed using the python script summarize_results4.py contained in
the shell script sumresults_48, which rank orders all the dockings, by binding energy. The
results were then analyzed to find the best-clustered compounds with lowest free energy
of binding as determined by Autodock.

A2.2.2. Overlay prediction of compounds likely to cause kidney developmental
defects
The DSSTox chemical library received as 2D SDF files. Using Pipeline Pilot60,
the protonation state was adjusted to reflect the most prevalent form of the molecule at a
pH of 7.4. Using Openeye’s Omega265, three dimensional coordinates were calculated
and stored in Openeye’s preferred file, .oeb.gz, for subsequent overlay evaluation. Rapid
Overlay of Chemical (ROCS) matches a chemical query to a database of chemicals in
search of hits. ROCS rank orders hits based on overlay of electrostatics and molecular
shape. By querying the DSSTox database with cyclopamine and Vismodegib, we can
prioritize chemicals that are more likely to interact with HH.

A2.2.3. In vitro kidney assay
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After timed pregnancy, female CD1 mice will be sacrificed at the postcoital day
12.5, according to our animal protocol. The gestational sac will be opened and embryos
will be retrieved. The isolated mouse kidney will be grown immediately at the air-liquid
interface on 0.45 mm Transwell (Corning) at 37°C, 100% humidity, 5% CO2, in serumfree media. The medium will be DMEM/F12 (HEPES and L-glutamine) with 45 mM
NaHCO3, pen/strep, 1X ITS (insulin-transferring-selenium) (Invitrogen), 2 nM T3, 70 nM
PGE2, and 100 nM trans-retinoic acid (Sigma){Miao, 2003 30716 /id}. Kidneys will be
cultured in presence of chemicals to be tested at concentrations of 1 pM, 1 nM & 1 mM
for 3 days, then fixed and imaged.
Transwel cultured embryonic kidneys will be fixed for 30 min at 4°C in 4%
paraformaldehyde, washed three times with PBS followed by additional incubation for 2h
with methanol on ice. The methanol will be removed and the kidneys subjected to three
PBS washes. Non-specific binding will be blocked with Protein-free blocker
(DakoCytomation) for 1h at room temperature then incubated overnight at 4°C in 1:700
dilution of anti-calbindin 28D antibody, to visualize UB-derived structures. After three
rinses in PBS–Tween for 20 minutes, secondary antibodies, goat anti-mouse conjugated
with Alexa-Fluor (Molecular Probes, Invitrogen), will be applied at 1:170 dilution, and
incubation will be carried out for 2 h at room temperature. After three washes in PBS,
kidneys will be subjected to post-fixation in 4% paraformaldehyde for 15 min, mounted
in fluorescent mounting medium (Vector Laboratories), then stored in the dark until
examination by confocal microscopy. Immunofluorescence analysis will be carried out
using a laser scanning confocal microscope using 4x, or 10x objective lenses (Leica TCS
SP5). After Z plan images are captured. 3D images will be assembled. The image will

211	
  
	
  
be used to count the number of UB branches, and measure the length of the stem between
branches. The degree of branching will be contrasted between test and control
experiments. These experiments will be performed in the El-Meanawy lab.

Figure A2.4. In vitro cultured mouse embryonic kidney incubated with control solution
of 16 ng/mL recombinant HHIP protein. There is 20% reduction in UB branch tips &
elongation of stems.
A2.3. Results and Discussion

Docking of the DSSTox chemical library resulted in a rank ordered list of
chemicals to be tested by the in vitro kidney assay. Table A2.1 shows the results of these
docking calculations. These chemicals positioned themselves in an empty cleft of the HH
protein vacated by the removal of the HHIP protein from the crystal structure. Figure
A2.5 shows the lowest binding energy pose for the chemical, mesotrione. One aspect for
this project was sourcing these chemicals for testing. Only chemicals that could be
purchased from a reputable vendor are discuss herein.
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Table A2.1. Top docking results for the docking of DSSTox into HH.
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Figure A2.5. Binding prediction of mesotrione (teal) in the HH protein. This pose was
predicted to bind in the lowest energy -8.69 kcal/mol from all chemicals in the DSSTox
library.
ROCS produced chemicals from the DSSTox library that resembled the queries
cyclopamine and Vismodegib, known to modulate HH activity. Cyclopamine was
overlaid with finasteride, a chemical that is known to influence prostate cancer.212 This
overlay is shown in Figure A2.6. Vismodegib matched 4,4-diaminobenzailide (Figure
A2.7).
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Figure A2.6. ROCS overlay of cyclopamine(violet) and finasteride (yellow, inset).

Figure A2.7. ROCS overlay of Vismodegib (green) and 4,4-diaminobenzailide (blue,
inset)
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A2.4. Summary
We have acquired some chemicals that are ready to be tested in the in vitro kidney
assay. Sourcing these chemicals proved challenging, though many could be purchased
from overseas laboratories. As chemical modulators for HH are identified, similar
chemicals can be identified using these same procedures creating structure-activity
relationships and pointing to classes of chemical compounds that warrant an increased
awareness for.
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Appendix III. In situ Fragment-based on Ligand Thiol Tethering using NMR Methods
A3.1. Introduction
Fragment assembly is a drug design strategy whereby low molecular weight (<
300 g/mol) compounds (“fragments”) are screened for low affinity binding to protein
drug targets128, 160, 188, 213. If it can be established that two fragments bind in close
proximity to each other, in a protein binding site, then they are chemically linked
together. If linkage is done properly, such that binding orientation is not perturbed, this
often results in a larger increase in affinity where the Kd for the tethered fragments is the
product of the Kd values for the individual, untethered fragments. Fragments that are used
for such drug discovery projects are chosen based on similarity to heterocyclic ring
systems that occur in presently prescribed drugs or fragments of those drugs. The first
step in fragment-based drug discovery is to identify fragments that bind a protein target.
NMR is one of the most widely-used methods widely used fragment-based
screening for binding to protein targets.214 There are a number of NMR techniques that
provide robust assays that are sensitive for detecting weak interactions, and are therefore
well suited for fragment-based screening.120 NMR screening methods can be divided into
those that detect interactions by observation of either a macromolecule NMR parameter
(limited typically to chemical shifts) or small molecule NMR parameter. For small
molecules, the choice of NMR parameters is more diverse, including longitudinal,
transverse or double-quantum relaxation, diffusion coefficients, transferred NOE, NOE
pumping, saturation transfer etc. Saturation Transfer Difference (STD) NMR114 is one
such NMR technique, which not only detects ligand binding to a protein, but also
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determines the binding epitope of a ligand.215 By binding epitope is meant the portion of
a ligand that contacts the protein surface (and therefore receives a stronger NOE), as
opposed to the region that is exposed to solvent. Such information is of prime importance
for the directed development of drugs. STD is well suited for screening compound
libraries for binding activity, because no isotope label is needed. In this experiment,
ligands are added to a solution of the receptor protein and one 1H-NMR experiment is
performed where a spectral region is selectively irradiated that contains only protein
signals (ex. 1 ppm); in a second step, a control irradiation frequency is set at a value that
is far from any protein or ligand signal, e.g. -10 ppm. Subtraction of these so called onand off-resonance irradiation experiments leads to a difference spectrum, in which the
only resonance that are visible result from signal attenuation via saturation transfer
(NOE) from protein to bound and exchanging ligand. STD is one of the few NMR
methods suitable for HTS (high throughput screening) of a large library of fragments,
because it can be automated and it requires relative little unlabeled protein. This method
offers several advantages for binding activity. First, the binding ligand can be usually
directly identified, so it can be utilized to screen pools of ligands, with the dissociation
constant Kd values ranging from mM to µM (higher affinity binding can’t be detected).
Second, regions of ligands or ligand fragments having the closest contact to the protein
show the most intense STD signals, enabling the mapping of ligand’s binding epitope
precisely. This means the STD signal for individual ligand protons reflects their
proximity to the protein surface, and can be used to describe the target-ligand
interactions. The third and most important advantage of STD screening is that there is no
need to isotopically enrich the target macromolecule, and there is no upper limit to the
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size of target that can be screened, as long as a 10-50 µM can be made. The main
disadvantage is that ligands with high affinity will be missed, and that no information
regarding ligand binding sites is directly available from the screening data. However,
competition STD allows the detection of high affinity ligands and their binding site
locations46. Also, competition STD experiments cab be used to obtain dissociation
constants for tight binding inhibitors. Herein, competition STD is adopted for high
throughput screening of DHPR ligands.
Thiol-tethering is an important fragment-based approach to increase the binding
interactions and affinity87, 88, 123, 161, 216. Tethering relies on a covalent, but reversible
reaction that occurs on the protein surface—a type of template-directed synthesis.
Tethering allows the identification of small-molecule fragments that bind to specific and
neighboring regions of a protein target. These fragments can then be elaborated,
combined with other molecules, or combined with one another to provide high-affinity
drug leads. It provides an in situ method for detection of low affinity ligands that can be
joined to make high affinity ligands217. Erlanson88, 90, 217 et al. were able to find highaffinity ligands for allosteric proteins using thiol-tethering fragment assembly, for
cysteine aspartyl preotease-3, and Protein Tyrosine Phosphate 1B (PTP1B). A crystal
structure of the fragment covalently bound to PTP1B revealed that it binds in the active
site by forcing open the so-called WPD loop to make room for its steric bulk. This
conformation of PTP1B is less commonly observed than the catalytically active “closed”
conformation. The fact that tethering selects for binding with protein in the open
conformation is typical of the empirical nature of the approach: the protein adapts to suit
the conformational needs of the fragments in the complex, leading to inhibitors that
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couldn’t be designed rationally. Another example is the drug target interleukin-2 (IL-2), a
powerful cytokine responsible for T-cell activation87. A compound was identified that
traps the conformation of the IL-2 receptor-binding site in a conformation that is quite
unlike the native structure of IL-2. Clearly, protein surfaces and active are dynamic, so
rational design using a static structure of the native cytokine would not have produced
this inhibitor or exploited its binding site. Such ligand fragments could only be found
empirically. In our application of thiol-tethering, the reversible covalent thiol-disulfide
exchange chemistry is adapted to amplify the affinity of a privileged scaffold (CRAA),
making inhibitors (bi-lidands) in situ on the protein surface—with applicability to any
dehydrogenase that binds the CRAA scaffold. This method will also control the binding
region, to eliminate nonspecific binding with protein targets based on the fact that CRAA
binds to the cofactor site that is common to dehydrogenases. This catechol-rhodanine
(CR)-based privileged scaffold, tailored to dehydrogenase enzymes, has recently been
reported by Sem64 et al. Because CRAA binds in a conserved orientation, it is a good
starting point for thio-tethering strategies to target this family of proteins. CRAA binds in
the active site of dehydrogenases with its carboxylic acid function group proximal to the
substrate binding site. This carboxylic group can easily be modified for identifying other
fragments that bind in the substrate site of dehydrogenases. Suitable fragments have
molecular weigh about 300 Da, following the ‘Rule of Three’ for fragment-based lead
discovery’ (Molecular weight ≤ 300; Octanol/water partition coefficient, ClogP ≤ 3;
number of H-bond donors and acceptors less than, or equal to 3; three or less flexible
bonds; polar surface area ≤ 60 Å2.)218. The strategy is to add a linker off of the carboxylic
acid group, which terminates in a thiol . The free thiol or disulfide group is used to tether
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to a dithiol or free thiol fragment library. This “tethering” reaction occurs in the DHPR
active site. If desired, initio screening for formation of a high affinity CRAA-S-SFragment bi-ligand can be done using competition STD high throughput screening
(HTS). This method will create and detect higher-affinity inhibitors in situ by using thioldisulfide equilibrium exchange catalyzed by the DHPR protein target. In this strategy,
formation of the high-affinity thiol-tethered bi-ligand prevents binding of lower affinity
reporter ligands that give the STD signal. In this case, reporter ligand might be NAD+
(blocked by CRAA). Figure A3.1 shows a depiction for the work proposed herein.

Figure A3.1. STD screening model: DHPR: 0.1 mM; NAD+: 10 mM; PDC: 10 mM;
CRAA2: 2 mM; Cystamine: 0 mM; Thiols: 2 mM.
While STD screening is fast (30-60 minutes per sample), it is difficult to automate
and consume much protein (0.5 mL of 20 µM/sample). MicroFlow NMR requires the
smallest volume of sample (i.e., a few microliters) of any NMR technique. Microcoils
provide greater sensitivity than conventional NMR detector coils on a per-mass basis,
relative to traditional probes. This sensitivity is explained by considering the process of
signal induction in the windings of the detection coil, which is more efficient when the
windings tightly couple to the sample. Microcoils allow us to use fewer samples for STD-
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based screening, while providing the same spectral information obtained using the larger
coil. The flow configuration also permits automation, by coupling to a liquid handle with
96-well sample vial capability. This NMR detection and automation system dramatically
lowers the cost and effort of NMR STD screening, using smaller amounts of protein and
ligands.
Increasing death population of human being caused by Mycobacterium
tuberculosis (TB) and contentiously occurring multiple drug resistant strain of TB
highlight the urgent demand for discovering new drugs for cursing this disease.
Dihydrodipicolinate reductase (DHPR) is on the lysine synthesis pathway and is the
potential drug targets for TB (Ref). Caterchol rhodanine acetic acid was known binding
multiple dehydrogenases, originally it was used to study binding to DHPR.219 Herein, we
report the high throughput screening method for accelerate our drug lead discovery
process for DHPR based on the privileged scaffold CRAA. The method is also potential
to be used for any other dehydrogenases to screen for higher affinity and highly specific
inhibitors based on this scaffold. Three strategies were essential for developing this HTS
screening method. First, thiol-tethering was used to amplify binging affinity of ‘biligand’ inhibitors, which can be formed in situ facilitated by protein template. That is,
CRAA derivative need to have the free thiol functional group on the terminal which also
pointing to the substrate binding site. The higher affinity of bi-ligand decreases the need
for higher solubility of detectable fragments, which is always a limitation for fragmentbased inhibitors. Secondly, competition STD was used to highlight the binding pockets
on DHPR surface. The medium high affinity reporter ligands (here are NAD+ and PDC)
should only lead to the high affinity hits. Both reporters have high solubility make them
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possible to be detectable in the short time and lower magnetic field, which equals to HTS.
Third, Protasis HTS system was used for this screening. The microflow NMR probe can
cut NMR sample to 10 µL, which means a lower cost for protein and reagents. High
throughput sample loader can cut the massive work for sample loading and the screening
can be done automatically.
To verify this competition STD strategy, 400 MHz Varian NMR instrument with
Protasis HTS system and 600 MHz Varian NMR instrument were used parallelly to
verify screening results. Compound 5 was used in situ in this screening or form bi-ligand
library first and then used in the competition STD study. The latter one showed higher
inhibition to DHPR based on our model bi-ligand 6.

A3.2. Results and Discussion

A3.2.1. STD Competition With Thiol-Disulfide System to DHPR

CRAA scaffold directed STD competition assay was developed. With a
microflow probe, it was clear that NADH could replace the NAD+ reporter bound to
DHPR (Figure A3.2). For the CRAA-directed thiol tethering study, a disulfide library can
be built by synthesis before screening (like 6) or thiol-tethered biligands can be formed in
situ, in a template-directed manner. The latter approach requires a higher concentration of
cystamine to creator a thiol-disulfide exchange system. The presence (or in situ formation
of) thiol tethered biligands can then be detected in the competition STD assay. For high
throughput NMR screening with a micro-probe, the protein should be well behaved. For
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example, it needs to have good solubility, be stable and be able to be prepared in a large
amount at high purity. The reporter ligands used in the competition also need to have
good solubility, so they can be used in high concentration (> 1 mM). The corresponding
thiol or disulfide fragment library should also be prepared 180, to screen for high affinity
thiol-tethered biligands.

Figure A3.2. STD of 0.1 mM DHPR with 10 mM PDC present, ± NAD+ and ± NADH.
.(a) 10 mM PDC only; (b) 10 mM PDC and 10 mM NAD+; (c) 10 mM PDC, 10 mM
NAD+ and 0.3 mM NADH. Assay was performed using a CapNMR microflow probe
from Protasis, using 10 µL sample volume.
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Table A3.1. STD intensity for 5’ in the presence of the DHPR-NAD+-PDC complex
interacts, with added TNB (TNB forms a mixed disulfide with 5 in situ, replacing
cysteamine). Competition was also performed directly with the bi-ligand 6.
[TNB]
(mM)

A2 (8.40 ppm)
STD

A8 (8.13 ppm)
STD

1D

PDC (7.97 ppm)
STD

1D

1D

0

22.6

48.7

48.2

30.6

109.9

120.4

2

20.6

48.2

44.1

31.1

93.8

119.5

10

15.6

44.2

33.1

29.0

62.6

116.0

[CRAATNB] (mM)

A2 (8.40 ppm)
STD

A8 (8.13 ppm)
STD

1D

PDC (7.97 ppm)
STD

1D

1D

0

23.6

53.0

50.7

30.6

106.3

99.5

1

17.6

48.5

39.1

33.4

86.3

103.2

2

12.0

38.7

28.6

29.8

66.7

93.8

4

5.5

29.4

13.5

25.7

40.1

80.0

A3.2.2. Docking
TNB was docked into the binding site that PDC was observed in the crystal
structure.220 This pose prediction is shown in Figure A3.3. This docking prediction shows
the potential to dock other thiols from commercial sources to create a library that could
be quickly screened.
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Figure A3.3. Binding prediction of TNB in DHPR. The ligand bound with a predicted
lowest binding energy of -6.77 kcal/mol.
A3.3. Summary

CRAA scaffold directed STD competition assay was developed. With a
microflow probe, it was clear that NADH could replace the NAD+ reporter bound to
DHPR. For the CRAA-directed thiol tethering study, a disulfide library can be built by
synthesis before screening or thiol-tethered biligands can be formed in situ, in a templatedirected manner. The latter approach requires a higher concentration of cystamine to
create a thiol-disulfide exchange system. The presence (or in situ formation of) thiol
tethered biligands can then be detected in the competition STD assay. For high
throughput NMR screening with a micro-probe, the protein should be well behaved. For
example, it needs to have good solubility, be stable and be able to be prepared in a large
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amount at high purity. The reporter ligands used in the competition also need to have
good solubility, so they can be used in high concentration (> 1 mM). The corresponding
thiol or disulfide fragment library should also be prepared to screen for high affinity
thiol-tethered biligands.

A3.4. Materials and Methods

All NMR experiments were performed on a 400 MHz Varian NMR System
instrument equipped with Protasis HTS system and a 600 MHz Varian NMR System
instrument equipped with a triple resonance cryoprobe and z-axis gradients. An HP
8452A diode array UV–Vis spectrophotometer was used for determining DHPR
concentration and for coupled enzyme assays. Salts, buffers and other chemical reagents
(including NAD+, NADH and PDC) are from Sigma–Aldrich and are of biochemical
reagent grade.
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Scheme A3.1. Synthesis of CRAA-based thiol tethering probe 5 and bi-ligand 6 .

A3.4.1. S-acetylcystamine hydrochloride (1)

To 7 g 2-aminoethanethiol hydrochloride, 10 mL acetyl chloride was added
slowly and allowed to react for 30 min., then another 10 mL acetyl chloride was added.
Reaction was kept at 50 0C for 2 hours. After cooling down to room temperature,
impurities were extracted with 80 mL ether and solid product was collected by filtration.
Crude product weighed 8.7 g (90% yield). Product was then recrystallized from ethanol,
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to give crystals 4.3 g (50% yield). M.p., 137 0C. The spectral data were as follows: 1H
NMR (D2O) δ 2.43 (s, 3H), 3.23 (m, 4H).

A3.4.2. 3-Rhodanine acetic acid 2’-acetylmercaptylethylamide (3)

2.4 mL oxalyl chloride was added slowly to a mixture of 1.91 g of 3-rhodanine
acetic acid and 40 mL benzene while stirring, then reacted at room temperature for 24
hours and warmed up to 50 0C for another 2 hours. The resulting dark brown solution was
evaporated thoroughly and the residue was dissolved into 50 mL chloroform. The
solution was added to a mixture of 1.71 g S-acetylcystamine hydrochloride, 100 mL
chloroform and 6.2 mL triethylamine. Reaction progressed at room temperature overnight
and then solvents were evaporated. The product was extracted with chloroform, washed
and dried. The product was purified by flash column chromatography using hexane: ethyl
acetate 1:1 as eluent and 0.58 g product was obtained (40% yield), m. p., 68-70 0C. The
spectral data were as follows: 1H NMR (d6-DMSO) δ 1.77 (s, 3H), 2.97 (t, J=6.8 Hz, 2H),
3.16 (dd, J=5.7, 6.8 Hz, 2H), 4.44 (s, 2H), 4.88(s, 2H), 8.07 (t, J=5.7 Hz). GC-MS m/z:
292, 174, 146, 118,104, and 72.

A3.4.3. 5-[(3,4-dihydroxyphenyl)methylene]-4-oxo-2-thioxo-3-thiazolidineacetic acid
2’-acetylmercaptoethyl amide (4)
Under a N2 atmosphere, a mixture of 0.32 g 3-rhodanine acetic acid 2’acetylmercaptylethylamide, 0.16 g 3,4-dihydroxybenzaldehyde, 0.22 g sodium acetate
and 15 mL acetic acid was heated to 95 0C and stirred for 6 hours. Yellow crystals
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formed after the solution cooled down. The mixture was poured into 15 mL cold water;
the crystals filtered off, washed well with water, then crystallized from ethanol, yielding
0.21 g (62% yield) of product, m. p., 188-189 0C. The spectral data were as follows: 1H
NMR (d6-DMSO) δ 1.78 (S, 3H), 2.97 (t, J=6.8 Hz, 2H), 3.17 (dd, J=5.7, 6.8, 2H), 5.02
(s, 2H), 6.90 (d, J=6.8 Hz, 1H), 7.15 (d, J=6.8 Hz, 2H), 7.68 (s, 1H), 8.08 (t(br), J=5.4Hz,
1H) 9.67 (s(br), 1H), 10.10 (s(br), 1H).

A3.4.4. 5-[(3,4-dihydroxyphenyl)methylene]-4-oxo-2-thioxo-3-thiazolidineacetic acid
2’-mercaptoethyl amide (5)221

5-[(3,4-dihydroxyphenyl)methylene]-4-oxo-2-thioxo-3-thiazolidineacetic acid 2’acetylmercaptylethyl amide was charged into the flask with magnetic stirring in an ice
bath , and 2 N sodium hydroxide was added dropwise over 10 minutes. Thin layer
chromatography (TLC) was used to monitor the reaction. After 1 hour later, the reaction
was finished. The product in solution could be used directly in the next step, to synthesize
disulfides. After the reaction finished, concentrated HCl was added slowly to the mixture
to adjust the pH to 4.0 while controlling the temperature at 0-5 0C. The desired product
formed in solution, but is not stable during column chromatography. As such, the acetyl
group was removed to create the free thiol (5) only just prior to use.

A3.4.5. Synthesis of 6 disulfide (6) 222

DTNB (5,5'-Dithio-bis(2-nitrobenzoic acid)) was dissolved into a small amount of
DMSO at the concentration of 600 mM, and then the solution was added to 0.5 M MOPS
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(3-(N-Morpholino)-propanesulfonic acid) buffer at pH 8.5 to a final concentration of 10
mM. To this solution, the freshly prepared 5 solution was added dropwise over 20
minutes in a 1:1 stoichiometry. The reaction was keep at r.t. for 2 hours while the 6
product formed in solution via disulfide exchange. The pH of this solution was adjusted
to 7.8. The solution was saved at -20 0C and used in the STD binding study, in the gel
competition assay and in the steady state competition assay.

A3.4.6. STD competition model using microflow probe

Because of its essential role in cell wall synthesis, DHPR is a potential target for
antimicrobial drug and herbicide design, DHPR can be expressed and purified in large
quantity and high purity form E. coli. Herein, DHPR is used to develop a screening
approach using microflow probe technology. The moderate binding affinity ligand NAD+
and PDC were chosen as reporter ligands for detecting high affinity ligands at both
cofactor and substrate binding sites. The STD study presented herein proves that NAD+
does not change the PDC binding epitope or affinity significantly. But, NADH does
change the binding conformation PDC. The detailed nature of this structural change was
discussed in Chapter IV. Both NAD+ and PDC have relatively high solubility, yet only
moderate binding affinity. Those two properties make them ideal for use as STD reporter
ligands. While, fragments with lower affinity to DHPR will not be found using this
competition assay, thiol tethering produces higher affinity ‘bi-ligand’ inhibitors in situ.
Formation of such a high affinity thiol tethered bi-ligand will decrease STD signal from,
and displace the reporter ligand.
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The first control experiment to validate the STD competition assay was done
using NADH to displace the weaker binding NAD+. In this experiment, samples were
prepared in 25 mM phosphate buffer, with DHPR at 100 mM, NAD+ and PDC at 10 mM.
NADH was added as a competitor at 0.3 mM. The NMR STD experiments were run on a
Varian 400 MHz instrument using standard and microflow (10 µL) probes. NAD+ signals
disappearance was observed on both probes. So, the test was implicated in higher
throughput on the microflow probe, where 100 thiol containing fragments were screened
using this assay. While, there were some thiol fragments decreased signals for the NAD+
and PDC reporter ligands. None caused complete disappearance of reporter ligand
signals. This experiment was designed to identify thiol fragments for later use in
template-directed thiol tethering.

A3.4.7. STD Competition assay using in situ thiol-tethering and previously
prepared disulfide tethered biligand (6)

In the STD competition experiment, 5 was prepared fresh before use (Scheme 2).
About 20 mg of acetyl-5 thiol ester was added to an eppendorf tube in an ice bath, and
100 µL of a 2 M NaOH solution was added and vertexed occasionally. Samples were also
kept in an ice bath for about 20 minutes. TLC was used to monitor the reaction, as
described in the synthesis of 5. Then, the CRAA sample was prepared as a 2-4 mM
solution, and to this solution 10 fold of excess cystamine hydrochloride salt was added to
form the mixed disulfide between 5 and cystamine. The final solution was adjusted to pH
7.8. DTNB was converted to TNB in a basic solution (pH 10.0) and a 20 mM stock was
adjusted to pH 7.8. 0.1 mM DHPR was prepared in 25 mM phosphate D2O buffer and 10
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mM NAD+, 10 mM PDC and 2 mM CR-cystamine mixture were added. 1D and STD
experiments were recorded as a control. Then, TNB was added to this sample at
concentrations of 2 mM and 10 mM. The A2 and A8 of adenosine protons NAD+ and the
degenerate PDC peak intensities were recorded, and compared to monitor decreases of
their reporter ligand signals.
In another experiment, 6 was synthesized as in Scheme 1. The decision to link 5
to TNB was based on identification of TNB in the previous competition STD assay. This
reaction mixture was then used for the STD competition study. DHPR was 0.1 mM,
NAD+ and PDC were 10 mM. The blank 1D and STD were recorded. Then, a 6 bi-ligand
solution was titrated into this sample, at concentrations of 0, 1, 2, and 4 mM. Again, A2,
A8 and PDC proton signal intensities were monitored in the STD experiment, to
determine if the NAD+ and/or PDC reporter ligands could be displaced by the 6 thioltethered bi-ligands.
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Scheme A3.2. Chemical reactions in templated-directed thiol-tethering process.

A3.4.8. In gel competition to verify 6 as a high-affinity biligand for DHPR

The above STD assays indicates 6 is a bi-ligand inhibitor of DHPR. These results
are now confirmed using a native in gel competition study. In this native gel (Figure
A3.1) competition assay, a diluted 6 solution was mixed with DHPR with increasing
concentrations of NADH at 1.5, 3, 6, 12, and 24 mM. CRAA used as a control for
cofactor site fragment (Kd = 26 µM)64. Then the 10% Tris-Glycine polyacrylamide gel
was run at 125 V using a Novex minicell chamber. About 30 minutes after gel elution
began, a strongly colored band for 6 was observed, the DHPR lane with CRAA present
showed no band. Also, the DHPR lane that had 6 along with NADH showed inhibition of
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6 binding, at highest NADH concentration, the colored bands were not visible. 6
concentration was ~ 2 mM. This result demonstrates that 6 binds with affinity
comparable to NADH and demonstrates the utility of in gel screening of thiol-tethered
biligand off the colored CR-privileged scaffold.

A3.4.9. Competition Assay of the 6 biligand using a steady-state Coupled Enzyme
Assay
Binding affinity was also measured quantitatively using a competition study
using a steady-state coupled enzyme assay. In this experiment, all reagents were used
from frozen stock solutions (DHPS, DHPR, ASA) or freshly prepared (NADH,
pyruvate). The assays were run in 100 mM Tris buffer, pH 7.8, with NADH
concentrations of 30, 40, 50, and 60 µM. At each NADH concentration, 10, 20, 30 and 40
µL diluted 6 stock (~ 1mM) was used for the competition assay, monitoring oxidation of
NADH at 340 nm. The data showed that 6 is a competitive inhibitor versus NADH,
binding with a Kis = 7.3 µM. Note that because DHP substrate is present at 3 mM, this
apparent Ki will be higher than the true Kd for the bi-ligand (Figure A3.4).

A3.4.10. Docking

Ligands were downloaded from Pubchem (http://pubchem.ncbi.nlm.nih.gov/) and
adjusted to the protonation state at a pH of 7.4 using Pipleline Pilot.60 To calculate the
three dimensional structures of the ligands, AutoDock Tools (ADT) was used prepare the
ligand files according to AutoDock requirements and assign Gasteiger charges.
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The DHPR protein (PDB code 1C3V) was prepared using the ‘A’ chain.220 ADT
was used to further prepare the ER-α receptor files by adding hydrogen atoms and adding
partial charges to each atom of the protein. The grid box was centered on the cocrystallized PDC, drawn to a box with the following dimensions 12.75 Å x 17.25 Å x
12.25 Å, then the PDC ligand was removed.29 Using Autodock4.2 with default
parameters except with 50 genetic algorithmic runs and 2,500,000 evaluations per run.2932
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Appendix IV. A Virtual Screening Strategy to Maximize Computational Time for
Extremely Large Chemical Libraries
A4.1 Introduction

Docking is the computational process of positioning a ligand into the binding site
of a protein to identify the preferred pose of the ligand. Using this pose, a binding affinity
for the ligand-protein complex can be calculated using a force field.6 Docking plays a
role in the design and discovery of drugs as drug candidates are docked against protein
targets to predict their affinity to the target. This process is called virtual screening. 7
Virtual screening is the process of automated docking of a chemical library into a
protein, with the goal of discovering chemicals that bind with high affinity for the
protein.7 It is used in the early phase of drug discovery, since it can substantially reduce
the resources dedicated to screening, so resources can be focused on the most promising
and relevant compounds.6 Zanamivir, an influenza therapeutic, is one example of a drug
developed in part using the docking process.164
The virtual screening process is most efficient if physical compounds are
available for rapid experimental verification of computational results.6 Depending on the
throughput of the experimental assay to verify the computational prediction, only a small
percentage of ligands are experimentally verified. Concordia University Wisconsin’s
Center for Structural Drug Design and Development (CSD3) uses an in-house screening
collection of 12,000 compounds that contain drug-like molecules and also includes
chemical dyes. The ZINC database maintains a collection of approximately 23 million
commercially available compounds for virtual screening and takes 270 GB of storage.66
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Among these chemicals, two important subsets are worth noting. The first is a fragmentlike subset.82 Fragments are molecules that if they bind proximally to each other in the
protein can be chemically linked to produce a more potent inhibitor.97 This subset is
350,000 chemicals and takes 2 GB in storage. The second is a set of lead-like chemicals
comprising of over 2.6 million compounds needing 27 GHz in storage.72 The physical
properties of these chemicals are typically associated with chemicals that the drug
discovery process begins with. Table A4.1 summarizes these chemical libraries.

Table A4.1. Relevant collections of chemicals for virtual screening
CSD3 Screening Collection

Chemical Collection
Size
10,000

ZINC fragment-like

350,000

2.6 GB

ZINC lead-like

2.6 million

27 GB

ZINC

23 million

270 GB

Chemical Collection Name

Storage Size
45 MB

Two popular, large scale, distributed docking projects exist. The
FightAIDS@home project uses the World Community Grid. This approach uses
Autodock to virtually screen for new inhibitors of HIV protease.223 The Docking@home
project uses the Berkeley Open Infrastructure for Network Computing (BOINC)
middleware to manage its volunteer computing grid.224
We present an incremental docking approach, which utilizes a cluster of machines
with a resource scheduling system, to investigate the heuristics for speeding up
distributed protein docking. We dock a subset of the chemical library and use a naiive
bayes scoring function to predict the binding energies of undocked ligands. Our
experiments illustrate that the average overall energy of the docking complexes and the
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enrichment of potential drug leads is significantly improved, with a significant reduction
in the amount of computations needed to identify better binding predictions. This will
improve the speed that we can dock our in house chemical libraries and improve the
reliability of the workflow by reducing the computational load. Additionally, this will
enable virtual screening studies of larger chemical libraries.

A4.2 Workflow development

The CSD3 has designed a virtual screening workflow, Scheme A4.1, built upon
Condor62, 225 and DAGMan.226 Using Autodock 4.28, this framework and system design
splits the virtual screening of large datasets to independent docking jobs and manages the
resulting files summarizing them to a single summary file.
This workflow uses a single input file containing all ligand, protein, and paramter
files. To further automate the virtual screen, we have written scripts to prepare the
Condor submit files, the DAGMan files, and other file management. Each node in the
directed-acyclic graph (DAG) shows a specific step in the virtual screen. The docking of
a single ligand-protein accounts for one vertex. After all dockings have completed, a
daughter job to each of the docking jobs is launched to summarize all the dockings.
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Scheme A4.1. An illustration of incremental docking architecture. An input file
containing the files necessary for a bulk docking experiment is provided. The data is
partitioned into single docking events and one docking experiment is assigned to each
available Condor worker. Upon completion, Condor aggregates the results from the
individual workers to present the user with a final single result file.

A subset of ligands is randomly chosen to initiate the incremental docking
experiment. As the experiment proceeds the DAG submission file is dynamically
populated, at run time utilizing a X-DAG structure, to determine which ligands to be
docked in the next iteration. The algorithm (Figure A4.1) is outlined as below:
• Select N ligands randomly for iteration 1.
• Sort the ligands docked in (K − 1)th iteration based on their binding energies.
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• Compare undocked ligands to docked ligands based on their properties
(molecular weight, lipophilicity and ability to accept or donate hydrogen bonds).
• Predict the binding energy of un-docked ligands based on the similarity in
properties.
• Sort the un-docked ligands based on their predicted binding energies.
• Pick the top N ligands which should be docked in the Kth increment.
• Repeat until 20% of the library is docked (or desired enrichment is achieved).

Figure A4.1. The algorithm for parallel submission of dockings for the incremental
approach. N ligands are randomly selected for docking in iteration 1.
The chemical nature of a compound is a result of its physical and chemical
attributes. Lipinski’s Rule-of-Five establishes the importance of four different properties
which make a good drug candidate viz. Molecular Weight, AlogP, Number of Hydrogen
Acceptors and Number of Hydrogen Donors.142 We extend this structure activity
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relationship, to hypothesize that similar ligands have similar binding properties. We
represent a ligand (L) as a function of these attributes. The expected binding energies are
then determined as below:

where, L is a docked ligand, li is the ith attribute of L, uL is an un-docked ligand for which
an energy bin is to be determined, ai is the ith attribute of uL, k is the total number of
ligand attributes, EuL is the predicted energy bin for uL, E is the energy bin, P(E|L) is the
probability of an undocked ligand of a predicted energy bin E, P(L|E) is the probability of
an energy bin given the docked ligands, P(E) is the probability of any energy bin, P(L) is
the probability of occurence of any ligand and is assumed to be a constant α, PL is the
probability of ai given an energy bin E, NE is the total number of docked ligands in
energy bin E, N is the total number of docked ligands in the iteration.
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A4.3 Docking
Four experiments on three distinct proteins were performed to evaluate the
performance of the incremental docking approach. The proteins chosen are drug targets
that are of interest in two different disease categories, with human health implications for
both rare and neglected diseases. The first set of proteins is Dihydrofolate Reductase
(DHFR) and Dihydrodipicolinate reductase (DHPR). These proteins are targets for the
disease Tuberculosis. The other protein drug target pursued in this study is Human Dual
Specificity Phosphatase 5 (DUSP5), an enzyme in humans encoded by the DUSP5
gene.227 DUSP5 protein has two domains and each of these domains participate in ligand
binding. For the docking experiment study, each of these domains were tested
individually and are referred to as DUSP5C and DUSP5R.
An in-house physical collection of 10, 573 ligands in the CSD3 is used [20]. The
library contains drug-like molecules, selected on the basis of their predicted binding to
dehydrogenases and kinases, and a general compliance with the Lipinski Rule of Five,
and other drug-like filters. The ligands were converted into a ready-to-dock format using
in Autodock tools.8
Autodock docks each ligand to a protein target in several poses; clusters similar
poses together; and then provides structures and calculated binding energies for each
docking pose. For each protein-ligand docking, the energies from all poses are sorted and
the lowest energy within the highest cluster size is then chosen as the most favorable
binding energy for a particular ligand-protein. This energy is defined as the binding
energy of the ligand . 500 ligands were docked in each iteration of incremental docking,
with a total of 22 iterations. For performance evaluation, all the ligands were docked and
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sorted on the basis of their binding energy. The top 1000 binders were identified and the
performance was evaluated based on the following metrics:

Dockings are performed using Autodock, an open source software commonly
used for protein docking that predicts how ligands bind to the pre-calculated docking area
(grid) on the target protein. Distributed computing systems require several basic software
tools to manage large scale computations. Condor is a resource management and
scheduling system for executing computation-intensive jobs har- nessing idle compute
power. The DAGMan (Directed Acyclic Graph Manager) is a meta-scheduler for Condor
jobs. We implement an X-DAG which dynamically evaluates the set of ligands that
should be tested for their binding potential.
The experiments were performed on Marquette University’s Pere cluster. The
cluster is composed of 1284 nodes, 2 × quad core Intel Xeon X5550, total of 1024 cores.
The processors feature 24 GB RAM per node, DDR Inifiband backbone, 20 Gb/s, Red
Hat Enterprise Linux 5.3. The proteins and ligands were processed and using the
MGLTools. Condor 7.4.4 for X86 64-LINUX RHEL5 is used a resource scheduler for
implementing High Throughput Computing. Python 2.4.3 was used as the language for
development.

A4.4 Results
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Figure A4.2 shows the plot between the average energy against the iteration
number. It is observed that the average energy of the protein-ligand complexes decreased
substantially after the very first iteration of Bayesian selection. Specifically, (i). The
average energy in iteration 2 is the lowest across all iterations, (ii). The average energy
starts to increase after an initial decrease and attains a value, which is higher than
iteration 1 in very few subsequent iterations, (iii). The average energy of the last iteration
is the highest and much greater than in iteration 1, which is selected randomly.

Figure A4.2. Plot between average energy of an iteration and iteration number. Iteration
2 and 3 show significant drop in average energy across all experiments.
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As expected from the improved binding energies plot there is a considerable
enrichment obtained in the first four iterations. Figure A4.3 shows the Ligand Enrichment
achieved after each iteration for each of the four experiments. The steep slope in
iterations 2 and 3, is an indication of higher rates of enrichment. Specifically, (i). For all
proteins, 200 of top 1000 (10%) binders are found by docking only 14% of the ligand
library, (ii). For all proteins, 500 of top 1000 (10%) ligands are found by docking 28% of
the ligand library, (iii). For all proteins, there is no significant gain in enrichment after
docking almost 70% of the ligand library, (iv). The enrichment for top 10 good ligands in
all proteins looks very good. Top 9 or 10 ligands are found within docking 19% of the
ligand library which is usually the number of compounds finally screened for laboratory
testing.
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Figure A4.3. (a). Plot of enrichment with top 1000 ligands in each iteration versus
iteration number. The cumulative enrichment of ligands with progressing iterations in
incremental approach with Bayesian selection (Black) is much higher than the
enrichment obtained by a random selection (Red).

A visual representation of the dockings is generated using Pymol.45 Figure 5
shows the predicted docking complex of the proteins with the best binding ligand in the
second iteration of docking. It is observed that the ligand (represented by stick model) is
strategically placed in the binding pocket of the protein molecule (represented by blue).
The relevant amino acid side chains are shown to illustrate potential intermolecular
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binding interactions. In all the four experiments top 1000 best binders were docked in
iterations 2 and 3 with a p − value < 0.0001. These results demonstrate that incremental
docking approach has a selective preference for better binding ligands and provides better
enrichment as compared to a completely random docking experiment.

Figure A4.4. (a). Docking Complex of DHFR with the ligand 103 in iteration 2. (b).
Docking Complex of DHPR with the ligand 210 in iteration 2. (c). Docking Complex of
DUSP5C with the ligand 270 in iteration 2. (d). Docking Complex of DUSP5R with the
ligand 51 in iteration 2.
A4.5 Summary
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This workflow is able to greatly improve the throughput of virtual screens
undertaken in the CSDDD. Table A4.2 shows the potential increased throughput for
docking datasets of increasing size.

Table A4.2. Times to dock representative chemical collections using Autodock 4.28, a
single Intel Xeon 2.67 GHz processor or Père’s 500 core Condor pool.
Chemical Collection Size

Single Core

500 Core Condor Pool

1

40 min

40 min

10,000

277 days (est.)

6 hours

350,000

27 years (est.)

51 days (est.)

2.6 million
23 million

198 years (est.)
1750 years (est.)

381 days (est.)
325 years (est.)

The ability to computationally predict ligands from extremely large chemical collections
without requiring extensive grid infrastructure to access the large computational
resources needed for such a task.223 This approach is simple and could be implemented
quickly with a small amount of overhead. Since preparation of the parameter files is
relatively easy, by automating the preparation, management, and summary of a virtual
screen of the entire Zinc chemical collection, a web portal could be developed that would
benefit a vast number of researchers across many areas of research.
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